<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery - Bryant, A - 2022 | Cochrane Library</title> <meta content="Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery - Bryant, A - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015048.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery - Bryant, A - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015048.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015048.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery" name="citation_title"/> <meta content="Andrew Bryant" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="andy.bryant@ncl.ac.uk" name="citation_author_email"/> <meta content="Shaun Hiu" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Patience T Kunonga" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Ketankumar Gajjar" name="citation_author"/> <meta content="1st Floor Maternity Unit, City Hospital Campus" name="citation_author_institution"/> <meta content="Dawn Craig" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Luke Vale" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Brett A Winter-Roach" name="citation_author"/> <meta content="Christie Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Ahmed Elattar" name="citation_author"/> <meta content="City Hospital &amp; Birmingham Treatment Centre" name="citation_author_institution"/> <meta content="Raj Naik" name="citation_author"/> <meta content="Northern Gynaecological Oncology Centre" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD015048.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/09/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015048.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015048.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015048.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Carcinoma, Ovarian Epithelial [drug therapy, surgery]; Chemotherapy, Adjuvant [methods]; *Clinical Decision-Making; Neoadjuvant Therapy [methods]; Neoplasm, Residual; *Ovarian Neoplasms [drug therapy, pathology, surgery]; Prognosis; Uncertainty" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015048.pub2&amp;doi=10.1002/14651858.CD015048.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015048\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015048\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ko","ms","fa","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015048.pub2",title:"Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery",firstPublishedDate:"Sep 26, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015048.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015048.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015048.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015048.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015048.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015048.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015048.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015048.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015048.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015048.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2889 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015048.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-sec-0013"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/appendices#CD015048-sec-0106"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/supinfo/CD015048StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/supinfo/CD015048StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Prognosis</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Andrew Bryant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0005">Shaun Hiu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0006">Patience T Kunonga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0007">Ketankumar Gajjar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0008">Dawn Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0009">Luke Vale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0010">Brett A Winter-Roach</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0011">Ahmed Elattar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information#CD015048-cr-0012">Raj Naik</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information/en#CD015048-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 September 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015048.pub2">https://doi.org/10.1002/14651858.CD015048.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015048-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015048-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015048-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015048-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015048-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015048-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015048-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015048-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015048-abs-0001" lang="en"> <section id="CD015048-sec-0001"> <h3 class="title" id="CD015048-sec-0001">Background</h3> <p>Ovarian cancer is the seventh most common cancer among women and a leading cause of death from gynaecological malignancies. Epithelial ovarian cancer is the most common type, accounting for around 90% of all ovarian cancers. This specific type of ovarian cancer starts in the surface layer covering the ovary or lining of the fallopian tube. Surgery is performed either before chemotherapy (upfront or primary debulking surgery (PDS)) or in the middle of a course of treatment with chemotherapy (neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS)), with the aim of removing all visible tumour and achieving no macroscopic residual disease (NMRD). The aim of this review is to investigate the prognostic impact of size of residual disease nodules (RD) in women who received upfront or interval cytoreductive surgery for advanced (stage III and IV) epithelial ovarian cancer (EOC). </p> </section> <section id="CD015048-sec-0002"> <h3 class="title" id="CD015048-sec-0002">Objectives</h3> <p>To assess the prognostic impact of residual disease after primary surgery on survival outcomes for advanced (stage III and IV) epithelial ovarian cancer. In separate analyses, primary surgery included both upfront primary debulking surgery (PDS) followed by adjuvant chemotherapy and neoadjuvant chemotherapy followed by interval debulking surgery (IDS). Each residual disease threshold is considered as a separate prognostic factor. </p> </section> <section id="CD015048-sec-0003"> <h3 class="title" id="CD015048-sec-0003">Search methods</h3> <p>We searched CENTRAL (2021, Issue 8), MEDLINE via Ovid (to 30 August 2021) and Embase via Ovid (to 30 August 2021). </p> </section> <section id="CD015048-sec-0004"> <h3 class="title" id="CD015048-sec-0004">Selection criteria</h3> <p>We included survival data from studies of at least 100 women with advanced EOC after primary surgery. Residual disease was assessed as a prognostic factor in multivariate prognostic models. We excluded studies that reported fewer than 100 women, women with concurrent malignancies or studies that only reported unadjusted results. Women were included into two distinct groups: those who received PDS followed by platinum‐based chemotherapy and those who received IDS, analysed separately. We included studies that reported all RD thresholds after surgery, but the main thresholds of interest were microscopic RD (labelled NMRD), RD 0.1 cm to 1 cm (small‐volume residual disease (SVRD)) and RD &gt; 1 cm (large‐volume residual disease (LVRD)). </p> </section> <section id="CD015048-sec-0005"> <h3 class="title" id="CD015048-sec-0005">Data collection and analysis</h3> <p>Two review authors independently abstracted data and assessed risk of bias. Where possible, we synthesised the data in meta‐analysis. To assess the adequacy of adjustment factors used in multivariate Cox models, we used the 'adjustment for other prognostic factors' and 'statistical analysis and reporting' domains of the quality in prognosis studies (QUIPS) tool. We also made judgements about the certainty of the evidence for each outcome in the main comparisons, using GRADE. </p> <p>We examined differences between FIGO stages III and IV for different thresholds of RD after primary surgery. We considered factors such as age, grade, length of follow‐up, type and experience of surgeon, and type of surgery in the interpretation of any heterogeneity. </p> <p>We also performed sensitivity analyses that distinguished between studies that included NMRD in RD categories of &lt; 1 cm and those that did not. This was applicable to comparisons involving RD &lt; 1 cm with the exception of RD &lt; 1 cm versus NMRD. We evaluated women undergoing PDS and IDS in separate analyses. </p> </section> <section id="CD015048-sec-0006"> <h3 class="title" id="CD015048-sec-0006">Main results</h3> <p>We found 46 studies reporting multivariate prognostic analyses, including RD as a prognostic factor, which met our inclusion criteria: 22,376 women who underwent PDS and 3697 who underwent IDS, all with varying levels of RD. </p> <p>While we identified a range of different RD thresholds, we mainly report on comparisons that are the focus of a key area of clinical uncertainty (involving NMRD, SVRD and LVRD). The comparison involving any visible disease (RD &gt; 0 cm) and NMRD was also important. </p> <p><i>SVRD versus NMRD in a PDS setting</i> </p> <p>In PDS studies, most showed an increased risk of death in all RD groups when those with macroscopic RD (MRD) were compared to NMRD. Women who had SVRD after PDS had more than twice the risk of death compared to women with NMRD (hazard ratio (HR) 2.03, 95% confidence interval (CI) 1.80 to 2.29; I<sup>2</sup> = 50%; 17 studies; 9404 participants; moderate‐certainty). The analysis of progression‐free survival found that women who had SVRD after PDS had nearly twice the risk of death compared to women with NMRD (HR 1.88, 95% CI 1.63 to 2.16; I<sup>2</sup> = 63%; 10 studies; 6596 participants; moderate‐certainty). </p> <p><i>LVRD versus SVRD in a PDS setting</i> </p> <p>When we compared LVRD versus SVRD following surgery, the estimates were attenuated compared to NMRD comparisons. All analyses showed an overall survival benefit in women who had RD &lt; 1 cm after surgery (HR 1.22, 95% CI 1.13 to 1.32; I<sup>2</sup> = 0%; 5 studies; 6000 participants; moderate‐certainty). The results were robust to analyses of progression‐free survival. </p> <p><i>SVRD and LVRD versus NMRD in an IDS setting</i> </p> <p>The one study that defined the categories as NMRD, SVRD and LVRD showed that women who had SVRD and LVRD after IDS had more than twice the risk of death compared to women who had NMRD (HR 2.09, 95% CI 1.20 to 3.66; 310 participants; I<sup>2</sup> = 56%, and HR 2.23, 95% CI 1.49 to 3.34; 343 participants; I<sup>2</sup> = 35%; very low‐certainty, for SVRD versus NMRD and LVRD versus NMRD, respectively). </p> <p><i>LVRD versus SVRD + NMRD in an IDS setting</i> </p> <p>Meta‐analysis found that women who had LVRD had a greater risk of death and disease progression compared to women who had either SVRD or NMRD (HR 1.60, 95% CI 1.21 to 2.11; 6 studies; 1572 participants; I<sup>2</sup> = 58% for overall survival and HR 1.76, 95% CI 1.23 to 2.52; 1145 participants; I<sup>2</sup> = 60% for progression‐free survival; very low‐certainty). However, this result is biased as in all but one study it was not possible to distinguish NMRD within the &lt; 1 cm thresholds. Only one study separated NMRD from SVRD; all others included NMRD in the SVRD group, which may create bias when comparing with LVRD, making interpretation challenging. </p> <p><i>MRD versus NMRD in an IDS setting</i> </p> <p>Women who had any amount of MRD after IDS had more than twice the risk of death compared to women with NMRD (HR 2.11, 95% CI 1.35 to 3.29, I<sup>2</sup> = 81%; 906 participants; very low‐certainty). </p> </section> <section id="CD015048-sec-0007"> <h3 class="title" id="CD015048-sec-0007">Authors' conclusions</h3> <p>In a PDS setting, there is moderate‐certainty evidence that the amount of RD after primary surgery is a prognostic factor for overall and progression‐free survival in women with advanced ovarian cancer. We separated our analysis into three distinct categories for the survival outcome including NMRD, SVRD and LVRD. </p> <p>After IDS, there may be only two categories required, although this is based on very low‐certainty evidence, as all but one study included NMRD in the SVRD category. The one study that separated NMRD from SVRD showed no improved survival outcome in the SVRD category, compared to LVRD. Further low‐certainty evidence also supported restricting to two categories, where women who had any amount of MRD after IDS had a significantly greater risk of death compared to women with NMRD. </p> <p>Therefore, the evidence presented in this review cannot conclude that using three categories applies in an IDS setting (very low‐certainty evidence), as was supported for PDS (which has convincing moderate‐certainty evidence). </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015048-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015048-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015048-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015048-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015048-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD015048-abs-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015048-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015048-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015048-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015048-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015048-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015048-abs-0002" lang="en"> <h3>The impact of remaining (residual) disease after surgery on the survival prognosis for women with advanced epithelial ovarian cancer </h3> <p><b>Review question</b> </p> <p>We aimed to assess the effect on survival (the 'prognostic impact') of the amount of disease remaining after surgery (residual disease) during the initial treatment stage for women with advanced ovarian cancer. We looked at both surgery before chemotherapy ('primary debulking surgery') followed by adjuvant (additional) chemotherapy and chemotherapy first ('neoadjuvant chemotherapy') followed by surgery ('interval debulking surgery'). This review should help to determine the prognostic impact of residual disease after surgery on survival and work out acceptable definitions of residual disease thresholds. </p> <p><b>Background</b> </p> <p>Ovarian cancer is the seventh most common cancer among women and a leading cause of death in women with gynaecological cancers. Ovarian cancers can develop from different cell types within the ovary/fallopian tubes. Most ovarian cancers are 'epithelial', arising from either the surface layer of the ovary or the lining of the fallopian tube. Newly diagnosed ovarian cancer is treated with a combination of surgery and chemotherapy, with surgery performed either before (called upfront or primary debulking surgery) or around the mid‐point of chemotherapy (called interval debulking surgery). Ovarian cancer has normally spread throughout the abdominal cavity by the time of diagnosis, so, unlike many other cancers, surgery is still performed, even though it may not remove the cancer in its entirety. The aim of surgery is to remove as much of the visible (macroscopic) cancer tissue as possible, which is called debulking or cytoreductive surgery. Studies have shown that the amount of the visible cancer that can be removed is likely to be an important prognostic factor for survival of women with advanced epithelial ovarian cancer. The aim of this review was to investigate how well the amount of remaining (residual) disease after surgery for newly diagnosed ovarian cancer predicts how long women will survive following a diagnosis of epithelial ovarian cancer (prognosis). </p> <p><b>Review methods</b> </p> <p>We searched electronic databases up to the end of August 2021 and we also searched for unpublished studies. We included studies that reported residual disease as a prognostic factor, which also examined other prognostic factors at the same time. </p> <p><b>Key results</b> </p> <p>We found 46 studies (including 22,376 women in 31 primary debulking surgery studies and 3697 women in 15 interval debulking surgery studies). Each study included more than 100 women, used statistical adjustment for important prognostic factors (multivariate analysis) and met our inclusion criteria. Our analyses showed the prognostic importance of surgery leaving no visible tumour deposits ('no macroscopic residual disease') both when women had upfront debulking surgery or interval debulking surgery. Both overall survival and progression‐free survival (survival without disease worsening, which was reported for upfront debulking surgery) were prolonged if this was achieved. </p> <p><i>Primary debulking surgery for newly diagnosed ovarian cancer</i> </p> <p>Complete surgical removal of all visible tumour after upfront or primary debulking surgery improved survival, and this was also the case for those with a small amount of residual disease (0.1 cm to 1 cm). There was evidence to suggest that three categories of residual disease should be used (no macroscopic residual disease, small‐volume and large‐volume residual disease (more than 1 cm). </p> <p><i>Interval debulking surgery for newly diagnosed ovarian cancer</i> </p> <p>When chemotherapy was given before surgery (interval debulking surgery), there was an association with improved survival if the remaining tumour was reduced to 'no macroscopic residual disease' (removal of all visible tumour). Women with small‐volume residual disease had no survival advantage compared to those with large‐volume residual disease, with both groups having a poorer prognosis compared to those with no visible tumour deposits; however, this evidence was of very low certainty. Any visible residual disease after interval debulking surgery was associated with poorer survival compared to women with none. </p> <p>Most interval debulking surgery studies included no visible tumour deposits in the small‐volume residual disease category, which limits our interpretation of these findings. </p> <p><b>Certainty of the evidence</b> </p> <p>We judged our certainty of the evidence as 'moderate' for overall survival and progression‐free survival in the analyses involving primary debulking surgery studies. For the interval debulking surgery studies, the certainty of evidence was very low for overall survival in all comparisons and those that involved progression‐free survival. This was largely due to all but one study including 'no macroscopic residual disease' in the small‐volume residual disease category. </p> <p><b>Main conclusions</b> </p> <p>The evidence in the review suggests that following primary debulking surgery three categories for the amount of residual disease should be used: no macroscopic residual disease, small‐volume and large‐volume residual disease. The evidence is more limited for interval debulking surgery and further studies are needed, but there may not be a survival difference between those with small‐ and large‐volume residual disease. Until there is evidence for a survival benefit for those with small‐volume compared to large‐volume residual disease, it may only be important to use two residual disease categories when classifying surgical outcomes: 'no macroscopic residual disease' and 'macroscopic residual disease' (remaining visible disease of more than 0 cm). However, this is based on very low‐certainty evidence and more information may change this finding. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015048-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015048-sec-0101"></div> <section id="CD015048-sec-0102"> <h3 class="title" id="CD015048-sec-0102">Implications for practice</h3> <p>In a primary debulking surgery (PDS) setting, this review provides moderate‐certainty evidence that residual disease (RD) after primary surgery is a strong prognostic factor for overall and progression‐free survival in women with advanced ovarian cancer. The certainty of the evidence for these outcomes was very low for studies involving interval debulking surgery (IDS). We conclude that there should be three distinct categories of RD after PDS, including no macroscopic residual disease (NMRD) (labelled as optimal), &lt; 1 cm (labelled as small‐volume residual disease (SVRD) and strictly meaning 0.1 cm to 1 cm) and &gt; 1 cm (large‐volume residual disease (LVRD)). </p> <p>After IDS, there may be only two categories required, although this is based on very low‐certainty evidence and it would be unwise to make any firm inferences or conclusions until further studies are added to the evidence base. </p> <p>It is acknowledged that there is considerable variation in achieving NMRD or SVRD between different surgeons and centres. Predicting the achievement of NMRD or SVRD prior to surgery will be dependent on this variation, resulting in difficulties in developing models of prediction, so deciding on whether to perform PDS or IDS at present is down to clinician preference. </p> <p>NMRD remains a key prognosticator of survival in advanced ovarian cancer. Whether PDS or IDS is the primary treatment, the surgical goal should be to completely remove all visible disease, although SVRD should still be regarded as a favourable outcome after PDS, as shown in this systematic review, although this is not clear following IDS. </p> <p>The evidence on the ability of different thresholds of RD to distinguish between a good and bad prognosis can aid decision‐making for clinicians and diagnosed individuals, where the survival advantage can be considered alongside any potential morbidity or adverse event trade‐offs. </p> </section> <section id="CD015048-sec-0103"> <h3 class="title" id="CD015048-sec-0103">Implications for research</h3> <p>The purpose of this systematic review was to assess RD as a prognostic factor in women who received primary surgery (PDS and IDS) for advanced epithelial ovarian cancer (stages III and IV). The results should encourage the surgical community to make trials in this area a priority. Future research should focus on investigations that determine whether increasing attempts at achieving NMRD have a direct effect in improving survival outcomes using methodologies and trial designs that reduce or eliminate confounding effects, such as the women's performance status, disease spread and tumour biology. </p> <p>Greater emphasis should be made in future studies to investigate IDS to raise the certainty of the evidence profiles. In both PDS and IDS settings, quality of life parameters and adverse effects and complications of the surgery need to be adequately addressed as there are significant deficiencies in previous studies in evaluating these outcome measures. It is unlikely that studies on prognosis will measure or report adverse events, so our focus in this review was on survival as an outcome. These additional evaluations should be given high priority, as this systematic review has identified large differences in survival outcomes associated with LVRD compared to when NMRD is achieved. The results of the SOCQER‐2 study suggest that quality of life may still be reasonable even after more extensive surgery, which is reassuring, although this was an observational study (<a href="./references#CD015048-bbs2-0221" title="SundarS , CumminsC , KumarS , LongJ , AroraV , BalegaJ , et al. Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. British Journal of Obstetrics and Gynaecology2022;129(7):1122-32. [DOI: 10.1111/1471-0528.17041] [PMCID: PMC9306902] [PMID: 34865316]">Sundar 2022</a>). An investigation of cytoreductive surgery during the initial treatment of epithelial ovarian cancer comparing PDS versus IDS has also been investigated in a TRUST (Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)) trial and we await the results in 2024 (<a href="./references#CD015048-bbs2-0214" title="ReussA , du BoisA , HarterP , FotopoulouC , SehouliJ , AlettiG , et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). International Journal of Gynecologic Cancer2019;29:1327-31.">Reuss 2019</a>). </p> <p>To avoid continuous confounding of results, observational studies should report the following to better assess the effect of surgical treatment in advanced ovarian cancer: </p> <p> <ul id="CD015048-list-0015"> <li> <p>Structural selection – the specific setting in which women are referred/seek care and which sample of the population (or population) has been chosen. </p> </li> <li> <p>To what extent the population of women with ovarian cancer are accounted for (selection of patients macro level). </p> </li> <li> <p>Institutional selection – how women were selected for surgery (choice of surgeon, patient, etc.). </p> </li> <li> <p>The extent of surgery needed to achieve complete resection, i.e. procedures and surgical complexity scores (surgical proficiency). </p> </li> <li> <p>Complete resection rates.</p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015048-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015048-sec-0008"></div> <div class="table" id="CD015048-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Small‐volume residual disease (SVRD) &lt; 1 cm versus NMRD in PDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Small‐volume residual disease (SVRD) (&lt; 1 cm) compared with NMRD after upfront primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after PDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> SVRD compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up<sup>1</sup>: </p> <p>Range: 28 to 77.7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.03</b> (1.80 to 2.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9404 participants<br/>(17 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms so we did not attempt it, as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p> </p> <p>There were no concerns with inconsistency and imprecision across studies due to restrictive inclusion criteria in a generally representative cohort of women with advanced EOC. Data were considerable in size in PDS studies with &gt; 9000 and &gt; 6500 women in the analyses of OS and PFS, respectively. </p> <p> </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may appear to represent moderate heterogeneity (as measured by the I<sup>2</sup> statistic), but we had no major concerns as the direction of effect was consistent throughout. </p> <p> </p> <p>There did not appear to be any evidence of small study biases, such as publication bias, or any irregularities with the data by visual inspection of funnel plots. While publication bias cannot be dismissed, it would take a lot of large statistically insignificant studies to overhaul the current results. Furthermore, studies showing harmful survival in women with NMRD compared to other thresholds of RD is implausible. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up<sup>1</sup>: </p> <p>Range: 28 to 77.7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR</b> </p> <p><b>1.88</b> (1.63 to 2.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6596 participants<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival; <b>SVRD:</b> small‐volume residual disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Range in <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> was 0 to 144 months. </p> <p><sup>2</sup>Downgraded by one level because was assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015048-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus no macroscopic residual disease (NMRD) in PDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>LVRD (&gt; 1 cm) compared with NMRD after upfront primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced ovarian cancer after PDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> LVRD &gt; 1 cm compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up:</p> <p>Range: 28 to 77.7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR</b> </p> <p><b>2.50</b> (2.13 to 2.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7988 participants<br/>(14 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms so we did not attempt it, as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p> </p> <p>There were no concerns with inconsistency and imprecision across studies due to restrictive inclusion criteria in a generally representative cohort of women with advanced EOC. Data were considerable in size in PDS studies with nearly n = 8000 in the analysis of OS and to lesser extent &gt; 2500 for PFS. </p> <p> </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may appear to represent moderate heterogeneity (as measured by the I<sup>2</sup> statistic), but we had no major concerns as the direction of effect was consistent throughout. </p> <p> </p> <p>There did not appear to be any evidence of small study biases, such as publication bias, or any irregularities with the data by visual inspection of funnel plots. While publication bias cannot be dismissed, it would take a lot of large statistically insignificant studies to overhaul the current results. Furthermore, studies showing harmful survival in women with NMRD compared to other thresholds of RD is implausible. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up:</p> <p>Range: 28 to 77.7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.10</b> (1.84 to 2.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2629 participants<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>LVRD</b> : large‐volume residual disease; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015048-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus small‐volume residual disease (SVRD) &lt; 1 cm in PDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>LVRD (&gt; 1 cm) compared with SVRD (&lt; 1 cm) after upfront primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after PDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> LVRD &gt; 1 cm compared with SVRD &lt; 1 cm </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up<sup>1</sup>: </p> <p>Range: 28 to 34.1 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 1.22</b> (1.13 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6000 participants<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms, so we did not attempt it as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p> </p> <p>There were no concerns with inconsistency and imprecision across studies (the smallest study comparison (n = 100) was imprecise but there were only n = 23 women with sub‐optimal RD) due to restrictive inclusion criteria in a generally representative cohort of women with advanced EOC. Data were considerable in size in PDS studies with n &gt; 6000 in the analysis of OS and to lesser extent &gt; 3000 for PFS. </p> <p> </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may not be important (as measured by the I<sup>2</sup> statistic) in meta‐analyses including PDS studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up<sup>1</sup>: 28 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR</b> </p> <p>1.30 (1.08 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3402 participants<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>LVRD</b> : large‐volume residual disease; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival; <b>SVRD:</b> small‐volume residual disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Range in <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> was 0 to 144 months. </p> <p><sup>2</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015048-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Small‐volume residual disease (SVRD) (&lt; 1 cm) versus NMRD in IDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>SVRD (&lt; 1 cm) compared with NMRD after primary interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after primary IDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> SVRD &lt; 1 cm compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.09</b> (1.20 to 3.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310 participants<br/>(1 study reporting on 2 groups) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms so we did not attempt it, as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up: 47 months</p> <p>Range: 3 to 181 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors of <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> found that the risk of disease progression for women with RD &lt; 1 cm after IDS was significantly higher than those with complete cytoreduction, but the magnitude of effect was not reported. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>IDS:</b> interval debulking surgery; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival; <b>SVRD:</b> small‐volume residual disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> <p><sup>2</sup>Downgraded by one level for sparse data. </p> <p><sup>3</sup>Downgraded by one level for lack of generalisability and validity of results as reported in single analysis or very few included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015048-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus no macroscopic residual disease (NMRD) in IDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Large‐volume residual disease (LVRD) (&gt; 1 cm) compared with NMRD after primary interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after primary IDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> LVRD &gt; 1 cm compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up:</p> <p>Not reported</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.23</b> (1.49 to 3.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343 participants<br/>(1 study reporting on 2 groups)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>123</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms, so we did not attempt it as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>IDS:</b> interval debulking surgery; <b>LVRD:</b> large‐volume residual disease; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> <p><sup>2</sup>Downgraded by one level for sparse data. </p> <p><sup>3</sup>Downgraded by one level for lack of generalisability and validity of results as reported in single analysis or very few included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015048-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus small‐volume residual disease (SVRD) &lt; 1 cm in IDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Large‐volume residual disease (LVRD) &gt; 1 cm compared with small‐volume residual disease (SVRD) &lt; 1 cm after primary interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after primary IDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> LVRD &gt; 1 cm compared with SVRD &lt; 1 cm </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up:</p> <p>Range: 34.3 to 43.5 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 1.60</b> (1.21 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1572 participants<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>verylow<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms, so we did not attempt it as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p> </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may represent substantial heterogeneity (as measured by the I<sup>2</sup> statistic) in meta‐analyses. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up</p> <p>Range: 38 to 43.5 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 1.76</b> (1.23 to 2.52)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1145 participants<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>verylow<sup>123</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>IDS:</b> interval debulking surgery; <b>LVRD:</b> large‐volume residual disease; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival; <b>SVRD:</b> small‐volume residual disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> <p><sup>2</sup>Downgraded by one level for heterogeneity across studies. </p> <p><sup>3</sup>Only one study reported a comparison of SVRD &lt; 1 cm versus LVRD &gt; 1 cm in the strict sense that SVRD &lt; 1 cm was mutually exclusive of NMRD (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015048-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Residual disease (RD) &gt; 0 cm versus NMRD in IDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Any remaining residual disease (RD) (&gt; 0 cm) compared with NMRD after primary interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after primary IDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> RD &gt; 0 cm compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up: range: 37 to 39 (reported in 2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.11</b> (1.35 to 3.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>906 participants<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms, so we did not attempt it as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent considerable heterogeneity (I<sup>2</sup> = 81%). </p> <p>The authors of <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> additionally found that the risk of death for women with any remaining RD (&gt; 0 cm) after IDS was significantly higher than those with NMRD (n = 163, P &lt; 0.01), but the magnitude of effect was not reported. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 1.36</b> (1.05 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors of <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> additionally found that the risk of disease progression for women with RD &gt; 0 cm after IDS was significantly higher than those with NMRD (n = 163, P &lt; 0.01), but the magnitude of effect was not reported. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>IDS:</b> interval debulking surgery; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> <p><sup>2</sup>Downgraded by one level for heterogeneity across studies. </p> <p><sup>3</sup>Downgraded by one level for lack of generalisability and validity of results as reported in single analysis or very few included studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015048-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015048-sec-0009"></div> <section id="CD015048-sec-0010"> <h3 class="title" id="CD015048-sec-0010">Description of the health condition and context</h3> <p>Ovarian cancer is the seventh most common cancer among women and a leading cause of death in women with gynaecological malignancies (<a href="./references#CD015048-bbs2-0187" title="(GLOBOCAN 2018) BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. Available from: http://gco.iarc.fr/today/home2018;68(394-424). [DOI: 10.3322/caac.21492]">GLOBOCAN 2018</a>). Globally, there are approaching 300,000 new cases per year, with approximately 6.6 new cases per 100,000 women per year. A woman's cumulative risk of developing ovarian cancer by the age of 75 years is 0.72%: 0.52% in low‐income countries and 0.92% in high‐income countries (<a href="./references#CD015048-bbs2-0187" title="(GLOBOCAN 2018) BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. Available from: http://gco.iarc.fr/today/home2018;68(394-424). [DOI: 10.3322/caac.21492]">GLOBOCAN 2018</a>). Ovarian cancer is rare in women under 40 years of age and most cancers in this age group are germ cell tumours. Above age 40, more than 90% are epithelial tumours and the risk increases with age (<a href="./references#CD015048-bbs2-0201" title="KurmanRJ , CarcangiuML , HerringtonCS . WHO Classification of Tumours of Female Reproductive Organs. 4 edition. Lyon: WHO Press, 2014.">Kurman 2014</a>; <a href="./references#CD015048-bbs2-0228" title="WebbPM , JordanSJ . Epidemiology of epithelial ovarian cancer. Clinical Obstetrics &amp; Gynaecology2017;41:3-14.">Webb 2017</a>). Epithelial ovarian cancer is the most common type, accounting for around 90% of all ovarian cancers. This specific type of ovarian cancer starts in the surface layer covering the ovary or lining of the fallopian tube. </p> <p>Ovarian cancer is best regarded as a peritoneal malignancy. The current understanding on the pathogenesis of epithelial ovarian cancer (EOC) recognises two pathways and two clinical groupings, classified as Type 1 and Type 2. Type 1 tumours comprise low‐grade serous, low‐grade endometrioid, clear‐cell and mucinous carcinomas, and Brenner tumours. Type 2 tumours comprise the high‐grade serous and endometrioid carcinomas, mixed mullerian tumours and undifferentiated carcinomas. Type 2 tumours are more common and are thought to have their origin within the fallopian tube (<a href="./references#CD015048-bbs2-0212" title="PeretsR , DrapkinR . It's totally tubular. Riding the new wave of ovarian cancer research. Cancer Research2016;76(1):10-7.">Perets 2016</a>). They are associated with the BRCA (breast cancer gene) germline and somatic mutations, and histopathologically identified with aberrant p53 expression and other characteristic immunohistochemical features (<a href="./references#CD015048-bbs2-0199" title="KurmanRJ , Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology2010;34(3):433-43.">Kurman 2010</a>; <a href="./references#CD015048-bbs2-0200" title="KurmanRJ , Shih IeM. Molecular pathogenesis and extra ovarian origin of epithelial ovarian cancer-shifting the paradigm. Human Pathology2011;42(7):918-31.">Kurman 2011</a>). </p> <p>The extent of dissemination of the disease is described using the International Federation of Gynecology and Obstetrics (FIGO) staging system; stage I disease is confined to the ovaries; stage II disease is confined to the true pelvis, stage III disease is an abdominal disease where there is spread to the lining (peritoneum) of the abdominal cavity outside the pelvis or regional lymph node spread; whilst stage IV disease is outside the abdomen or parenchymatous metastases, e.g. disease with spread to distant organs such as the chest or liver (<a href="./references#CD015048-bbs2-0165" title="BerekJS , KehoeST , KumarL , FriedlanderM . Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics2018;143:59-78.">Berek 2018</a>). Thirty per cent of women with ovarian cancer present with early‐stage disease, whilst 70% have advanced stage at presentation (<a href="./references#CD015048-bbs2-0224" title="TorreLA , TrabertB , DeSantisCE , MillerK , SamimiG , RunowiczC , et al. Ovarian cancer statistics. CA: a Cancer Journal for Clinicians2018;68(4):284–96.">Torre 2018</a>). In Europe, just over a third of women with ovarian cancer are alive five years after diagnosis (<a href="./references#CD015048-bbs2-0180" title="SantM , Chirlaque LopezMD , AgrestiR , Sánchez PérezMJ , HolleczekB , Bielska LasotaM , et al, EUROCARE-5 Working Group. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. European Journal of Cancer2015;51(15):2191-205.">EUROCARE 2015</a>), largely because most women with ovarian cancer are diagnosed when the cancer is already at an advanced stage (<a href="./references#CD015048-bbs2-0196" title="JemalA , WardE , JohnsonC , CroninK , MaJ , RyersonB , et al. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival Cancer Statistics. Journal of the National Cancer Institute2017;109:https://doi.org/10.1093/jnci/djx030.">Jemal 2017</a>). This is, in part, due to the biology of the disease and immediate acces to the abdominal cavity and non‐specific symptoms, which include progressive feelings of: abdominal distension, bloating, indigestion, urinary frequency, urgency, early satiety, weight loss, reduced appetite, abdominal and pelvic pain and, less commonly, vaginal bleeding (<a href="./references#CD015048-bbs2-0217" title="ShafiM , BoltonH , GajjarK , editor(s). Gynaecological Oncology for the MRCOG. Cambridge: Cambridge University Press, 2018. [DOI: 10.1017/9781316986844]">Shafi 2018</a>). </p> </section> <section id="CD015048-sec-0011"> <h3 class="title" id="CD015048-sec-0011">Description of the surgical interventions and residual disease as a prognostic factor</h3> <p>Surgery and chemotherapy are the mainstay of treatment for the 70% of women who present with advanced disease (FIGO stage III/IV) when surgery alone cannot be curative (<a href="./references#CD015048-bbs2-0181" title="FaderAN , RosePG . Role of surgery in ovarian carcinoma. Journal of Clinical Oncology2007;25(20):2873-83.">Fader 2007</a>; <a href="./references#CD015048-bbs2-0224" title="TorreLA , TrabertB , DeSantisCE , MillerK , SamimiG , RunowiczC , et al. Ovarian cancer statistics. CA: a Cancer Journal for Clinicians2018;68(4):284–96.">Torre 2018</a>). </p> <p>Appropriate initial investigations usually include ultrasonography, tumour markers and a CT scan, if malignancy is suggested by tumour markers and ultrasound. If required, an ultrasound‐guided biopsy of metastatic spread is carried out to obtain histological diagnosis (<a href="./references#CD015048-bbs2-0217" title="ShafiM , BoltonH , GajjarK , editor(s). Gynaecological Oncology for the MRCOG. Cambridge: Cambridge University Press, 2018. [DOI: 10.1017/9781316986844]">Shafi 2018</a>). </p> <p>Traditionally, upfront debulking surgery (PDS) is performed to remove as much visible disease as possible, as the amount of residual tumour is one of the most important prognostic factors for survival of epithelial ovarian cancer (<a href="./references#CD015048-bbs2-0169" title="BristowRE , TomacruzRS , ArmstrongDK , TrimbleEL , MontzFJ . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology2002;20(5):1248-59.">Bristow 2002</a>; <a href="./references#CD015048-bbs2-0171" title="ChangSJ , HodeibM , ChangJ , BristowRE . Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecologic Oncology2013;130(3):493–8.">Chang 2013</a>; <a href="./references#CD015048-bbs2-0178" title="du BoisA , ReussA , Pujade-LauraineE , HarterP , Ray-CoquardI , PfistererJ . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115(6):1234–44.">du Bois 2009</a>; <a href="./references#CD015048-bbs2-0190" title="Griffiths. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Journal of the National Cancer Institute Monographs1975;42:1014.">Griffiths 1975</a>; <a href="./references#CD015048-bbs2-0193" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma: a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology1994;170:974-80.">Hoskins 1994</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>). Platinum‐based chemotherapy is the standard of care, in combination with debulking surgery (<a href="./references#CD015048-bbs2-0173" title="ColomboN , SessaC , du BoisA , LedermannJ , McCluggageWG , McNeishI , et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology2019;30(5):672–705.">Colombo 2019</a>; <a href="./references#CD015048-bbs2-0207" title="National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, ovarian cancer including fallopian tube cancer and primary peritoneal cancer. http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf2020.">National Comprehensive Cancer Network 2020</a>). </p> <p>Chemotherapy followed by interval debulking surgery (IDS) is an alternative primary treatment option for women diagnosed with advanced ovarian cancer. A Cochrane Review, which comprised five randomised controlled trials (RCTs), comprehensively reviewed the evidence in this area (<a href="./references#CD015048-bbs2-0172" title="ColeridgeSL , BryantA , KehoeS , MorrisonJ . Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD005343. [DOI: 10.1002/14651858.CD005343]">Coleridge 2021</a>). The review assessed survival, quality of life and morbidity outcomes in trials that compared upfront primary and interval debulking surgery. The five trials included two large, well‐documented RCTs (CHORUS (<a href="./references#CD015048-bbs2-0098" title="KehoeS , HookJ , NankivellM , JaysonGC , KitchenerH , LopesT , et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet2015;386(9990):249-57. [12185455]KehoeS , HookJ , NankivellM . Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Journal of Clinical Oncology2013;31 Suppl(15):Abstract 5500. [12185456]KehoeS , WheelerS . CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=9 (accessed 18/6/2012). [12185457]LawK , MurrayC , KehoeS . CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. In: Annual Meeting of the British Gynaecological Cancer Society; 2006 Nov 30-Dec 1; Manchester, UK. 2006:90. [12185459]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185460]">Kehoe 2015</a>) and EORTC 55971 (<a href="./references#CD015048-bbs2-0150" title="GreimelE , KristensenG , VergoteI , HoskinsP , van derBurgME , Casado HerraezA , et al. Quality of life in advanced ovarian cancer patients: a randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy. International Journal of Gynaecological Cancer2011;21:S620. [12185466]GreimelE , KristensenGB , van derBurgME , CoronadoP , RustinG , delRioAS , et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology2013;131(2):437-44. [12185467]VergoteI , AmantF , KristensenG , EhlenT , ReedNS , CasadoA . Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer2011;47(Suppl 3):S88-91. [12185468]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185469]VergoteI , PecorelliS , StuartG . Intergroup Study (EORTC 55971/NCIC OV13). Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/clinicaltrials/EORTC-55971 2003 (accessed 17 June 2012). [12185470]VergoteI , TropéCG , AmantF , EhlenT , ReedNS , CasadoA . Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology2011;29(31):4076-8. [12185471]VergoteI , TropeCG , AmantF , KristensenGB , EhlenT , JohnsonN , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine2010;363(10):943-53. [12185472] [Incl. Supplementary Appendix and Protocol]VerleyeL , OttevangerPB , KristensenGB , EhlenT , JohnsonN , van derBurgME , et al. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. European Journal of Cancer2011;47(1):57-64. [12185473]">Vergote 2010</a>)), which reported no significant difference in survival between IDS compared with PDS. It was suggested that IDS may have better overall survival in stage IV disease. One included study suggested that women with FIGO stage IIIC disease with extrapelvic metastases smaller than 5 cm may have better progression‐free survival after upfront debulking (<a href="./references#CD015048-bbs2-0151" title="VergoteI , CoensC , NankivellM , KristensenG , ParmerM , EhlenT , et al. Meta-analysis of the randomized EORTC and chorus neoadjuvant versus primary debulking trials in advanced tubo-ovarian cancer. International Journal of Gynecological Cancer2016;26(Suppl 3):24-5. VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19(12):1680-7. VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19(12):1680-7. ">Vergote 2018</a>). The selection of women with advanced ovarian cancer for PDS or IDS remains controversial (<a href="./references#CD015048-bbs2-0226" title="VergoteI , du BoisA , AmantF , HeitzF , LeunenK , HarterP . Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree?Gynecologic Oncology2013;128:6-11.">Vergote 2013</a>). An investigation of maximum effort cytoreductive surgery during the initial treatment of epithelial ovarian cancer comparing PDS versus IDS is being investigated in the TRUST trial (Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)), and results are expected in 2024 (<a href="./references#CD015048-bbs2-0214" title="ReussA , du BoisA , HarterP , FotopoulouC , SehouliJ , AlettiG , et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). International Journal of Gynecologic Cancer2019;29:1327-31.">Reuss 2019</a>). </p> <p>The terms cytoreductive and debulking surgery are often used interchangeably to indicate surgical efforts aimed at removing the bulk of the tumour. No macroscopic residual disease (NMRD) (also known as 'complete' macroscopic resection or R0) is achieved when there is no visible tumour left at the end of surgery. Previously, the term 'optimal cytoreduction' had been variably defined as referring to a maximal diameter of residual tumour left behind after surgery measuring 0 to 2 cm, and in 1994 the Gynaecologic Oncology Group (GOG) defined optimal cytoreduction as having residual disease &lt; 1 cm (<a href="./references#CD015048-bbs2-0193" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma: a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology1994;170:974-80.">Hoskins 1994</a>). However, in 2010 the Gynaecological Cancer Inter‐Group defined 'optimal' as having no visible residual tumour nodules, i.e. NMRD ('complete' is a misnomer as microscopic disease remains in the majority of patients) (<a href="./references#CD015048-bbs2-0220" title="StuartGC , KitchenerH , BaconM , duBoisA , FriedlanderM , LedermannJ , et al. Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. International Journal of Gynecological Cancer2011;21(4):750–5.">Stuart 2011</a>), which has been shown to result in better survival than small‐volume residual disease (SVRD) to &lt; 1 cm (also referred to as near‐optimal) and large‐volume residual disease (LVRD) which is &gt; 1 cm (also referred to as suboptimal) and to be a better predictor of survival (<a href="./references#CD015048-bbs2-0167" title="BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419-25.">Bookman 2009</a>; <a href="./references#CD015048-bbs2-0171" title="ChangSJ , HodeibM , ChangJ , BristowRE . Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecologic Oncology2013;130(3):493–8.">Chang 2013</a>; <a href="./references#CD015048-bbs2-0178" title="du BoisA , ReussA , Pujade-LauraineE , HarterP , Ray-CoquardI , PfistererJ . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115(6):1234–44.">du Bois 2009</a>; <a href="./references#CD015048-bbs2-0222" title="SørensenSM , SchnackTH , HøgdallC . Impact of residual disease on overall survival in women with federation of gynecology and obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery. Acta Obstetricia et Gynecologica Scandinavica2019;98(1):34–43.">Sørensen 2019</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>). While there is now less controversy about the prognostic importance of maximum cytoreduction, there remains divided opinion about the effects of any remaining residual disease after PDS or IDS, and about what attempts should be made for maximal efforts at debulking. All women would potentially do better if there was NMRD after surgery, and obviously no surgeon sets out for suboptimal cytoreduction from the onset. However, different philosophies are evident within the surgical community and there are also other important considerations, such as surgical skills and training, surgical and critical care resources, the woman's fitness for more radical treatment, morbidity, mortality and quality of life. The questions about PDS in ovarian cancer that appear to have become more important and relevant over the last 10 years of practice as other evidence has emerged relate to the timing of maximal surgical effort (still within initial treatment phase), and to consideration of whether there are some histological subtypes that may have better outcomes with PDS. In this review we only consider the epithelial subtype of ovarian cancer, since it comprises 90% of histological subtypes. </p> <p>Surgery to achieve NMRD  appears to be associated with the best chance of prolonged survival (<a href="./references#CD015048-bbs2-0167" title="BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419-25.">Bookman 2009</a>). An attempt to achieve NMRD is the recommended standard for cytoreductive surgery for advanced ovarian cancer, as advised by the British Gynaecological Cancer Society (BGCS) (<a href="./references#CD015048-bbs2-0166" title="BGCS. https://www.bgcs.org.uk/wp-content/uploads/2019/05/BGCS-Guidelines-Ovarian-Guidelines-2017.pdf2017.">BGCS 2017</a>), European Society of Medical Oncology (ESMO) and European Society of Gynaecological Oncology (ESGO) (<a href="./references#CD015048-bbs2-0173" title="ColomboN , SessaC , du BoisA , LedermannJ , McCluggageWG , McNeishI , et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology2019;30(5):672–705.">Colombo 2019</a>), and the National Comprehensive Cancer Network (NCCN) (<a href="./references#CD015048-bbs2-0207" title="National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, ovarian cancer including fallopian tube cancer and primary peritoneal cancer. http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf2020.">National Comprehensive Cancer Network 2020</a>). </p> <p>A Cochrane Review assessed the role of a further attempt at cytoreductive effort after LVRD remained after primary surgery (<a href="./references#CD015048-bbs2-0223" title="TangjitgamolS , ManusirivithayaS , LaopaiboonM , LumbiganonP , BryantA . Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD006014. [DOI: 10.1002/14651858.CD006014]">Tangjitgamol 2016</a>). The results from three studies in the review found that a further attempt at cytoreductive surgery after chemotherapy in first‐line treatment was only of benefit to those who had not had their initial surgery performed by a gynaecological oncologist (<a href="./references#CD015048-bbs2-0213" title="RedmanCW , WarwickJ , LuesleyDM , VarmaR , LawtonFG , BlackledgeGR . Intervention debulking surgery in advanced epithelial ovarian cancer. British Journal of Obstetrics and Gynaecology1994;101:142-6.">Redman 1994</a>; <a href="./references#CD015048-bbs2-0120" title="RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al and the Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):89-97. ">Rose 2004</a>; <a href="./references#CD015048-bbs2-0225" title="van derBurgME , vanLentM , BuyseM , KobierskaA , ColomboN , FavalliG , et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer co-operative group of the European organization for research and treatment of cancer. New England Journal of Medicine1995;332(10):629-34.">Van der Burg 1995</a>). </p> <p>Over the last few decades, efforts have been made to increase NMRD resection rates. It has been shown that surgery performed by gynaecologists with training in gynaecological oncology, by high‐volume surgeons and high‐volume centres, is associated with increased likelihood of NMRD  (<a href="./references#CD015048-bbs2-0170" title="BristowRE , ZahurakML , Diaz-MontesTP , GiuntoliRL , ArmstrongDK . Impact of surgeon and hospital ovarian cancer surgical case volume on in hospital mortality and related short-term outcomes. Gynecologic Oncology2009;115(3):334-8.">Bristow 2009</a>; <a href="./references#CD015048-bbs2-0086" title="GreggiS , FalconeF , CarputoR , RaspagliesiF , ScaffaC , LaurelliG , et al. Primary surgical cytoreduction in advanced ovarian cancer: an outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Gynecologic Oncology2016;140(3):425-9. ">Greggi 2016</a>; <a href="./references#CD015048-bbs2-0231" title="WooYL , KyrgiouM , BryantA , EverettT , DickinsonHO . Centralisation of services for gynaecological cancer. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD007945. [DOI: 10.1002/14651858.CD007945.pub2]">Woo 2012</a>). </p> <p>There is a widespread belief that tumour biology has a significant role to play in ovarian cancer outcomes. The relationship between surgical outcome and tumour biology is complex and remains unclear. The biological rationale behind the benefit of surgical cytoreduction is that removal of certain ovarian cancer tumour cells will create a supportive microenvironment to enhance chemotherapy effect (<a href="./references#CD015048-bbs2-0174" title="CovensAL . A critique of surgical cytoreduction in advanced ovarian cancer. Gynecologic Oncology2000;78:269-74.">Covens 2000</a>; <a href="./references#CD015048-bbs2-0206" title="NapoletanoC , BellatiF , LandiR , PauselliS , MarchettiC , ViscontiV , et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. Journal of Cellular and Molecular Medicine2010;14(12):2748-59.">Napoletano 2010</a>). Whether it is the intrinsic biological behaviour of the tumour or the surgeon’s ability to cytoreduce that determines optimal cytoreduction is not well studied. However, among the relevant prognostic factors, the extent of surgery and consequent residual disease are the most important prognostic factors. The extent of surgical effort (standard versus extensive surgery) to achieve NMRD and its impact on survival is not fully understood, as determined by a previous Cochrane Review (<a href="./references#CD015048-bbs2-0194" title="HuiS , BryantA , KunongaP , GajjarK , NaikR . Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews2022, Issue In Press.">Hui 2022</a>). </p> <p>Within the advanced ovarian cancer group, women with stage IV ovarian cancer represent a heterogeneous group with extraperitoneal metastases. While it has been shown in a previously published guideline that NMRD resection is associated with the best chance of prolonged survival (<a href="./references#CD015048-bbs2-0227" title="VergoteI , VlayenJ , HeusP , HoogendamJP , DamenJA , Van de WeteringFT , et al. Ovarian cancer: diagnosis, treatment and follow-up; KCE Report 28Cs; 2016. Available at: kce.fgov.be/sites/default/files/atoms/files/KCE_268Cs_Ovarian_cancer_summary.pdf2016.">Vergote 2016</a>), the data are not as convincing for stage IV ovarian cancer. The presence of microscopic disease in the extraperitoneal locations has not been assessed and can potentially be even more frequent. While some stage IV diseases could be amenable to resection to NMRD (isolated splenic parenchymal lesion or resectable liver metastasis), others could be difficult (extensive mediastinal, axillary, or supraclavicular nodes or multiple, unresectable hepatic metastases). Therefore, it is worth investigating the impact of residual disease in stage IV cancers, and in particular in relation to extra‐peritoneal residual disease (thoracic, mediastinum, groin, axilla, neck). The EORTC55971 trial confirmed that neoadjuvant chemotherapy results in superior survival compared with primary debulking surgery in the management of women with stage IV disease (<a href="./references#CD015048-bbs2-0150" title="GreimelE , KristensenG , VergoteI , HoskinsP , van derBurgME , Casado HerraezA , et al. Quality of life in advanced ovarian cancer patients: a randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy. International Journal of Gynaecological Cancer2011;21:S620. [12185466]GreimelE , KristensenGB , van derBurgME , CoronadoP , RustinG , delRioAS , et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology2013;131(2):437-44. [12185467]VergoteI , AmantF , KristensenG , EhlenT , ReedNS , CasadoA . Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer2011;47(Suppl 3):S88-91. [12185468]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185469]VergoteI , PecorelliS , StuartG . Intergroup Study (EORTC 55971/NCIC OV13). Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/clinicaltrials/EORTC-55971 2003 (accessed 17 June 2012). [12185470]VergoteI , TropéCG , AmantF , EhlenT , ReedNS , CasadoA . Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology2011;29(31):4076-8. [12185471]VergoteI , TropeCG , AmantF , KristensenGB , EhlenT , JohnsonN , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine2010;363(10):943-53. [12185472] [Incl. Supplementary Appendix and Protocol]VerleyeL , OttevangerPB , KristensenGB , EhlenT , JohnsonN , van derBurgME , et al. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. European Journal of Cancer2011;47(1):57-64. [12185473]">Vergote 2010</a>). However, there is a need for further investigation into the impact of residual disease on survival between the PDS and IDS subgroups. </p> <p>This review sets out to determine the prognostic impact of residual disease on survival rates in women with advanced epithelial ovarian cancer. There are no universally established patient selection criteria, but certain baseline characteristics are important when investigating the impact of residual disease on prognosis. These include age, nutritional status, FIGO stage, comorbidities, ASA score (American Society of Anaesthesiologists’ (ASA) classification of Physical Health), ECOG (Eastern Cooperative Oncology Group) performance status (score of symptom and functional status with respect to ambulatory status and need for care), BRCA status, presence of ascites on preoperative imaging and histological grade (<a href="./references#CD015048-bbs2-0178" title="du BoisA , ReussA , Pujade-LauraineE , HarterP , Ray-CoquardI , PfistererJ . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115(6):1234–44.">du Bois 2009</a>). To date, there are no specific predictive models for surgical success that are clinically useful, and the majority of previous studies have limitations in design that make their interpretation difficult (<a href="./references#CD015048-bbs2-0168" title="BorleyJ , Wilhelm-BenartziC , BrownR , Ghaem-MaghamiS . Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. British Journal of Cancer2012;107(7):1069-74.">Borley 2012</a>). </p> <p>If the surgical outcome and prognosis are to be determined by tumour biology alone, the residual disease after surgery may have little influence on overall survival. However, tumour biology and the extent of disease may influence the likelihood of achieving NMRD  after surgery (<a href="./references#CD015048-bbs2-0173" title="ColomboN , SessaC , du BoisA , LedermannJ , McCluggageWG , McNeishI , et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology2019;30(5):672–705.">Colombo 2019</a>). The extent of residual disease and prognosis could be influenced by the extent of disease measured intraoperatively by the peritoneal cancer index (PCI) score, surgical complexity score (SCS) (<a href="./references#CD015048-bbs2-0179" title="ElzarkaaAA , ShaalanW , ElemamD , MansourH , MelisM , MalikE , et al. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. Journal of Gynecologic Oncology2018;29(4):e47.">Elzarkaa 2018</a>), type and extent of surgery (<a href="./references#CD015048-bbs2-0163" title="AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;187(6):676.">Aletti 2007</a>), characteristics of the surgical team (gynaecological oncologist in a specialist centre with a high volume of cases) (<a href="./references#CD015048-bbs2-0170" title="BristowRE , ZahurakML , Diaz-MontesTP , GiuntoliRL , ArmstrongDK . Impact of surgeon and hospital ovarian cancer surgical case volume on in hospital mortality and related short-term outcomes. Gynecologic Oncology2009;115(3):334-8.">Bristow 2009</a>) and presence of ascites during surgery (<a href="./references#CD015048-bbs2-0178" title="du BoisA , ReussA , Pujade-LauraineE , HarterP , Ray-CoquardI , PfistererJ . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115(6):1234–44.">du Bois 2009</a>). </p> </section> <section id="CD015048-sec-0012"> <h3 class="title" id="CD015048-sec-0012">Why it is important to do this review</h3> <p>A greater understanding of the biology of ovarian cancer variants, especially with respect to BRCA gene mutations, has led to more sophisticated treatment regimens. These include the emergence of tailored adjuvant and maintenance chemotherapeutic options for women with BRCA somatic and germline mutations, and greater options for the chemotherapeutic approach to recurrent disease (<a href="./references#CD015048-bbs2-0173" title="ColomboN , SessaC , du BoisA , LedermannJ , McCluggageWG , McNeishI , et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology2019;30(5):672–705.">Colombo 2019</a>). </p> <p>While the place of surgery in the context of treatment of ovarian cancer is well established, the distinctive biological phenotypes (e.g. type and grade of disease, extent of disease) should be anticipated to lead to some heterogeneity in the level of benefit derived from maximal surgical effort. There may be a greater willingness to rely on PDS for women with known subtypes of disease, such as low‐grade serous cancer, that are known to be less chemo‐responsive (<a href="./references#CD015048-bbs2-0188" title="GrabowskiJP , HarterP , HeitzF , Pujade-LauraineE , ReussA , KristensenG , et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecologic Oncology2016;140(3):457-62.">Grabowski 2016</a>). PDS for highly chemo‐responsive disease has also been questioned by a growing acceptance of the non‐inferiority of interval debulking surgery (<a href="./references#CD015048-bbs2-0172" title="ColeridgeSL , BryantA , KehoeS , MorrisonJ . Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD005343. [DOI: 10.1002/14651858.CD005343]">Coleridge 2021</a>). The current position in many settings, in the UK and elsewhere, is to reserve PDS in advanced disease for those women who have a good performance status, and in whom it is anticipated that NMRD or SVRD can be achieved. Performance status is relevant in consideration of PDS. Though true advocates of PDS remain, many clinicians recognise that women presenting with poor performance status are likely to be too frail to undergo a PDS without significant comorbidity. In such a situation, clinical optimisation and initiation of treatment with chemotherapy is preferable with a possible benefit of reduced morbidity by reduction in disease burden with chemotherapy (<a href="./references#CD015048-bbs2-0198" title="KumarA , LangstraatCL , DeJongSR , McGreeME , Bakkum-GamezJN , WeaverAL , et al. Functional not chronologic age: frailty index predicts outcomes in advanced ovarian cancer. Gynecologic Oncology2017;147(1):104-9.">Kumar 2017</a>). </p> <p>There is consensus that the surgery performed during the initial treatment of ovarian cancer, whether PDS or IDS, should aim to leave NMRD, if possible. The need for clarity on the location (cancer centre or unit) and timing from diagnosis of first look surgery (intensive staging and cytoreductive surgery) for advanced ovarian cancer has never been more relevant. Women, clinicians and commissioners of specialist cancer services need to know what the overall benefit of cytoreductive surgery for ovarian cancer is, and to determine if there are subgroups of women for whom this intervention is of greater value. Given the diversity recognised within the overall group of women with advanced‐stage ovarian cancer, it is anticipated that an ethos of individualised surgical planning, whilst recognising overarching principles, would be appropriate. One recent cohort study compared operative approaches/philosophies, where an ultra‐radical approach to surgery was introduced at a population level (<a href="./references#CD015048-bbs2-0182" title="FalconerH , JoneborgU , KrawiecK , PalsdottirK , BottaiM , SalehiS . Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population. Gynecologic Oncology2020;159(1):58-65.">Falconer 2020</a>). In this population‐based cohort study, all women with suspected EOC in a region of Stockholm in two national cancer registries were selected in two three‐year cohorts, based on year of diagnosis (before (cohort 1) or after (cohort 2) change in surgical treatment algorithm) and followed for at least three years. The study reported five‐year overall survival in non‐surgically and surgically treated women. A similar study into system reorganisation that uses either a controlled before‐and‐after component or interrupted time series design would be able to look at the impact of any centralisation of more radical surgery on survival. </p> <p>Although the size of residual tumour mass after surgery has been shown to be an important prognostic factor for advanced ovarian cancer, there is limited evidence to support the conclusion that the surgical procedure is directly responsible for the superior outcome associated with less residual disease (<a href="./references#CD015048-bbs2-0186" title="GirlingJC , SoutterWP . Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: a topic for debate. International Journal of Gynecological Cancer1996;1:81-4.">Girling 1996</a>; <a href="./references#CD015048-bbs2-0195" title="HunterRW , AlexanderND , SoutterWP . Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis?American Journal of Obstetrics and Gynecology1992;166:504-11.">Hunter 1992</a>). </p> <p>Whether optimal cytoreduction is more feasible in women with biologically less aggressive tumours is a subject of continued debate. Tumour biology is not thought to be the only factor affecting prognosis (<a href="./references#CD015048-bbs2-0222" title="SørensenSM , SchnackTH , HøgdallC . Impact of residual disease on overall survival in women with federation of gynecology and obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery. Acta Obstetricia et Gynecologica Scandinavica2019;98(1):34–43.">Sørensen 2019</a>), and its impact seems to be partially overruled by the extent of residual disease, i.e. whether NMRD or SVRD was achieved (<a href="./references#CD015048-bbs2-0178" title="du BoisA , ReussA , Pujade-LauraineE , HarterP , Ray-CoquardI , PfistererJ . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115(6):1234–44.">du Bois 2009</a>). It has also been suggested that further evaluation of biological factors may help select women who are most likely to benefit from PDS (<a href="./references#CD015048-bbs2-0178" title="du BoisA , ReussA , Pujade-LauraineE , HarterP , Ray-CoquardI , PfistererJ . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115(6):1234–44.">du Bois 2009</a>; <a href="./references#CD015048-bbs2-0202" title="MakarAP , TropéCG , TummersP , DenysH , VandecasteeleK . Advanced ovarian cancer: primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: Primary ebulking surgery and interval debulking surgery for advanced ovarian cancer. Oncologist2016;21(6):745‐54.">Markar 2016</a>). It has been suggested that women whose cancer is cytoreduced to NMRD and SVRD at PDS may have super‐imposable progression‐free survival, meaning that women with high tumour load, completely resected at the time of surgery, may have micro/macroscopic unrecognised residual disease (<a href="./references#CD015048-bbs2-0079" title="FagottiA , FerrandinaG , VizzielliG , FanfaniF , GallottaV , ChianteraV , et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. European Journal of Cancer2016;59:22-33. [12185453]FagottiA , FerrandinaMG , VizzielliG , PasciutoT , FanfaniF , GallottaV , et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer2020;30(11):1657-64. [PMID: 10.1136/ijgc-2020- 001640]FagottiA , VizzielliG , FerrandinaG , FanfaniF , GallottaV , ChianteraV , et al. Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial). Journal of Clinical Oncology2018;36(15):5516. [12185454]">Fagotti 2020</a>). In this review, we will analyse PDS and IDS separately, as PDS achieving cytoreduction to &lt; 1 cm may be equivalent to IDS achieving cytoreduction to NMRD. </p> <p>The aim of this review is to investigate the effects of residual disease in women who received PDS or IDS for advanced epithelial ovarian cancer. This review should help to determine the prognostic impact of residual disease after surgery on survival. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015048-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015048-sec-0013"></div> <p>To assess the prognostic impact of residual disease after primary surgery on survival outcomes or advanced (stage III and IV) epithelial ovarian cancer. In separate analyses, primary surgery included both upfront primary debulking surgery (PDS) followed by adjuvant chemotherapy and neoadjuvant chemotherapy followed by interval debulking surgery (IDS). Each residual disease threshold is considered as a separate prognostic factor. </p> <section id="CD015048-sec-0014"> <h3 class="title" id="CD015048-sec-0014">Investigation of sources of heterogeneity</h3> <p>We examined differences between FIGO stages III and IV in different thresholds of residual disease after primary surgery. We considered factors such as age, grade, length of follow‐up, type and experience of surgeon, and type of surgery in the interpretation of any heterogeneity. </p> <p>We also performed sensitivity analyses that distinguished between studies that included NMRD in residual disease (RD) categories of &lt; 1 cm and those that did not. This was applicable to comparisons involving RD &lt; 1 cm with the exception of RD &lt; 1 cm versus NMRD. </p> <p>We evaluated women undergoing PDS and IDS in separate analyses.</p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015048-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015048-sec-0015"></div> <section id="CD015048-sec-0016"> <h3 class="title" id="CD015048-sec-0016">Criteria for considering studies for this review</h3> <section id="CD015048-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included data from RCTs, prospective and retrospective cohort studies, and unselected case series of 100 or more women that included a concurrent comparison of different RD thresholds after primary surgical intervention. Any data collected from RCTs were retrospective and taken from trials that randomised groups of women to various chemotherapy protocols after primary or interval debulking surgery. We categorised the surgical outcome as macroscopic, optimal and suboptimal debulking, based on the maximum size of postoperative residual disease. </p> <p>In order to minimise bias, we only included studies of multivariate Cox regression models that used sensible adjustment factors associated with survival in women with advanced EOC (e.g. age, stage, grade, extent of disease at diagnosis). We excluded studies that only reported unadjusted results. To assess the adequacy of adjustment factors used in multivariate Cox models, we used the 'adjustment for other prognostic factors' and 'statistical analysis and reporting' domains of the quality in prognosis studies (QUIPS) tool (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). Therefore, in theory, only one other factor needed to be adjusted for the study to meet the criteria for inclusion in the review, but we judged such studies as being at high risk of bias in these domains. </p> <p>We excluded case‐control studies, studies that did not have concurrent comparison groups and case series of fewer than 100 women. This was to attempt to optimise the quality of the review, as poor study designs would have introduced additional forms of bias. The inclusion of adequately sized studies, although pragmatic, may also provide more reliable estimates due to restricting results to those reporting multiple adjustments in statistical models. </p> </section> <section id="CD015048-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adult women (over 18 years of age) with surgically staged advanced epithelial ovarian cancer (FIGO stages III and IV) who had confirmed histological diagnoses. We excluded women with other concurrent malignancies. </p> <p>Women were included into two distinct groups: those who received primary debulking surgery (PDS) followed by platinum‐based chemotherapy and those who received interval debulking surgery (IDS), which involves receiving the surgery sandwiched between a schedule of chemotherapy. We analysed these distinct groups separately. </p> </section> <section id="CD015048-sec-0019"> <h4 class="title">Details of prognostic factor</h4> <p>The surgical intervention for which we assessed the resulting prognostic factor was primary debulking surgery (upfront and interval debulking). </p> <p>We included studies that reported all RD thresholds after surgery but we defined optimal RD as surgery leading to residual tumours with a maximum diameter of any threshold up to 1 cm. The main RD thresholds of interest were microscopic RD (labelled as no macroscopic residual disease (NMRD)); RD &lt; 1 cm and exclusive of 0 cm, categorised as small‐volume residual disease (SVRD); and RD &gt; 1 cm, categorised as large‐volume residual disease (LVRD). However, we included studies reporting any size of RD but restricted to the most pertinent comparisons in key summary sections. We noted details of any women who had primary surgery that resulted in RD that did not meet the criteria specified in the study as ‘optimal’, namely not categorised as NMRD or SVRD cytoreduction. </p> <p>We applied the above RD thresholds to both PDS (primary debulking surgery followed by platinum‐based chemotherapy) and IDS (platinum‐based chemotherapy followed by interval debulking surgery) settings. </p> <p> <ul id="CD015048-list-0001"> <li> <p>No macroscopic residual disease (NMRD) after PDS (RD = 0 cm).</p> </li> <li> <p>Small‐volume residual disease (SVRD) after primary cytoreduction (RD 0.1 cm to 1 cm).</p> </li> <li> <p>Large‐volume residual disease (LVRD) after cytoreduction (RD &gt; 1 cm).</p> </li> </ul> </p> </section> <section id="CD015048-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p> <ul id="CD015048-list-0002"> <li> <p>Overall survival: survival until death from any cause. We assessed survival from the time at which women were enrolled in the study. </p> </li> <li> <p>Progression‐free survival.</p> </li> </ul> </p> <p>We extracted survival estimates as time‐to‐event data from an adjusted multivariate Cox model (as outlined above in 'Types of studies'). This is the most appropriate way to analyse these outcomes as it accounts for any loss to follow‐up and will correctly allow for censoring. </p> </section> </section> <section id="CD015048-sec-0021"> <h3 class="title" id="CD015048-sec-0021">Search methods for identification of studies</h3> <p>We sought papers in all languages and translated them when necessary.</p> <p>We searched the following electronic databases on 30 August 2021:</p> <p> <ul id="CD015048-list-0003"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 8), in the Cochrane Library; </p> </li> <li> <p>MEDLINE via Ovid (1950 to 30 August 2021);</p> </li> <li> <p>Embase via Ovid (1950 to 2021 week 34).</p> </li> </ul> </p> <p>The MEDLINE, EMBASE and CENTRAL search strategies were based on terms related to the review topic and are presented in <a href="./appendices#CD015048-sec-0107">Appendix 1</a>, <a href="./appendices#CD015048-sec-0108">Appendix 2</a> and <a href="./appendices#CD015048-sec-0109">Appendix 3</a>, respectively. We searched the databases from 1950 up to end of August 2021. </p> <p>We identified all relevant articles found on PubMed and used the 'related articles' feature to carry out a further search for newly published articles. </p> <section id="CD015048-sec-0022"> <h4 class="title">Searching other resources</h4> <section id="CD015048-sec-0023"> <h5 class="title">Unpublished and grey literature</h5> <p>We searched metaRegister, Physicians Data Query, <a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled-trials.com/rct</a>, <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> and <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a> for ongoing trials. </p> </section> <section id="CD015048-sec-0024"> <h5 class="title">Handsearching</h5> <p>We checked the citation lists of relevant publications, abstracts of scientific meetings and included studies through handsearching, and we contacted experts in the field to identify further reports of studies. We handsearched reports of conferences from the following sources. </p> <p> <ul id="CD015048-list-0004"> <li> <p><i>Gynecologic Oncology</i> (Annual Meeting of the American Society of Gynecologic Oncologists). </p> </li> <li> <p><i>International Journal of Gynecological Cancer</i> (Annual Meeting of the International Gynecologic Cancer Society). </p> </li> <li> <p><i>British Journal of Cancer</i>. </p> </li> <li> <p>British Cancer Research Meeting.</p> </li> <li> <p>Annual Meeting of European Society of Medical Oncology (ESMO).</p> </li> <li> <p>Annual Meeting of the American Society of Clinical Oncology (ASCO).</p> </li> </ul> </p> </section> <section id="CD015048-sec-0025"> <h5 class="title">Correspondence</h5> <p>We contacted authors of relevant trials to ask if they knew of further data, which may or may not have been published. </p> </section> </section> </section> <section id="CD015048-sec-0026"> <h3 class="title" id="CD015048-sec-0026">Data collection and analysis</h3> <section id="CD015048-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to the reference management database Endnote. After removing duplicates, three review authors (AB, PK, SH) examined the remaining references independently. We excluded those studies that clearly did not meet the inclusion criteria and obtained copies of the full text of potentially relevant references. Three review authors (AB, PK, SH) assessed the eligibility of retrieved papers independently. We resolved disagreements by discussion between the three review authors or, when necessary, by appeal to a fourth review author (RN, KG). We documented the reasons for exclusion. </p> </section> <section id="CD015048-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For included studies, we extracted items relevant to prognostic factor studies, derived from the checklist for critical appraisal and data extraction for systematic reviews of prediction modelling studies (CHARMS) (<a href="./references#CD015048-bbs2-0204" title="MoonsKGM , deGrootJAH , BouwmeesterW , VergouweY , MallettS , AltmanDG , et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLOS Medicine2014;11(10):e1001744.">Moons 2014</a>). This included data on the following: </p> <p> <ul id="CD015048-list-0005"> <li> <p>Author, year of publication and journal citation (including language).</p> </li> <li> <p>Country.</p> </li> <li> <p>Setting.</p> </li> <li> <p>Inclusion and exclusion criteria.</p> </li> <li> <p>Study design, methodology.</p> </li> <li> <p>Study population:</p> <ul id="CD015048-list-0006"> <li> <p>total number enrolled in each group;</p> </li> <li> <p>participant characteristics;</p> </li> <li> <p>age;</p> </li> <li> <p>comorbidities.</p> </li> </ul> </li> <li> <p>Ovarian cancer details at diagnosis:</p> <ul id="CD015048-list-0007"> <li> <p>FIGO stage (III or IV);</p> </li> <li> <p>histological cell type;</p> </li> <li> <p>preoperative tumour volume;</p> </li> <li> <p>ascites (large or small volume);</p> </li> <li> <p>tumour grade;</p> </li> <li> <p>extent of disease.</p> </li> </ul> </li> <li> <p>Surgical intervention details:</p> <ul id="CD015048-list-0008"> <li> <p>details of primary optimal cytoreductive surgery;</p> </li> <li> <p>upfront and interval debulking settings.</p> </li> </ul> </li> <li> <p>Details of platinum‐based chemotherapy:</p> <ul id="CD015048-list-0009"> <li> <p>dose;</p> </li> <li> <p>number of chemotherapy cycles before and after surgery;</p> </li> <li> <p>type of surgeon (gynaecological oncologist, gynaecologist, general surgeon);</p> </li> <li> <p>experience of surgeon;</p> </li> <li> <p>type of surgery (ultra‐radical or standard).</p> </li> </ul> </li> <li> <p>Details of prognostic factor:</p> <ul id="CD015048-list-0010"> <li> <p>details of residual disease;</p> </li> <li> <p>definition of residual disease thresholds in study;</p> </li> <li> <p>covariates included in multivariate Cox models for survival that include residual disease. </p> </li> </ul> </li> <li> <p>Risk of bias in study (see 'Assessment of risk of bias in included studies').</p> </li> <li> <p>Duration of follow‐up.</p> </li> <li> <p>Outcomes (see 'Types of outcome measures').</p> </li> </ul> </p> <p>For time‐to‐event data (survival and progression‐free survival), we extracted the log of the hazard ratio (log(HR)) and its standard error from study reports. If the study did not report these, we did not attempt to estimate the log(HR) and its standard error using the methods of <a href="./references#CD015048-bbs2-0211" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>, as we only included adjusted analyses. </p> <p>We noted the time points at which outcomes were collected and reported.</p> <p>Three review authors (AB, PK, SH) independently extracted data using a data collection form specially designed for the review. We resolved differences between review authors by discussion or by appeal to a fourth review author (KG), when necessary. </p> </section> <section id="CD015048-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors independently extracted data and assessed risk of bias. We extracted the data using the CHARMS‐PF (checklist for critical appraisal and data extraction for systematic reviews ‐ prognostic factor studies; <a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). We assessed the risk of bias for each outcome (overall survival and progression‐free survival) in each study. We assessed risk of bias (and appraised quality) in the prognostic assessment of residual disease in the included studies using the quality in prognosis studies (QUIPS) tool (<a href="./appendices#CD015048-sec-0110">Appendix 4</a>). QUIPS is a tool designed to assess risk of bias in prognostic factor studies (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). It assesses bias across the following six domains using intermediate signalling questions to aid the decision‐making process. </p> <p> <ol id="CD015048-list-0011"> <li> <p>Participant selection</p> </li> <li> <p>Study attrition</p> </li> <li> <p>Prognostic factor measurement</p> </li> <li> <p>Outcome measurement</p> </li> <li> <p>Adjustment for other prognostic factors</p> </li> <li> <p>Statistical analysis and reporting</p> </li> </ol> </p> <p>In addition, we considered the applicability of the study for four of the domains, as reported in other tools (<a href="./references#CD015048-bbs2-0229" title="WhitingPF , RutjesAW , WestwoodME , MallettS , Deeks, JJ, ReitsmaJB , et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529-36.">Whiting 2011</a>; <a href="./references#CD015048-bbs2-0230" title="WolffRF , MoonsKGM , RileyRD , WhitingPF , WestwoodM , CollinsGS , et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Annals of Internal Medicine2019;170(1):51-8.">Wolff 2019</a>). We judged risk of bias and concerns regarding applicability using the tools shown in <a href="./appendices#CD015048-sec-0110">Appendix 4</a>. The questions regarding applicability included the following. </p> <p> <ul id="CD015048-list-0012"> <li> <p>Domain 1: participant selection. Are there concerns that the included women do not match the review question? </p> </li> <li> <p>Domain 3: prognostic factor measurement. Are there concerns that residual disease, the way that it is measured, or the way that it is interpreted, differ from the review question? </p> </li> <li> <p>Domain 4: outcome measurement. Are there concerns that the outcome does not match the review question or that follow‐up was not of sufficient duration? </p> </li> <li> <p>Domain 5: adjustment for other prognostic factors. Did the prognostic factors adjusted for match the review question? </p> </li> </ul> </p> <p>Three review authors (AB, PK, SH) applied the risk of bias tool independently and resolved differences by discussion or by appeal to a fourth review author (KG). We presented the results in a risk of bias summary table. We interpreted the results of meta‐analyses in light of the findings with respect to risk of bias. </p> </section> <section id="CD015048-sec-0030"> <h4 class="title">Measures of effect</h4> <p>For time‐to‐event data (overall and progression‐free survival), we used the adjusted hazard ratio (HR). We did not use unadjusted results, as outlined above in 'Types of studies'. </p> </section> <section id="CD015048-sec-0031"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing outcome data for any of the outcomes.</p> </section> <section id="CD015048-sec-0032"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies by visual inspection of forest plots, by estimation of the percentage of heterogeneity between trials that cannot be ascribed to sampling variation (<a href="./references#CD015048-bbs2-0192" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD015048-bbs2-0176" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.">Deeks 2001</a>), and, where possible, by subgroup analyses (see 'Subgroup analysis and investigation of heterogeneity'). If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this. </p> </section> <section id="CD015048-sec-0033"> <h4 class="title">Assessment of reporting biases</h4> <p>We examined the symmetry of funnel plots corresponding to meta‐analyses of overall survival to assess the potential for small study effects in analyses containing 10 or more studies. We tested for asymmetry where evidence of asymmetry may have been an indicator of publication bias (<a href="./references#CD015048-bbs2-0175" title="DebrayTPA , MoonsKGM , RileyRD . Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests. Research Synthesis Methods2018;9(1):41-50.">Debray 2018</a>; <a href="./references#CD015048-bbs2-0219" title="SterneJAC , EggerM , Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.">Sterne 2011</a>). </p> </section> <section id="CD015048-sec-0034"> <h4 class="title">Data synthesis</h4> <p>If sufficient clinically similar studies were available, we pooled their adjusted results in meta‐analyses. We reported results by FIGO stage (see 'Subgroup analysis and investigation of heterogeneity'). </p> <p> <ul id="CD015048-list-0013"> <li> <p>For time‐to‐event data, we pooled hazard ratios (HRs) using the generic inverse variance facility of <a href="./references#CD015048-bbs2-0215" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>. </p> </li> <li> <p>We used random‐effects models with inverse variance weighting for all meta‐analyses (<a href="./references#CD015048-bbs2-0177" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">DerSimonian 1986</a>). </p> </li> <li> <p>We reported analyses separately for women who received upfront and interval debulking surgery. </p> </li> </ul> </p> </section> <section id="CD015048-sec-0035"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We considered factors such as age, grade, length of follow‐up, type and experience of surgeon, and type of surgery in the interpretation of any heterogeneity. </p> <p>We performed subgroup analyses grouping studies by women with FIGO stage III versus stage IV disease. </p> <p>We analysed women undergoing PDS and IDS in separate analyses (see above).</p> </section> <section id="CD015048-sec-0036"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to perform sensitivity analysis that restricted the analyses to studies we judged to be at an overall low risk of bias. However, the overall profiles of the included studies were largely very similar. </p> <p>We performed a sensitivity analysis that distinguished between studies that included NMRD in residual disease categories of &lt; 1 cm and those that did not. This was applicable to some comparisons involving RD &lt; 1 cm, with the exception of SVRD versus NMRD. In this area, RD &lt;1 cm should be exclusive of NMRD and is often described as RD = 0.1 cm to 1 cm in the literature, for clarity. </p> <p>We also conducted a number of post hoc sensitivity analyses. This included excluding one study (<a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>), which included a proportion of women with early and unknown stage disease. </p> </section> <section id="CD015048-sec-0037"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Guidance on the use of GRADE for prognostic factor studies has not yet been published (<a href="./references#CD015048-bbs2-0184" title="ForoutanF , GuyattG , ZukV , VandvikPO , AlbaAC , MustafaR , et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. Journal of Clinical Epidemiology2020;121:62-70. [DOI: 10.1016/j.jclinepi.2019.12.023; PubMed: 31982539]">Foroutan 2020</a>; <a href="./references#CD015048-bbs2-0189" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490-4.">GRADE Working Group</a>), but we attempted to appraise the quality and certainty of the evidence where possible. We constructed summary of findings tables to present the results of outcomes in the review for the main comparisons involving prognostic factor thresholds of NMRD, SVRD (0.1 cm to 1cm) and LVRD. We used the GRADE system to rank the certainty of the evidence (<a href="./references#CD015048-bbs2-0184" title="ForoutanF , GuyattG , ZukV , VandvikPO , AlbaAC , MustafaR , et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. Journal of Clinical Epidemiology2020;121:62-70. [DOI: 10.1016/j.jclinepi.2019.12.023; PubMed: 31982539]">Foroutan 2020</a>; <a href="./references#CD015048-bbs2-0189" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490-4.">GRADE Working Group</a>). Two review authors (AB, SH) independently graded the evidence and resolved differences by discussion or by involving a third review author (PK). We based our judgements on the strength of the body of evidence based on the domains presented in <a href="./appendices#CD015048-sec-0111">Appendix 5</a>. Where the evidence was based on single studies, or where there was no evidence on a specific outcome for comparisons, we included the outcome in the summary of findings table and graded or explained in a narrative account accordingly. We gave the rationale for each judgement in the table footnotes. We interpreted the results of the review in light of this graded evidence. Summary of findings tables are given for PDS studies in <a href="./full#CD015048-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD015048-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD015048-tbl-0003">summary of findings Table 3</a> and in IDS studies in <a href="./full#CD015048-tbl-0004">summary of findings Table 4</a>, <a href="./full#CD015048-tbl-0005">summary of findings Table 5</a> and <a href="./full#CD015048-tbl-0006">summary of findings Table 6</a>. The comparison involving any remaining macroscopic disease (RD &gt; 0 cm) and NMRD in an IDS setting was also an important comparison so we additionally gave this a certainty of evidence judgement (<a href="./full#CD015048-tbl-0007">summary of findings Table 7</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015048-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015048-sec-0038"></div> <section id="CD015048-sec-0039"> <h3 class="title" id="CD015048-sec-0039">Results of the search</h3> <p>The search strategy identified 8606 unique references (<a href="#CD015048-fig-0001">Figure 1</a>). The title and abstract screening of these references identified 200 studies as potentially eligible for the review. The full‐text screening of the 200 references identified 13 references, reporting on two RCTs (<a href="./references#CD015048-bbs2-0098" title="KehoeS , HookJ , NankivellM , JaysonGC , KitchenerH , LopesT , et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet2015;386(9990):249-57. [12185455]KehoeS , HookJ , NankivellM . Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Journal of Clinical Oncology2013;31 Suppl(15):Abstract 5500. [12185456]KehoeS , WheelerS . CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=9 (accessed 18/6/2012). [12185457]LawK , MurrayC , KehoeS . CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. In: Annual Meeting of the British Gynaecological Cancer Society; 2006 Nov 30-Dec 1; Manchester, UK. 2006:90. [12185459]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185460]">Kehoe 2015</a>; <a href="./references#CD015048-bbs2-0150" title="GreimelE , KristensenG , VergoteI , HoskinsP , van derBurgME , Casado HerraezA , et al. Quality of life in advanced ovarian cancer patients: a randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy. International Journal of Gynaecological Cancer2011;21:S620. [12185466]GreimelE , KristensenGB , van derBurgME , CoronadoP , RustinG , delRioAS , et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology2013;131(2):437-44. [12185467]VergoteI , AmantF , KristensenG , EhlenT , ReedNS , CasadoA . Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer2011;47(Suppl 3):S88-91. [12185468]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185469]VergoteI , PecorelliS , StuartG . Intergroup Study (EORTC 55971/NCIC OV13). Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/clinicaltrials/EORTC-55971 2003 (accessed 17 June 2012). [12185470]VergoteI , TropéCG , AmantF , EhlenT , ReedNS , CasadoA . Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology2011;29(31):4076-8. [12185471]VergoteI , TropeCG , AmantF , KristensenGB , EhlenT , JohnsonN , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine2010;363(10):943-53. [12185472] [Incl. Supplementary Appendix and Protocol]VerleyeL , OttevangerPB , KristensenGB , EhlenT , JohnsonN , van derBurgME , et al. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. European Journal of Cancer2011;47(1):57-64. [12185473]">Vergote 2010</a>), but these trials did not meet the inclusion criteria as they did not report results across residual disease thresholds; instead they gave comparisons of residual disease by type of surgery. These trials were reported in a recent Cochrane Review (<a href="./references#CD015048-bbs2-0172" title="ColeridgeSL , BryantA , KehoeS , MorrisonJ . Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD005343. [DOI: 10.1002/14651858.CD005343]">Coleridge 2021</a>), which assessed chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer along with another three trials (<a href="./references#CD015048-bbs2-0066" title="ChekmanC , LayouneR , HocineO , RaissiN , FerhatHA , Ali KhodjaH , et al. An open prospective randomized trial comparing primary complete cytoreduction surgery to debulking surgery after chemotherapy in advanced stage (FIGO's IIIC) ovarian carcinoma. In: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015; 2015 Oct 24-27; Nice, France. 2015:1316. [12185451]">Chekman 2015</a>; <a href="./references#CD015048-bbs2-0079" title="FagottiA , FerrandinaG , VizzielliG , FanfaniF , GallottaV , ChianteraV , et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. European Journal of Cancer2016;59:22-33. [12185453]FagottiA , FerrandinaMG , VizzielliG , PasciutoT , FanfaniF , GallottaV , et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer2020;30(11):1657-64. [PMID: 10.1136/ijgc-2020- 001640]FagottiA , VizzielliG , FerrandinaG , FanfaniF , GallottaV , ChianteraV , et al. Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial). Journal of Clinical Oncology2018;36(15):5516. [12185454]">Fagotti 2020</a>; <a href="./references#CD015048-bbs2-0113" title="OndaT , MatsumotoK , ShibataT , SatoA , FukudaH , KonishiI , et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Japanese Journal of Clinical Oncology2008;38(1):74-7. [12185462]OndaT , SatohT , OgawaG , SaitoT , KasamatsuT , NakanishiT , et al, Japan Clinical Oncology Group. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. European Journal of Cancer2020;130:114-25. OndaT , SatohT , SaitoT , KasamatsuT , NakanishiT , NakamuraK , et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. European Journal of Cancer2016;64:22-31. [12185463]OndaT , SatohT , SaitoT , KasamatsuT , NakanishiT , TakeharaK , et al. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. Journal of Clinical Oncology2018;36(15 Suppl). [12185464]">Onda 2020</a>), which did not report any of their outcomes for extent of disease by type of initial surgery. </p> <div class="figure" id="CD015048-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD015048-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We excluded 133 references reporting on 115 studies that investigated the effects of residual disease after primary surgery for the reasons described in the table <a href="./references#CD015048-sec-0123" title="">Characteristics of excluded studies</a>. The remaining 67 references, reporting on 46 unique studies, met our inclusion criteria and are described in the table <a href="./references#CD015048-sec-0122" title="">Characteristics of included studies</a>. Fifty‐two of these, reporting on 30 unique studies, reported on residual disease for PDS. One included publication, <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>, reported results based on four individual RCTs but each one alone did not meet the inclusion criteria due to different scope so we included the combined analysis reported in <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>. One study reported on two separate groups of women in different histology sub‐types so for the purposes of the review we split it into two separate studies (<a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>), therefore we refer to 31 included studies throughout. The other 15 studies reported on residual disease for IDS. </p> <p>Searches of the grey literature did not identify any additional relevant trials.</p> <p>There were three RCTs evaluating the effectiveness of surgery in advanced‐stage epithelial ovarian cancer (<a href="./references#CD015048-bbs2-0117" title="RedmanJR , PetroniGR , SaigoPE , GellerNL , HakesTB . Prognostic factors in advanced ovarian carcinoma. Journal of Clinical Oncology1986;4(4):515-23. ">Redman 1986</a>; <a href="./references#CD015048-bbs2-0120" title="RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al and the Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):89-97. ">Rose 2004</a>; <a href="./references#CD015048-bbs2-0147" title="Van Der BurgMEL , Van LentM , BuyseM , KobierskaA , MaggioniA , FavalliG , et al. The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study. International Journal of Gynecological Cancer1996;6:30-8. ">Van Der Burg 1996</a>). However, we excluded all three of these trials as they were designed to evaluate the benefits of surgery after an induction period with chemotherapy treatment, where the surgery was performed as a secondary procedure after initial (primary) surgery and they have been evaluated in a separate Cochrane Review (<a href="./references#CD015048-bbs2-0223" title="TangjitgamolS , ManusirivithayaS , LaopaiboonM , LumbiganonP , BryantA . Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD006014. [DOI: 10.1002/14651858.CD006014]">Tangjitgamol 2016</a>). </p> </section> <section id="CD015048-sec-0040"> <h3 class="title" id="CD015048-sec-0040">Characteristics of included studies</h3> <p>See <a href="./references#CD015048-sec-0122" title="">Characteristics of included studies</a> table. </p> <section id="CD015048-sec-0041"> <h4 class="title">Residual disease after upfront primary debulking surgery (PDS)</h4> <p>The 31 included studies assessed a total of 22,376 women (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). Three studies included a small proportion of women with early‐stage (predominantly stage II) or unknown disease. Although not stringently part of our initial inclusion criteria, we included a study if the proportion with unknown or early‐stage disease in the entire cohort was small. The proportion of women with early or unknown stage of disease in <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> (9.3%), <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a> (6.6%) and <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> (12.5%) was not going to affect the applicability of the results. The analyses in <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> included 1182 women with stage IIB to IIIB disease and 3684 had stage IIIC to IV disease. The study contributed heavily to the analyses, but the results were robust to its exclusion in a sensitivity analysis. The four individual RCTs used in the analyses could not be included separately because residual disease (RD) was not reported. </p> <p>Four studies reported exclusively on women with stage IV epithelial ovarian cancer (EOC) and included 225, 326, 573 and 360 stage IV women respectively (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). </p> <p>Five studies reported exclusively on women with stage IIIC EOC (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>); whereas <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a> and <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> reported women with stage IIIA to C disease; whilst 16 studies reported on both stage III and IV EOC (<a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>). </p> <p>The number of women included in all studies varied from 104 in the <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a> study to 5055 women in the <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> analysis. The larger studies tended to combine results from primary studies but generally it was not possible to report the results of these separately due to the scope of the original publications that had a different focus. </p> <p>For a summary of the total number of women included in each study, as well as stage and residual disease details see <a href="#CD015048-tbl-0008">Table 1</a>. </p> <div class="table" id="CD015048-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of stage and residual disease in included upfront primary debulking surgery (PDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p> <b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No.</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Stage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Optimal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Suboptimal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median age in years</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>III n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IV n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Months</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>(Range)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2: 70 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2: 155 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.5 (13 to 112)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> <p>(26 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 46 (24)</p> <p>&lt; 1: 85 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2: 22 (11)</p> <p>&gt; 2: 41 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.4</p> <p>(0.2 to 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> <p>(24 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 157 (55)</p> <p>&lt; 1: 88 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 41 (14)</p> <p>NS: n = 40 exc.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> <p>(IQR: 12 to 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 65: 205 (63)</p> <p>&gt; 65: 121 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> <p>Austria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>0: 209 (52)</p> <p>&lt; 1: 196 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(Range not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> <p>(81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1: 71 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 33 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> <p>(6 to 142)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean was 50.5 years</p> <p>and 61 years for younger</p> <p>and older women, respectively</p> <p>(Range: 22 and 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> <p>(93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> <p>(7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 63 (31)</p> <p>&lt; 1: 77 (38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 63 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(1 to 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> <p>(30 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 61 (32)</p> <p>&lt; 1: 67 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 61 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> <p>(30 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> <p>(77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1: 71 (25)</p> <p>1 to 2: 73 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2: 137 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 to 139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(22 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 67 (14)</p> <p>&lt; 1: 169 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 229 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>(1 to 199)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> <p>(22 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>0: 55 (25)</p> <p>&lt; 1: 163 (75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (18 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 351 (86)</p> <p>&lt; 1: 41 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 16 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.8</p> <p>(24 to 91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>n = 567 (91) stage III/IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 209 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0: 416 (67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (3 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (30 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> <p>(83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 121 (63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0: 70 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 57: 98</p> <p>&gt; 57: 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428</p> <p>(54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365</p> <p>(46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 482 (61)</p> <p>&lt; 1: 226 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> <p>(IQR: 18 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (19 to 88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5055</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>4488/5130 (87.5)</p> <p>stage III/IV; n = 4850 in RD analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 1779 (37)</p> <p>&lt; 1: 1442 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 1629 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: 57.4</p> <p>(SD 10.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> <p>France</p> <p>Denmark</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> <p>(76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> <p>(24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 61 (22)</p> <p>&lt; 1: 120 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 95 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 years</p> <p>(0 to 15.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: 73.5</p> <p>(65 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 133 (75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0: 45 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.6</p> <p>(IQR 32.9 to 66.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 years (IQR 50.8 to 72.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 (67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All sub‐optimal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2 cm:</p> <p>85 (18.6)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2 cm:</p> <p>373 (81.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241</p> <p>(78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> <p>(22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 141 (59)</p> <p>&lt; 1: 77 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 23 (9)</p> <p>n = 66 missing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 60: 200 (65)</p> <p>&gt; 60: 107 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4954</p> <p>(77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1506</p> <p>(23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 2048 (46)</p> <p>&lt; 1: 1848 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 546 (12)</p> <p>1571 missing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 60: 2803 (47)</p> <p>&gt; 60: 3210 (53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370</p> <p>(88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> <p>(12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 107 (26)</p> <p>&lt; 1: 147 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 165 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (3 to 164)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean = 54.5 (SD 10.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199 (76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 115 (44)</p> <p>&lt; 1: 83 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2: 18 (7)</p> <p>&gt; 2: 43 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (22 to 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 99 (41)</p> <p>&lt; 1: 106 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 32 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.7 (22 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II: 15 (7)</p> <p>III: 174 (77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 157 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0: 69 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0</p> <p>(1 to 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: 57.5 (SD 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>III/IV (n = 276)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (20 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1241</p> <p>(72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 (28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 85 (5)</p> <p>&lt; 1: 701 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 932 (54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.5 to 60.2 for 0 to &gt; 1 cm RD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>794</p> <p>(81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> <p>(19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 408 (42)</p> <p>&lt; 1: 378 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 192 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.7 (1 to 198)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (19 to 95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2 cm: 92 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2 cm:</p> <p>127 (58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (24 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>573</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 70 (12)</p> <p>&lt; 1: 168 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 335 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(19 to 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> <p>France</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1895</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 437 (23)</p> <p>&lt; 1: 791 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 667 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> <p>(16 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 cm: 29 (8)</p> <p>&lt;  1 cm: 79 (22)</p> <p>Total: 108 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(24 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>IQR:</b> interquartile range; <b>RD:</b> residual disease; <b>SD:</b> standard deviation </p> </div> </div> <section id="CD015048-sec-0042"> <h5 class="title">Design</h5> <p>All analyses examining residual disease thresholds following surgery were retrospective in nature. </p> <p>Four studies were primarily prospective cohort studies (<a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>). </p> <p>The <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>, <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> and <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> studies were retrospective analyses of six, four and four randomised controlled trials of various chemotherapy protocols, respectively. The <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> study reported on women with stage III EOC, <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> reported on women with stage IV EOC and <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> a mix of stages included a small proportion of early and unknown. <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> included women from GOG protocols 111, 114, 132, 152, 158 and 172 (<a href="./references#CD015048-bbs2-0164" title="ArmstrongDK , BundyB , WenzelL , HuangHQ , BaergenR , LeleS , et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43.">Armstrong 2006</a>; <a href="./references#CD015048-bbs2-0203" title="MarkmanM , BundyBN , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7.">Markman 2001</a>; <a href="./references#CD015048-bbs2-0109" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. ">McGuire 1996</a>; <a href="./references#CD015048-bbs2-0205" title="MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelAL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15.">Muggia 2000</a>; <a href="./references#CD015048-bbs2-0210" title="OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , MannelRA , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200.">Ozols 2003</a>; <a href="./references#CD015048-bbs2-0120" title="RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al and the Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):89-97. ">Rose 2004</a>), <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> included women from GOG protocols 111, 132, 152 and 162 (<a href="./references#CD015048-bbs2-0109" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. ">McGuire 1996</a>; <a href="./references#CD015048-bbs2-0205" title="MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelAL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15.">Muggia 2000</a>; <a href="./references#CD015048-bbs2-0120" title="RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al and the Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):89-97. ">Rose 2004</a>; <a href="./references#CD015048-bbs2-0218" title="SpriggsDR ,  BradyM ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71.">Spriggs 2007</a>) and <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> reported a combined analysis of four individual RCTs (OVAR 3, 5, 7 and 9). Likewise, the <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a> study was a retrospective analysis of a randomised controlled trial of two different chemotherapy protocols. </p> <p>All remaining studies were analyses of retrospective data from hospital databases, medical records and cancer registries. </p> </section> <section id="CD015048-sec-0043"> <h5 class="title">Participant characteristics</h5> <p>Fourteen studies were conducted in the USA (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>), whilst four were set in South Korea (<a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>), nine set predominantly in Europe including Germany, Belgium, France, Spain, Italy, Austria and the UK (<a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>); the study <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a> was set in Turkey, <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> in China and the <a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a> study was conducted in 24 centres in Japan. One of the studies included populations from multiple locations: <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> (Italy and the USA). </p> <p>The mean or median age reported for women with advanced EOC varied between 50.9 years (<a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>) to 73.5 (<a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>) years with the range between 16 to 91 years. </p> </section> <section id="CD015048-sec-0044"> <h5 class="title">Details of PDS reported in studies</h5> <p>RD thresholds ranged from NMRD up to &gt; 5 cm across the included studies. The most common comparisons were of RD thresholds NMRD, SVRD (described in most studies as being &lt; 1 cm, but exclusive of NMRD) and LVRD. We did identify studies where optimal RD was defined up to &lt; 2 cm, but more recent studies and guidelines (<a href="./references#CD015048-bbs2-0166" title="BGCS. https://www.bgcs.org.uk/wp-content/uploads/2019/05/BGCS-Guidelines-Ovarian-Guidelines-2017.pdf2017.">BGCS 2017</a>; <a href="./references#CD015048-bbs2-0178" title="du BoisA , ReussA , Pujade-LauraineE , HarterP , Ray-CoquardI , PfistererJ . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115(6):1234–44.">du Bois 2009</a>) state that surgery should not be considered optimal beyond 1 cm (however, we assessed RD as a prognostic factor and we included studies that included all RD thresholds, but only reported the most pertinent comparisons in the key sections of the review). </p> <p>Women in all the studies described above underwent PDS followed by platinum‐based adjuvant chemotherapy. All women were confirmed histologically to have invasive epithelial ovarian cancer. </p> <p>The speciality of the surgeon who performed PDS (for example, general surgeon, gynaecologic surgeon or specialist gynaecologic oncology surgeon) was not reported in 20 of the included studies (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>); whereas specialist gynaecologic oncology surgeons undertook PDS in 11 studies (<a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>). </p> <p>The mean duration of PDS was reported to be 210 minutes (range: 40 to 480 minutes) in <a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>. Similarly the median duration of PDS was reported to be 194 minutes (range: 60 to 750 minutes) and 180 minutes (range: 55 to 480 minutes) in the <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a> and <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> studies respectively. All three studies reported on women with stage IIIC disease. On the other hand, the <a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a> study reported on women with stage IV disease and the median duration of PDS was found to be 240 minutes (range 40 to 780 minutes). Two studies reported on the mean duration of PDS on women with stage III and IV disease: 270 minutes (range: 70 to 480 minutes) in <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> and 280 minutes (range: 36 to 893 minutes) in <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>. </p> <p>The duration of PDS was not reported in the remaining 25 studies (<a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). </p> <p>The median estimated operative blood loss was 500 mL (range 20 mL to 7500 mL); 850 mL (range 30 mL to 5000 mL) and 1085 mL (range 40 mL to 11,000 mL) in the <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>, <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> and <a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a> studies, respectively. In the latter study, blood transfusion was given to 112 women (50%) intra‐ and postoperatively. <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> and <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> reported the estimated blood loss using different measures as 700 mL (range 50 mL to 6000 mL) and 1000 mL (range 200 mL to 8500 mL), respectively. Intraoperative blood transfusion was given to 112 (43.2%) and 152 (64%) women in <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> and <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> respectively, while postoperative blood transfusion was given to 140 (50.1%) women in <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> and 150 (63%) women in <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>. The <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a> study did not report on the estimated blood loss, however they reported that nine of 185 women (4.86%) required blood transfusion. </p> <p>Only five studies reported on the length of hospital stay (LHS). In the studies by <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>, <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> and <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> the median LHS was 10 days, with a range of 0 to 59, 0 to 93 and 4 to 24 days, respectively. The median LHS was 9 days and 8 days (range: 1 to 22 days) in <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> and <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>, respectively. </p> <p>Postoperative mortality within 30 days of PDS ranged from 0.4% to 4.3% in eight studies reporting this outcome (<a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>). One study reported a postoperative mortality rate of 45% but this was during a median follow‐up period of 49.6 months (interquartile range (IQR) 32.9 to 66.3) (<a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>). </p> <p>Postoperative mortality and morbidity were not reported in 19 studies (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). </p> <p>Two studies used a postoperative residual disease cutoff of &lt; 2 cm to define an optimal level of remaining RD after surgery (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>). Eighteen studies considered that an optimal outcome was achieved only if NMRD was left behind at the conclusion of PDS (<a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>). Four studies used a postoperative RD cutoff of &lt; 1 cm to define the optimal level of remaining RD (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>). The remaining seven studies did not define what is considered optimal in the study methodology but analysed the outcome by a range of postoperative RD (<a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). </p> <p>Four studies did not make direct comparisons against NMRD. These studies included NMRD in the RD &lt; 1 cm (<a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>) and RD &lt; 2 cm categories (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>). None of the studies reported the proportion of participants with NMRD. While <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> did give a breakdown of various RD categories, the authors additionally reported a comparison involving RD &gt; 1 cm versus &lt; 1 cm with the latter including NMRD (n = 29/107). </p> <p>The rate of NMRD after surgery was reported in 20 studies (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). It was achieved in 4906 out of 15,246 women (32.2%) with the lowest macroscopic disease rate reported by <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a> (4.9%) and the highest (86%) reported by <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>. </p> <p>Postoperative RD &lt; 1 cm (SVRD) was achieved in 8201 out of 19,185 women (42.75%) as calculated from 19 studies (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). The lowest rate for RD &lt; 1 cm was 25.3% (71/281) in the <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> study and the highest was 96% (392/408) in the <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> study. </p> <p>In 26 studies all women received postoperative platinum‐based chemotherapy (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). In four studies the majority of women (95.1%, 96%, 97%, 98.4%, 99% respectively) received postoperative platinum‐based chemotherapy (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>). The main reason for not receiving postoperative chemotherapy was postoperative death within 30 days of surgery and absent records (<a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>). Other reasons for not receiving postoperative chemotherapy or receiving non‐platinum‐based chemotherapy were poorly reported. The study by <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a> did not report the number of women who received postoperative chemotherapy. </p> <p>Fourteen studies reported the survival outcome for NMRD (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). </p> </section> <section id="CD015048-sec-0045"> <h5 class="title">Outcomes</h5> <p>The median duration of follow‐up varied from 28 months (<a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>) to 77.7 months (<a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>), with a range between 1 and 199 months (<a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>). The duration of follow‐up was not reported in seven studies (<a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>). </p> <p>Only two studies did not report overall survival (<a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>), while 16 studies reported progression‐free survival and used appropriate statistical techniques (hazard ratios to correctly allow for censoring) (<a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). Prognostic factors were adjusted for in the analysis of survival outcomes in each study using Cox regression. Between them, the 30 studies (31 with Melamed split (<a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>)) included 29 different prognostic factors in the analysis. The number of prognostic factors included in the analysis ranged from two in <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> to 10 in <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>. The prognostic factors most frequently included in the analyses are (in order of frequency) residual disease (26 studies), age (23 studies), stage (21 studies), performance status (nine studies), histology (nine studies) and tumour grade (six studies). A list of the different prognostic factors is shown in <a href="./appendices#CD015048-sec-0112">Appendix 6</a>. </p> <p>For the distribution of these factors at baseline for each study and by residual disease, see the table <a href="./references#CD015048-sec-0122" title="">Characteristics of included studies</a>. </p> </section> </section> <section id="CD015048-sec-0046"> <h4 class="title">Residual disease after interval debulking surgery (IDS)</h4> <p>The 15 included studies assessed a total of 3697 women (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). One study, whilst it reported descriptive statistics for 102 women, only had 85 women who underwent interval debulking surgery (IDS) (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>). Although this was not strictly part of our inclusion criteria (i.e. n ≥ 100), we noted this study as a caveat. Additionally, adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were not reported in <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> and <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> in their multivariate Cox models; however, P values were reported in both. Two of the included studies were abstracts only (<a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>). </p> <p>All studies included women with advanced EOC who underwent IDS (neoadjuvant chemotherapy (NACT) given prior to surgery). Twelve of the studies provided descriptive statistics of FIGO stage ‐ all of which included samples of women with FIGO stages III and IV (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). For the three remaining studies, only <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a> and <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> reported in their methods that women with stage IIIC and IV ovarian cancer were included; we could not determine FIGO staging for <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>. </p> <p>Study sample size varied from 102 (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>) to 672 (<a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). </p> <p>For a summary of the total number of women included in each study, as well as stage and residual disease details see <a href="#CD015048-tbl-0009">Table 2</a>. </p> <div class="table" id="CD015048-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of stage and residual disease in included interval debulking surgery (IDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No.</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Stage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Optimal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Suboptimal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median age in years</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> </tr> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>III n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IV n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Months</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>(Range)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 37 (44)</p> <p>&lt; 1: 20 (23)<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1: 28 (33)<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age</p> <p>≥ 70 years: 74.5 (41%)<br/>&lt; 70 years: 58.3 (59%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>IIIC: 114 (40)</p> <p>IV: 101 (36)</p> <p>Assumed AOC: 57 (20)</p> <p>Unknown: 10 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 165 (59)<sup>‡</sup> </p> <p>≤ 1: 63 (22)<sup>‡</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 to 2: 6 (2)<sup>‡</sup> </p> <p>&gt; 2: 37 (13)<sup>‡</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.9 (34.1 to 84.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIIB: 6 (5)</p> <p>IIIC: 77 (62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1: 113 (91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1: 11 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5 (5 to 142)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (29 to 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 1: 165 (81)<sup>§</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 36 (19)<sup>§</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5 (1 to 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (28 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251 (78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No definition of optimal given</p> <p>0: 236 (73)</p> <p>≤ 1: 36 (11)</p> <p>&gt; 1: 50 (16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (3 to 181)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 65: 226 (70%)</p> <p>&gt; 65: 96 (30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 255 (64)</p> <p>&lt; 1: 55 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1: 88 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: 63.9</p> <p>(95% CI 42.2 to 85.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 80 (68)</p> <p>&lt; 1: 31 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1: 7 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (37 to 88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 (85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 59 (30)</p> <p>&lt; 1: 38 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2: 8 (4)</p> <p>&gt; 2: 30 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.5 (IQR 38.5 to 56.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (38 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564 (84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 1: 486 (72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 186 (28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (5 to 103)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (30 to 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>†</sup>85/102 participants underwent debulking surgery following neoadjuvant chemotherapy. </p> <p><sup>‡</sup>Residual disease data available for n = 271/282. </p> <p><sup>§</sup>Residual disease data available for n = 201/203. </p> <p><b>AOC:</b> advanced ovarian cancer; <b>CI:</b> confidence interval; <b>IQR:</b> interquartile range </p> </div> </div> <section id="CD015048-sec-0047"> <h5 class="title">Design</h5> <p>All analyses examining RD thresholds were retrospective in nature with data collected from past medical records and databases. The exceptions were <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>, which was a secondary analysis of the CHIVA double‐blind randomised phase II GINECO study that sought to examine the effects of nintedanib in combination with NACT (<a href="./references#CD015048-bbs2-0183" title="FerronG , De RauglaudreG , ChevalierA , CombeP , JolyF , LortholaryA , et al. Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study. Journal of Clinical Oncology2019;37(15 Suppl):5512.">Ferron 2019</a>); <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>, whose sample comprised data collected retrospectively from medical records as well as prospective participants(the purpose of the prospective data collection being to explore the role of minimally invasive surgery following NACT); and <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>, whose sample was from a multicentre cohort study of women with histologically confirmed advanced epithelial ovarian cancer who all consented to participation. </p> </section> <section id="CD015048-sec-0048"> <h5 class="title">Participant characteristics</h5> <p>Three of the studies were conducted in Italy (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>), three in France (<a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>), three in China (<a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>), two in the USA (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>), two in Japan (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>), and one study was conducted in Turkey (<a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>), and the UK (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>) each. Five of the studies were conducted across multiple centres: <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> collected data from nine French referral centres, <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> from three US institutions, <a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a> from two US institutions, <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a> from five Italian centres, and <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a> from two Chinese institutions. </p> <p>The median age reported for women with advanced EOC varied between 55 years (<a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>) and 64 years (<a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>) with the range between 28 and 88 years. </p> </section> <section id="CD015048-sec-0049"> <h5 class="title">Details of interval debulking surgery reported in studies</h5> <p>RD thresholds ranged from NMRD up to &gt; 2 cm across the included studies. The most common comparisons were of RD thresholds NMRD, ≤ 1 cm (although the majority included NMRD in this threshold, rather than 0.1 cm to 1 cm, which we defined as SVRD), and &gt; 1 cm (LVRD). Optimal RD was commonly defined as less than 1 cm (RD &lt; 1) or less than or equal to 1 cm (≤ 1 cm), consistent with recent studies and guidelines (<a href="./references#CD015048-bbs2-0166" title="BGCS. https://www.bgcs.org.uk/wp-content/uploads/2019/05/BGCS-Guidelines-Ovarian-Guidelines-2017.pdf2017.">BGCS 2017</a>; <a href="./references#CD015048-bbs2-0178" title="du BoisA , ReussA , Pujade-LauraineE , HarterP , Ray-CoquardI , PfistererJ . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115(6):1234–44.">du Bois 2009</a>), which state that surgery should not be considered optimal beyond 1 cm. Four studies did not provide an explicit definition of optimal RD (<a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>). This was due to the nature of the information for the middle two cases (i.e. abstracts). For <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>, although no definition of optimal RD was given, thresholds of NMRD, RD ≤ 1 cm and RD &gt; 1 cm were provided. For <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>, thresholds of NMRD, RD ≤ 0.25 cm, and RD 0.25 cm to 2.5cm were used. <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> utilised two definitions of optimal RD (NMRD and RD ≤ 1 cm) in their study although only the latter was used in their multivariate Cox model. </p> <p>Six studies compared SVRD versus LVRD (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). Six of the studies did not make direct comparisons against NMRD and included NMRD in their SVRD category (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). Consequently, comparisons of SVRD (0.1 cm to 1 cm) and LVRD (&gt; 1 cm) suffered from serious bias as a result of the inclusion of NMRD in the near‐optimal category. Of these six studies, only three reported the number of participants with NMRD within the SVRD category: <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a> (n = 37/57 participants with SVRD), <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> (n = 165/228) and <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a> (n = 59/156). Only one study appropriately treated NMRD as a distinct category from SVRD (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). </p> <p>Women in all the studies were treated by platinum‐based neoadjuvant chemotherapy followed by IDS. One possible exception may be <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>, but it was assumed that the NACT was platinum‐based. All women were confirmed histologically to have invasive EOC. </p> <p>The median number of NACT cycles varied from three (<a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>) to six (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>), with a range of 1 to 13. The large range is partially contributed by <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>, which was conducted in women receiving delayed IDS (after six or more cycles). Two studies did not provide descriptive statistics of NACT cycles (<a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>), but reported in their methodology that women received three or between three to four cycles. Information on the NACT regimen was provided in all but one study (<a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>). Carboplatin plus paclitaxel was most commonly reported and varied between 37.2 % (<a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>), 96.6% (<a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>), and 100%; although no details were reported for <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>, <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> (with reference to <a href="./references#CD015048-bbs2-0183" title="FerronG , De RauglaudreG , ChevalierA , CombeP , JolyF , LortholaryA , et al. Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study. Journal of Clinical Oncology2019;37(15 Suppl):5512.">Ferron 2019</a>), and <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>, they reported all women received carboplatin plus paclitaxel in their methods. Route of administration was reported in <a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a> in which NACT was administrated intraperitoneally in 28% and intravenously in 72%, and <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a> in which NACT was administrated intraperitoneally in 45% and intravenously in 55%. Response to NACT according to RECIST criteria was reported in three studies in which complete/partial response was observed in 66.6% (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>), 66.1% (<a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>), and in all participants in <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> (however, this was based on n = 380/501 with data on NACT response). </p> <p>Information on the specialty of the surgeon performing the IDS was only reported in <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a> where all 118 surgeries were conducted by two surgeons with experience in ovarian cancer surgery and <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a> where gynaecologic oncologists were involved in all surgeries. Duration of IDS was only reported in two studies and varied from a median of 194 minutes (<a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>) to 419 minutes (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>), with a range of 45 to 611 minutes. Length of hospital stay (LHS) was only reported in <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a> with a median of 10 days (range: 2 to 44) and <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> (median of 10 days (range: 6 to 13) in the group with ≤ 4 NACT cycles and median of 11 days (range: 7 to 14) in the group with &gt; 4 NACT cycles). Postoperative morbidity/complications and mortality (defined as death within 30 days of IDS) was only reported in two studies (<a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>). Postoperative mortality varied from 0% to 1.7%, whilst postoperative morbidity/complications varied from 18% to 22% in these studies. Complications after discharge and within 30 days of surgery were reported only in <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>. Approximately 11% experienced post‐discharge complications of whom 6.4% were re‐admitted. Operative blood loss was reported in <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>, with a median blood loss of 1291 mL (range: 220 mL to 5640 mL) and <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>, where 57% of patients required blood transfusion (based on n = 77/501 with available data). <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> reported intraoperative complications in 15% of patients (based on n = 387/501 with available data). <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> also reported postoperative complications in 22% of participants (based on n = 421/501 patients with available data) but this was across an undefined time frame. </p> <p>Information on postoperative chemotherapy following IDS was reported in 11 studies, albeit with varying levels of detail (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>). Clear reporting of platinum‐based adjuvant chemotherapy was observed in five studies (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> (with reference to <a href="./references#CD015048-bbs2-0183" title="FerronG , De RauglaudreG , ChevalierA , CombeP , JolyF , LortholaryA , et al. Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study. Journal of Clinical Oncology2019;37(15 Suppl):5512.">Ferron 2019</a>); <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>), whilst it was implied (<a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>) or unstated (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>) in the remaining six studies. Six of the studies did not provide descriptive statistics for adjuvant chemotherapy cycles or regimen and only reported in their methods that participants received chemotherapy following IDS (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> (with reference to <a href="./references#CD015048-bbs2-0183" title="FerronG , De RauglaudreG , ChevalierA , CombeP , JolyF , LortholaryA , et al. Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study. Journal of Clinical Oncology2019;37(15 Suppl):5512.">Ferron 2019</a>); <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>). However, with the exception of <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>, they did report in their methods that their participants received two (<a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>), two to three (<a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> (with reference to <a href="./references#CD015048-bbs2-0183" title="FerronG , De RauglaudreG , ChevalierA , CombeP , JolyF , LortholaryA , et al. Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: the CHIVA double-blind randomized phase II GINECO study. Journal of Clinical Oncology2019;37(15 Suppl):5512.">Ferron 2019</a>)), or two to six (<a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>) cycles of adjuvant chemotherapy. <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a> did not report the number of adjuvant cycles but did report the total (NACT + adjuvant chemotherapy) cycles. Six studies reported descriptive statistics (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>). The median number of cycles ranged from three (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>) to five (<a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>), and ranged from one to eight in these three studies. </p> <p>Optimal RD was most commonly defined as RD &lt; 1 cm (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>) or RD ≤ 1 cm (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). Four studies did not provide a definition of optimal RD in their methodology but included RD thresholds in their multivariable Cox models (<a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>). <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> utilised two definitions of optimal RD (NMRD and SVRD) in their study, although only the latter was used in their multivariate Cox model. NMRD was reported in 12 studies (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>), however descriptive statistics for the rate of NMRD were only reported in 10 studies (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>). <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> reported missing data for RD in n = 30/501 women and did not report any imputation method. Rate of NMRD varied from the lowest of 29.5% (<a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>) to the highest of 79% (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>). Across the 10 studies that reported descriptive statistics, NMRD was achieved in 1451 out of 2237 women (64.9%). </p> <p>Across the six studies that provided descriptive statistics for RD &lt; 1 cm (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>), RD &lt; 1 cm was achieved in 897 out of 1096 women (81.8%). Rates per study varied from 71% (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>) to 94% (<a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>). </p> <p>Across the four studies that provided descriptive statistics for RD ≤ 1 cm (<a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>), RD ≤ 1 cm was achieved in 1151 out of 1466 women (78.5%). Rates per study varied from 72% (<a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>) to 84% (<a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>). </p> <p>Nine studies reported the survival outcome in models comparing RD threshold(s) against NMRD (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>). </p> </section> <section id="CD015048-sec-0050"> <h5 class="title">Outcomes</h5> <p>The median duration of follow‐up was reported in nine studies (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>), and varied from a median of 29.5 months (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>) to 47 months (<a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>), with a range between 1 and 181 months. The duration of follow‐up was not reported in four studies (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). </p> <p>Only one study did not report overall survival (<a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>). Three studies did not provide adjusted HRs and 95% confidence intervals from their multivariate survival models predicting overall survival (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>). One study only brought RD forward into the "multivariate" model for overall survival after univariate analysis, however the criteria for selection was not mentioned in the methods (<a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>). Eight studies reported progression‐free survival and used appropriate statistical techniques (hazard ratios to correctly allow for censoring) (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). One study reported using multivariate logistic regression to predict progression‐free survival in their methods but reported hazard ratios in their results, so it may be inferred that multivariate Cox regression had actually been used (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>). Disease‐specific overall survival (DSS) was reported in <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>. Disease‐free survival (DFS) was reported in <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>. Prognostic factors were adjusted for in the analysis of survival outcomes in each study using Cox regression. Between them, the 15 studies included 29 different prognostic factors in the analysis. The precise prognostic factors used in <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a> could not be determined beyond the complete cytoreduction, ECOG performance status and number of NACT cycles. The number of prognostic factors included in the analysis ranged from one in <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> to nine in <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>. The prognostic factors most frequently included in the analyses are (in order of frequency): residual disease (15 studies), number of NACT cycles (eight studies), age (seven studies), FIGO stage (seven studies), performance status (six studies), ascites (four studies), response to NACT (four studies), NACT regimen (three studies), CA‐125 (two studies) and lymphadenectomy (two studies). A list of the different prognostic factors is shown in <a href="./appendices#CD015048-sec-0113">Appendix 7</a>. </p> <p>One study, which included 501 women, had missing RD data for 30 (6%) (<a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>). Furthermore, other variables in the multivariate Cox model for overall survival had larger rates of missing data such as the Charlson Index (missing data for n = 203, 41%) and response to NACT (missing for n = 121, 24%). It is likely that the multivariate Cox model was based on a complete case analysis and therefore the estimates reported are based on ≤ 298 women, but the exact number cannot be known. For the multivariate model for progression‐free survival, the estimates are based on ≤ 380 women as response to NACT was included as a covariate. </p> <p>For the distribution of these factors at baseline for each study and by RD threshold see the table <a href="./references#CD015048-sec-0122" title="">Characteristics of included studies</a>. </p> </section> </section> </section> <section id="CD015048-sec-0051"> <h3 class="title" id="CD015048-sec-0051">Excluded studies</h3> <p>We excluded 133 references reporting on 115 studies after obtaining the full text, for the following primary reasons. </p> <p> <ul id="CD015048-list-0014"> <li> <p>We excluded 42 references reporting on 40 studies because they did not include at least 100 women with advanced epithelial ovarian cancer (<a href="./references#CD015048-bbs2-0049" title="AlphsHH , ZahurakML , BristowRE , Diaz-MontesTP . Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecologic Oncology2006;103(3):1048-53. ">Alphs 2006</a>; <a href="./references#CD015048-bbs2-0051" title="AndersenES , KnudsenA , SvarrerT , LundB , NielsenK , GroveA , et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecologic Oncology2005;99(3):552-6. ">Andersen Soegaard 2005</a>; <a href="./references#CD015048-bbs2-0056" title="Benedetti-PaniciP , ManeschiF , ScambiaG , CutilloG , GreggiS , MancusoS . The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Obstetrics &amp; Gynecology1996;87(4):532-8. ">Benedetti‐Panici 1996</a>; <a href="./references#CD015048-bbs2-0063" title="BristowRE , MontzFJ , LagasseLD , LeuchterRS , KarlanBY . Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecologic Oncology1999;72(3):278-87. ">Bristow 1999</a>; <a href="./references#CD015048-bbs2-0064" title="CaiHB , ZhouYF , ChenHZ , HouHY . The role of bowel surgery with cytoreduction for epithelial ovarian cancer. Clinical Oncology2007;19(10):757-62. ">Cai 2007</a>; <a href="./references#CD015048-bbs2-0065" title="CeresoliM , VerrengiaA , MontoriG , BusciL , CoccoliniF , AnsaloniL , et al. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study. Journal of Gynecologic Oncology2018;29(3):e53. ">Ceresoli 2018</a>; <a href="./references#CD015048-bbs2-0068" title="ColozzaM , MosconiAM , GoriS , BelsantiV , BasurtoC , De AngelisV , et al. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide. American Journal of Clinical Oncology1997;20(5):522-6. ">Colozza 1997</a>; <a href="./references#CD015048-bbs2-0075" title="Del CampoJM , FelipE , RubioD , BermejoB , ColomerR , ZanonV . Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecologic Oncology1994;53(1):27-32. ">Del Campo 1994</a>; <a href="./references#CD015048-bbs2-0080" title="GaoJ , ZhengA , ChenW , PengZ , CaoZ . A study of prognostic factors of stage IV epithelial ovarian cancer [Chinese]. Journal of West China University of Medical Sciences2001;32(2):309-12. ">Gao 2001</a>; <a href="./references#CD015048-bbs2-0083" title="GershensonDM , WhartonJ , TaylorC , StringerLJ , EdwardsCA , CreightonL , et al. Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide. Gynecologic Oncology1989;32(3):336-41. ">Gershenson 1989</a>; <a href="./references#CD015048-bbs2-0085" title="GershensonDM , MorrisM , BurkeTW , LevenbackC , KavanaghJJ , FrommGL . Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gynecologic Oncology1995;58(3):349-55. ">Gershenson 1995</a>; <a href="./references#CD015048-bbs2-0087" title="GremJ , O'DwyerP , ElsonP , SimonN , TrumpD , FrontieraM , et al. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. Journal of Clinical Oncology1989;9(10):1793-800. ">Grem 1991</a>; <a href="./references#CD015048-bbs2-0088" title="HainsworthJD , BurnettLS , Jones HW 3rd, GroshWW , JohnsonDH , GrecoFA . High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Journal of Clinical Oncology1990;8(3):502-8. ">Hainsworth 1990</a>; <a href="./references#CD015048-bbs2-0089" title="HakesTB , ChalasE , HoskinsWJ , JonesWB , MarkmanM , RubinSC , et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology1992;45(3):284-9. ">Hakes 1992</a>; <a href="./references#CD015048-bbs2-0090" title="HamidD , RohrS , BaldaufJJ , RitterJ , KurtzE , DufourP , et al. Interest of intestinal resection for treatment of advanced ovarian carcinoma [Intérét des exéréses digestives dans le traitement des cancers écolués de l'ovaire]. Annales de Chirurgie2002;127(1):40-7. ">Hamid 2002</a>; <a href="./references#CD015048-bbs2-0091" title="HardyJR , WiltshawE , BlakePR , HarperP , SlevinM , PerrenTJ , et al. Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Annals of Oncology1991;2(2):131-6. ">Hardy 1991</a>; <a href="./references#CD015048-bbs2-0094" title='HoskinsPJ , SwenertonKD , PikeJA , McMurtrieEM , LeeN . "MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer. Gynecologic Oncology1996;63(3):345-51. '>Hoskins 1996</a>; <a href="./references#CD015048-bbs2-0097" title="KaernJ , AghmeshehM , NeslandJM , DanielsenHE , SandstadB , FriedlanderM , et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?International Journal of Gynecological Cancer2005;15(6):1014-22. ">Kaern 2005</a>; <a href="./references#CD015048-bbs2-0101" title="KirmaniS , BralyPS , McClayEF , SaltzsteinSL , PlaxeSC , Kim S et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecologic Oncology1994;54(3):338-44. ">Kirmani 1994</a>; <a href="./references#CD015048-bbs2-0102" title="KristensenGB , BaekelandtM , VergoteIB , TropeC . A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. European Journal of Cancer1995;31(11):1778-80. ">Kristensen 1995</a>; <a href="./references#CD015048-bbs2-0105" title="FumaruloVV , LoizziV , CormioG , MurgiaF , VecchioV , MinicucciV , et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a single institution experience and a review of the literature. In: International Journal of Gynecological Cancer. Vol. 26. 2016:1-1193. LoizziV , LeoneL , CamporealeA , RestaL , SelvaggiL , CicinelliE , et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a single-institution experience and a review of the literature. Oncology2016;91(4):211-6. ">Loizzi 2016</a>; <a href="./references#CD015048-bbs2-0106" title="LorussoV , LeoneB , Di VagnoG , ManzioneL , PalmeriS , VallejoC . Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. Gynecologic Oncology1998;68(2):172-7. ">Lorusso 1998</a>; <a href="./references#CD015048-bbs2-0107" title="MalikIM , KhanZK , KhanWA , HussainM , MoidI , RizviJ . Continuous infusion of ifosfamide and cisplatin as first-line therapy of patients with suboptimally debulked stage III/IV epithelial ovarian cancer. International Journal of Gynecological Cancer1998;8(2):138-43. ">Malik 1998</a>; <a href="./references#CD015048-bbs2-0108" title="MarchettiDL , LeleSB , PrioreRL , McPheeME , HreshchyshynMM . Treatment of advanced ovarian carcinoma in the elderly. Gynecologic Oncology1993;49(1):86-91. ">Marchetti 1993</a>; <a href="./references#CD015048-bbs2-0111" title="NganHY , ChooYC , CheungM , WongLC , MaHK , CollinsR . A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy1989;35(3):221-7. ">Ngan 1989</a>; <a href="./references#CD015048-bbs2-0114" title="PalmerMC , ShepertE , SchepanskyA , MacLeanGD . Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer. International Journal of Gynecological Cancer1992;2(6):301-6. ">Palmer 1992</a>; <a href="./references#CD015048-bbs2-0118" title="RisumS , LoftA , EngelholmSA , HøgdallE , BerthelsenAK , NedergaardL , et al. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer. International Journal of Gynecologic Cancer2012;22(7):1163-9. ">Risum 2012</a>; <a href="./references#CD015048-bbs2-0117" title="RedmanJR , PetroniGR , SaigoPE , GellerNL , HakesTB . Prognostic factors in advanced ovarian carcinoma. Journal of Clinical Oncology1986;4(4):515-23. ">Redman 1986</a>; <a href="./references#CD015048-bbs2-0122" title="RuttenMJ , BoldinghJH , SchuitE , TrumH , Van DrielW , MolBW , et al. Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer. Gynecologic Oncology2014;35(1):13-8. RuttenMJ , BoldinghJH , SchuitE , TrumH , Van DrielW , MolBW , et al. Prognostic model for survival of epithelial ovarian cancer patients treated with primary or interval debulking surgery. InInternational Journal Of Gynecological Cancer2013;23:8. ">Rutten 2014</a>; <a href="./references#CD015048-bbs2-0125" title="ShapiroJD , RothenbergML , SarosyGA , SteinbergSM , AdamoDO , ReedE , et al. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer1998;83(9):1980-8. ">Shapiro 1998</a>; <a href="./references#CD015048-bbs2-0131" title="SonJH , KongTW , PaekJ , SongKH , ChangSJ , RyuHS . Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer. International Journal of Gynaecology and Obstetrics2017;193(3):352-7. ">Son 2017</a>; <a href="./references#CD015048-bbs2-0134" title="StraussG , LundB , HansenM , HansenOP , HansenHH . Combined high-dose platinum and etoposide in previously untreated ovarian cancer patients with residual disease. International Journal of Gynecological Cancer1996;6(5):410-4. ">Strauss 1996</a>; <a href="./references#CD015048-bbs2-0137" title="SuttonGP , StehmanFB , EinhornLH , RothLM , BlessingJA , EhrlichCE . Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. Journal of Clinical Oncology1989;7:223-9. ">Sutton 1989</a>; <a href="./references#CD015048-bbs2-0140" title="TaySK , ChangTC . An evaluation of the policy of routine treatment of advanced epithelial ovarian carcinoma by debulking surgery and combined platinum-cyclophosphamide chemotherapy in Singapore. International Journal of Gynecological Cancer1996;6(1):44-8. ">Tay 1996</a>; <a href="./references#CD015048-bbs2-0141" title="TaylorAE , WiltshawE , GoreME , FryattI , FisherC . Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. Journal Of Clinical Oncology1994;12(10):2066-70. ">Taylor 1994</a>; <a href="./references#CD015048-bbs2-0146" title="VallejosC , SolidoroA , CastellanoC , BarrigaC , GaldosO , CasanovaR , et al. Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer. Gynecologic Oncology1997;67(2):168-71. ">Vallejos 1997</a>; <a href="./references#CD015048-bbs2-0156" title="WillemsePHB , De VriesEGE , KloppenburgM , FonteinDL , AaldersJG , BoonstraH , et al. Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis. International Journal of Gynecological Cancer1992;2(5):236-43. ">Willemse 1992</a>; <a href="./references#CD015048-bbs2-0157" title="WilsJA . Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. Oncology1990;47(2):115-20. ">Wils 1990</a>; <a href="./references#CD015048-bbs2-0160" title="ZangRY , ZhangZY , CaiSM , LiZT , ChenJ , TangMQ , et al. Cytoreductive surgery for stage IV epithelial ovarian cancer. Journal of Experimental &amp; Clinical Cancer Research1999;18(4):449-54. ">Zang 1999</a>; <a href="./references#CD015048-bbs2-0161" title="ZhangLY , LiPL , WangTZ , ZhangXC . Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer. Archives of Gynecology and Obstetrics2015;292(4):891-7. ">Zhang 2015</a>). </p> </li> <li> <p>Twenty‐two studies either did not report multivariate analyses or did not include or adequately report residual disease as a variable to enable an analysis (<a href="./references#CD015048-bbs2-0048" title="AlbertsDS , LiuPY , HanniganEEV , O'TooleRW , StephenDY , JamesAF , et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine1996;335(26):1950-5. ">Alberts 1996</a>; <a href="./references#CD015048-bbs2-0050" title="AltmanAD , NelsonG , ChuP , NationJ , GhatageP . Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery. Journal of Obstetrics and Gynaecology Canada2012;34(6):558-66. ">Altman 2012</a>; <a href="./references#CD015048-bbs2-0057" title="BertelsenK . Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecologic Oncology1990;38(2):203-9. ">Bertelsen 1990</a>; <a href="./references#CD015048-bbs2-0059" title="BianC , YaoK , LiL , YiT , ZhaoX . Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Archives of Gynecology and Obstetrics2016;293(1):163-8. ">Bian 2016</a>; <a href="./references#CD015048-bbs2-0061" title="BrinkhuisM , BaakJPA , Van DiestPJ , LundB , WilsJ . In Dutch and Danish patients with FIGO III ovarian carcinoma, geographic survival differences are associated with differences in quantitative pathologic features. International Journal of Gynecological Cancer1996;6(2):108-14. ">Brinkhuis 1996a</a>; <a href="./references#CD015048-bbs2-0067" title="ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al. Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment. In: Annals of Oncology. Vol. 29. 2018:viii336. ">Clamp 2018</a>; <a href="./references#CD015048-bbs2-0086" title="GreggiS , FalconeF , CarputoR , RaspagliesiF , ScaffaC , LaurelliG , et al. Primary surgical cytoreduction in advanced ovarian cancer: an outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Gynecologic Oncology2016;140(3):425-9. ">Greggi 2016</a>; <a href="./references#CD015048-bbs2-0092" title="HeitzF , HarterP , AlesinaPF , WalzMK , LorenzD , GroebenH , et al. Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecologic Oncology2016;141(2):264-70. ">Heitz 2016</a>; <a href="./references#CD015048-bbs2-0099" title="KessousR , LaskovI , AbitbolJ , BitharasJ , YasmeenA , SalvadorS , et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology2017;144(3):474-9. ">Kessous 2017</a>; <a href="./references#CD015048-bbs2-0100" title="Keyver-PaikMD , AbramianA , DomröseC , DöserA , HöllerT , FriedrichM , et al. Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer. Journal of Cancer Research and Clinical Oncology2016;142(2):481-7. ">Keyver‐Paik 2016</a>; <a href="./references#CD015048-bbs2-0104" title="LeeYY , LeeJW , LuL , XuW , KollaraA , BrownT , et al. Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. International Journal of Gynaecology and Obstetrics2018;143(3):325-32. ">Lee 2018</a>; <a href="./references#CD015048-bbs2-0109" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. ">McGuire 1996</a>; <a href="./references#CD015048-bbs2-0115" title="RiverMS , FanningJ , SpranceHE . Five-year survival for cisplatin-based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery. Journal of Surgical Oncology1991;48(1):39-44. ">Piver 1991</a>; <a href="./references#CD015048-bbs2-0116" title="RaspagliesiF , BoganiG , MatteucciL , CasarinJ , SabatucciI , TamberiS , et al. Surgical efforts might mitigate difference in response to neoadjuvant chemotherapy in stage IIIC–IV unresectable ovarian cancer: a case-control multi-institutional study. International Journal of Gynecologic Cancer2018;28(9):1706-13. ">Raspagliesi 2018</a>; <a href="./references#CD015048-bbs2-0119" title="RodriguezN , MillerA , RichardSD , RungruangB , HamiltonCA , BookmanMA , et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG). Gynecologic Oncology2013;130(3):487-92. ">Rodriguez 2013</a>; <a href="./references#CD015048-bbs2-0124" title="SessaC , ColomboN , BolisG , MarsoniS , MangioniC . Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results. Cancer Treatment Reviews1991;18(18 Suppl A):37-46. ">Sessa 1991</a>; <a href="./references#CD015048-bbs2-0127" title="SioulasVD , SchiavoneMB , KadouriD , ZivanovicO , RocheKL , O'CearbhaillR , et al. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?Gynecologic Oncology2017;145(1):15-20. ">Sioulas 2017</a>; <a href="./references#CD015048-bbs2-0133" title="StewartJM , ToneAA , JiangH , BernardiniMQ , FergusonS , LaframboiseS , et al. The optimal time for surgery in women with serous ovarian cancer. Canadian Journal of Surgery2016;59(4):223-32. ">Stewart 2016</a>; <a href="./references#CD015048-bbs2-0135" title="SuidanRS , ZhouQ , IasonosA , O’CearbhaillRE , ChiDS , RocheKC , et al. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. International Journal of Gynecologic Cancer2015;25(4):599-606. ">Suidan 2015</a>; <a href="./references#CD015048-bbs2-0152" title="VidalF , GuerbyP , LuyckxM , HaddadP , StoeckleE , MoriceP , et al. Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?PlOS One2016;11(1):e0147787. [DOI: 10.1371/journal.pone.0147787]">Vidal 2016</a>; <a href="./references#CD015048-bbs2-0154" title="WallaceS , KumarA , McGreeM , WeaverA , MarianiA , LangstraatC , et al. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecologic Oncology2017;145(1):21-6. ">Wallace 2017</a>; <a href="./references#CD015048-bbs2-0158" title="WimbergerP , LehmannN , KimmigR , BurgesA , MeierW , Du BoisA . Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology2007;106(1):69-74. ">Wimberger 2007</a>). </p> </li> <li> <p>Fourteen studies did not report survival by residual disease (<a href="./references#CD015048-bbs2-0047" title="AlbertsDS , DahlbergS , GreenSJ , GarciaD , HanniganEV , O'TooleR , et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer1993;71(2 Suppl):618-27. ">Alberts 1993</a>; <a href="./references#CD015048-bbs2-0058" title="BertelsenK , JakobsenA , StrøyerJ , NielsenK , SandbergE , AndersenJE , et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group Trial (DACOVA). Gynecologic Oncology1993;49:30-6. ">Bertelsen 1993</a>; <a href="./references#CD015048-bbs2-0062" title="BrinkhuisM , LundB , MeijerGA , BaakJPA . Quantitative pathological variables as prognostic factors for overall survival in Danish patients with FIGO stage III ovarian cancer. International Journal of Gynecological Cancer1996;6(3):168-74. ">Brinkhuis 1996b</a>; <a href="./references#CD015048-bbs2-0069" title="ContePF , BruzzoneM , CarninoF , ChiaraS , DonadioM , FacchiniV , et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. Journal of Clinical Oncology1991;9(4):658-63. ">Conte 1991</a>; <a href="./references#CD015048-bbs2-0070" title="ContePF , BruzzoneM , CarninoF , GadducciA , AlgeriR , BelliniA , et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. Journal of Clinical Oncology1996;14(2):351-6. ">Conte 1996</a>; <a href="./references#CD015048-bbs2-0072" title="CreasmanWT , OmuraGA , BradyMF , YordanE , DiSaiaPJ , BeechamJ . A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group Study. Gynecologic Oncology1990;39(3):239-43. ">Creasman 1990</a>; <a href="./references#CD015048-bbs2-0084" title="GershensonDM , MitchellMF , AtkinsonN , ElvioG , KavanaghJ , BurkeM , et al. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: maintenance therapy reconsidered. Gynecologic Oncology1992;47(1):7-13. ">Gershenson 1992</a>; <a href="./references#CD015048-bbs2-0093" title="HoskinsWJ , BundyBN , ThigpenJT , OmuraGA . The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology1992;47(2):159-66. ">Hoskins 1992</a>; <a href="./references#CD015048-bbs2-0095" title="HoskinsWJ , McGuireWP , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Combination paclitaxel (Taxol(R))-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer. International Journal of Gynecological Cancer1997;7:9-13. ">Hoskins 1997</a>; <a href="./references#CD015048-bbs2-0096" title="ItamochiH , KigawaJ , SugiyamaT , KikuchiY , SuzukiM , TerakawaN . Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstetrics &amp; Gynecology2002;100(2):281-7. ">Itamochi 2002</a>; <a href="./references#CD015048-bbs2-0130" title="SolmazU , MatE , DereliML , TuranV , PekerN , TosunG , et al. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?Journal of Balkan Union of Oncology2015;20(3):847-54. ">Solmaz 2015</a>; <a href="./references#CD015048-bbs2-0145" title="UyarD , FrasureHE , MarkmanM , Von GruenigenVE . Treatment patterns by decade of life in elderly women ([greater-than or equal to]70 years of age) with ovarian cancer. Gynecologic Oncology2005;98(3):403-8. ">Uyar 2005</a>; <a href="./references#CD015048-bbs2-0153" title="WadlerS , YeapB , VoglS , CarboneP . Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results - Eastern Cooperative Oncology Group study E2878. Cancer1996;77(4):733-42. ">Wadler 1996</a>; <a href="./references#CD015048-bbs2-0155" title="WarwickJ , KehoeS , EarlH , LuesleyD , RedmanC , ChanKK . Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. British Journal of Cancer1995;72(6):1513-7. ">Warwick 1995</a>). </p> </li> <li> <p>Non‐platinum based chemotherapy was given to all women in one study (<a href="./references#CD015048-bbs2-0148" title="Van DrielW , SikorskaK , Schagen van LeeuwenJ , SchreuderH , HermansR , deHinghI , et al. A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. Journal of Clinical Oncology2017;35(15 Suppl):5519. ">Van Driel 2017</a>), a proportion of women in four studies (<a href="./references#CD015048-bbs2-0055" title="BardaG , MenczerJ , ChetritA , LubinF , BeckD , PiuraB , et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. American Journal of Obstetrics and Gynecology2004;190(4):1039-45. ">Barda 2004</a>; <a href="./references#CD015048-bbs2-0060" title="BonnefoiH , A'HernRP , FisherC , MacfarlaneV , BartonD , BlakeP , et al. Natural history of stage IV epithelial ovarian cancer [see comment]. Journal of Clinical Oncology1999;17(3):767-75. ">Bonnefoi 1999</a>; <a href="./references#CD015048-bbs2-0076" title="deOliveiraCF , LacaveAJ , VillaniC , WolffJP , di ReF , NamerM , et al. Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study. European Journal of Gynaecologic Oncology1990;11(5):323-30. ">de Oliviera 1990</a>; <a href="./references#CD015048-bbs2-0142" title="TingulstadS , SkjeldestadFE , HagenB . The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstetrics and Gynecology2003;102(3):499-505. ">Tingulstad 2003</a>), and chemotherapy data were absent in the <a href="./references#CD015048-bbs2-0053" title="BaileyJ , MurdochJ , AndersonR , WeeksJ , FoyC . Stage III and IV ovarian cancer in the South West of England: five-year outcome analysis for cases treated in 1998. International Journal of Gynecological Cancer2006;1:25-9. ">Bailey 2006</a> study. Women received preoperative chemotherapy in two studies (<a href="./references#CD015048-bbs2-0126" title="ShinozukaT , MiyamotoT , MuramatsuT , HirasawaT , MurakamiM , MakinoT , et al. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients. Cancer1999;85(7):1555-64. ">Shinozuka 1999</a>; <a href="./references#CD015048-bbs2-0136" title="SunT , FengY , ZhuY, ZhengY . Therapeutic strategy in the management of stage II - IV epithelial ovarian carcinoma. Chinese Medical Journal2000;113(7):625-7. ">Sun 2000</a>). </p> </li> <li> <p>Four studies included women who received neoadjuvant chemotherapy and interval debulking surgery but did not report an appropriate comparison by extent of disease (<a href="./references#CD015048-bbs2-0074" title="DaoF , SchlappeBA , TsengJ , LesterJ , NickAM , LutgendorfSK , et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecologic Oncology2016;141:260-3. ">Dao 2016</a>; <a href="./references#CD015048-bbs2-0143" title="TodoY , SakuragiN , OikawaM , NegishiH , YamamotoR , YoshiakiK , et al. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma. International Journal of Clinical Oncology2003;8(2):90-6. ">Todo 2003</a>; <a href="./references#CD015048-bbs2-0147" title="Van Der BurgMEL , Van LentM , BuyseM , KobierskaA , MaggioniA , FavalliG , et al. The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study. International Journal of Gynecological Cancer1996;6:30-8. ">Van Der Burg 1996</a>; <a href="./references#CD015048-bbs2-0149" title="vanVlietMML , SchreuderHWR , Pasker-de JongPCM , DukMJ . Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital. European Journal of Obstetrics, Gynecology, and Reproductive Biology2015;192:72-8. ">van Vliet 2015</a>). </p> </li> <li> <p>Seven studies included women with early‐stage disease and it was not possible to distinguish between early‐ and advanced‐stage participants (<a href="./references#CD015048-bbs2-0071" title="CrawfordSC , VaseyPA , PaulJ , HayA , DavisJA , KayeSB . Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. Journal of Clinical Oncology2005;23(34):8802-11. ">Crawford 2005</a>; <a href="./references#CD015048-bbs2-0077" title="di ReF , BaiocchiG , FontanelliR , GrossoG , CobellisL , RaspagliesiF , et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecologic Oncology1996;62(3):360-5. ">di Re 1996</a>; <a href="./references#CD015048-bbs2-0082" title="GeislerJP , TammelaJE , ManahanKJ , GeislerHE , MillerGA , ZhouZ , et al. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up. European Journal of Gynaecological Oncology2004;25(2):165-8. ">Geisler 2004</a>; <a href="./references#CD015048-bbs2-0128" title="SkarlosDV , AravantinosG , KosmidisP , PavlidisN , GennatasK , BeerM , et al. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic Co-operative Oncology Group study. European Journal of Cancer1996;32(3):421-8. ">Skarlos 1996</a>; <a href="./references#CD015048-bbs2-0129" title="SmitsA , SmitsE , LopesA , DasN , HughesG , TalaatA , et al. Body mass index, physical activity and quality of life of ovarian cancer survivors: time to get moving?Gynecologic Oncology2015;139(1):148-54. ">Smits 2015</a>; <a href="./references#CD015048-bbs2-0138" title="TakanoMJ , KikuchiY , YaegashiN , SuzukiM , TsudaH , SagaeS , et al. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncology Reports2006;16(6):1301-6. ">Takano 2006</a>; <a href="./references#CD015048-bbs2-0139" title="TakanoM , SugiyamaT , YaegashiN , SuzukiM , SagaeS , Udagawa, et al. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. International Journal of Clinical Oncology2007;12(4):256-60. ">Takano 2007</a>). The <a href="./references#CD015048-bbs2-0103" title="LeT , KrepartGV , Lotocki RJ , HeywoodMS . Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?Gynecologic Oncology1997;67(2):208-14. ">Le 1997</a> study did not report the survival data from the stage IIIC and IV subgroup and the authors no longer had access to these data. </p> </li> <li> <p>Two studies reported a HR for overall survival but did not include the corresponding 95% confidence interval, standard error (SE) (lnHR) or exact P value (<a href="./references#CD015048-bbs2-0054" title="BakerTR , PiverMS , HemplingRE . Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer1994;74(2):656-63. ">Baker 1994</a>; <a href="./references#CD015048-bbs2-0112" title="OmuraGA , BundyBN , BerekJS , CurryS , Delgado G MortelR . Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1989;7(4):457-65. ">Omura 1989</a>). </p> </li> <li> <p>The study <a href="./references#CD015048-bbs2-0120" title="RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al and the Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):89-97. ">Rose 2004</a> reported on outcomes after secondary debulking surgery. However, the trial statistician (Dr Mark Brady) of the included study <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> alerted us to the results of GOG 152, which reported by residual disease after primary cytoreductive surgery. </p> </li> <li> <p><a href="./references#CD015048-bbs2-0123" title="SalaniR , ZahurakML , SantillanA , GiuntoliRL , BristowRE . Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecologic Oncology2007;107(3):495-9. ">Salani 2007</a> was excluded because it was a case‐control study. </p> </li> <li> <p>The <a href="./references#CD015048-bbs2-0159" title="YamamotoS , TsudaH , YoshikawaT , KudohK , KitaT , FuruyaK , et al. Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. American Journal of Surgical Pathology2007;31(7):999-1006. ">Yamamoto 2007</a> study included 67 selected women with rare histological subtypes and the <a href="./references#CD015048-bbs2-0081" title="GasimliK , BraicuEI , NassirM , RichterR , BabayevaA , ChekerovR , et al. Lymph node involvement pattern and survival differences of FIGO IIIC and FIGO IIIA1 ovarian cancer patients after primary complete tumor debulking surgery: a 10-year retrospective analysis of the tumor bank ovarian cancer network. Annals of Surgical Oncology2016;23(4):1279-86. ">Gasimli 2016</a> study included a selective group of women with cytoreduction of tumour to macroscopic optimal disease (0 cm). </p> </li> <li> <p>The <a href="./references#CD015048-bbs2-0052" title="AnuradhaS , DonovanPJ , WebbPM , BrandAH , GohJ , FriedlanderM , et al. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer–a population-based study. Acta Oncologica2016;55(2):226-33. ">Anuradha 2016</a> study focused only on the time interval between surgery and chemotherapy and the <a href="./references#CD015048-bbs2-0110" title="MichaanN , ChongWY , HanNY , LimMC , ParkSY . Prognostic value of pathologic chemotherapy response score in patients with ovarian cancer after neoadjuvant chemotherapy. International Journal of Gynecologic Cancer2018;28(9):1676-82. ">Michaan 2018</a> study focused on chemotherapy response score as an outcome, which is a histopathological scoring system based on morphological features of cancer tissue removed at IDS, but the same as optimal cytoreduction. </p> </li> <li> <p>Six references reporting on three RCTs comparing upfront versus delayed surgery did not report outcomes for extent of residual disease by type of initial primary surgery (<a href="./references#CD015048-bbs2-0066" title="ChekmanC , LayouneR , HocineO , RaissiN , FerhatHA , Ali KhodjaH , et al. An open prospective randomized trial comparing primary complete cytoreduction surgery to debulking surgery after chemotherapy in advanced stage (FIGO's IIIC) ovarian carcinoma. In: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015; 2015 Oct 24-27; Nice, France. 2015:1316. [12185451]">Chekman 2015</a>; <a href="./references#CD015048-bbs2-0079" title="FagottiA , FerrandinaG , VizzielliG , FanfaniF , GallottaV , ChianteraV , et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. European Journal of Cancer2016;59:22-33. [12185453]FagottiA , FerrandinaMG , VizzielliG , PasciutoT , FanfaniF , GallottaV , et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer2020;30(11):1657-64. [PMID: 10.1136/ijgc-2020- 001640]FagottiA , VizzielliG , FerrandinaG , FanfaniF , GallottaV , ChianteraV , et al. Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial). Journal of Clinical Oncology2018;36(15):5516. [12185454]">Fagotti 2020</a>; <a href="./references#CD015048-bbs2-0113" title="OndaT , MatsumotoK , ShibataT , SatoA , FukudaH , KonishiI , et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Japanese Journal of Clinical Oncology2008;38(1):74-7. [12185462]OndaT , SatohT , OgawaG , SaitoT , KasamatsuT , NakanishiT , et al, Japan Clinical Oncology Group. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. European Journal of Cancer2020;130:114-25. OndaT , SatohT , SaitoT , KasamatsuT , NakanishiT , NakamuraK , et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. European Journal of Cancer2016;64:22-31. [12185463]OndaT , SatohT , SaitoT , KasamatsuT , NakanishiT , TakeharaK , et al. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. Journal of Clinical Oncology2018;36(15 Suppl). [12185464]">Onda 2020</a>). </p> </li> <li> <p>Sixteen references reporting on three studies compared the threshold of residual disease based on type of intervention delivered (<a href="./references#CD015048-bbs2-0098" title="KehoeS , HookJ , NankivellM , JaysonGC , KitchenerH , LopesT , et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet2015;386(9990):249-57. [12185455]KehoeS , HookJ , NankivellM . Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Journal of Clinical Oncology2013;31 Suppl(15):Abstract 5500. [12185456]KehoeS , WheelerS . CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=9 (accessed 18/6/2012). [12185457]LawK , MurrayC , KehoeS . CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. In: Annual Meeting of the British Gynaecological Cancer Society; 2006 Nov 30-Dec 1; Manchester, UK. 2006:90. [12185459]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185460]">Kehoe 2015</a>; <a href="./references#CD015048-bbs2-0150" title="GreimelE , KristensenG , VergoteI , HoskinsP , van derBurgME , Casado HerraezA , et al. Quality of life in advanced ovarian cancer patients: a randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy. International Journal of Gynaecological Cancer2011;21:S620. [12185466]GreimelE , KristensenGB , van derBurgME , CoronadoP , RustinG , delRioAS , et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology2013;131(2):437-44. [12185467]VergoteI , AmantF , KristensenG , EhlenT , ReedNS , CasadoA . Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer2011;47(Suppl 3):S88-91. [12185468]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185469]VergoteI , PecorelliS , StuartG . Intergroup Study (EORTC 55971/NCIC OV13). Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/clinicaltrials/EORTC-55971 2003 (accessed 17 June 2012). [12185470]VergoteI , TropéCG , AmantF , EhlenT , ReedNS , CasadoA . Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology2011;29(31):4076-8. [12185471]VergoteI , TropeCG , AmantF , KristensenGB , EhlenT , JohnsonN , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine2010;363(10):943-53. [12185472] [Incl. Supplementary Appendix and Protocol]VerleyeL , OttevangerPB , KristensenGB , EhlenT , JohnsonN , van derBurgME , et al. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. European Journal of Cancer2011;47(1):57-64. [12185473]">Vergote 2010</a>; <a href="./references#CD015048-bbs2-0151" title="VergoteI , CoensC , NankivellM , KristensenG , ParmerM , EhlenT , et al. Meta-analysis of the randomized EORTC and chorus neoadjuvant versus primary debulking trials in advanced tubo-ovarian cancer. International Journal of Gynecological Cancer2016;26(Suppl 3):24-5. VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19(12):1680-7. VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19(12):1680-7. ">Vergote 2018</a>). </p> </li> <li> <p>Four studies were excluded because there was inadequate reporting and/or the full text was not available (<a href="./references#CD015048-bbs2-0073" title="CumminsC , HannahP , LongJ , KumarS , SundarS , BramleyG . VP100 Ultraradical ovarian cancer surgery comparative clinical effectiveness. International Journal of Technology Assessment in Health Care2019;35(S1):97. ">Cummins 2019</a>; <a href="./references#CD015048-bbs2-0078" title="ElgamalM , SahaS , CherryM , SaharanV , ButtarR , WieseD , et al. Prognostic implications of lymph node metastasis in advanced ovarian cancer: analysis of the National Cancer Database 2006 to 2014. Journal of Clinical Oncology2019;0:e17042. ">Elgamal 2019</a>; <a href="./references#CD015048-bbs2-0132" title="StewartJM , ToneAA , BernardiniMQ , FergusonSE , DodgeJ , LaframboiseS , et al. Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy. Gynecologic Oncology2015;137(Suppl 1):43. ">Stewart 2015</a>; <a href="./references#CD015048-bbs2-0144" title="TrhlíkM , SoumarováR , BartošP , KoláčekJ , HorováI , TěžkáM . Neoadjuvant chemotherapy for primary advanced ovarian cancer. In: Biomedical Papers. Vol. 157. 2013:S98. ">Trhlík 2013</a>). </p> </li> <li> <p>One study did not distinguish between upfront and interval debulking primary surgery (<a href="./references#CD015048-bbs2-0121" title="RuscitoI , GasparriML , MarchettiC , CrispinoS , La RussaC , PetrigliaG , et al. Obesity is a key prognostic factor in stage IIIC-IV ovarian cancer diagnosed prior to 65 years of age: a 10-year survival analysis. Gynecologic Oncology2016;141:204. ">Ruscito 2016</a>). </p> </li> </ul> </p> <p>For further details of all the excluded studies see the <a href="./references#CD015048-sec-0123" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD015048-sec-0052"> <h3 class="title" id="CD015048-sec-0052">Risk of bias and quality appraisal in included studies</h3> <p>We assessed the risk of bias at outcome level for overall survival and progression‐free survival for each study using the QUIPS tool (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). Most studies reported overall survival (only two of all PDS studies (<a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>), and just one study of all IDS studies (<a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>) did not report overall survival). The detailed assessments are depicted in the 'Risk of bias (QUIPS)' section in the <a href="./references#CD015048-sec-0122" title="">Characteristics of included studies</a>. </p> <p>We judged most studies included in the review as being at an overall 'moderate' risk of bias as they satisfied some but not all of the domains using the QUIPS tool. (See <a href="#CD015048-tbl-0010">Table 3</a>; <a href="#CD015048-tbl-0011">Table 4</a>; <a href="#CD015048-tbl-0012">Table 5</a>; <a href="#CD015048-tbl-0013">Table 6</a> for risk of bias assessment using the QUIPS tool for overall survival and progression‐free survival in the PDS and IDS studies). </p> <div class="table" id="CD015048-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for overall survival (OS) in primary debulking surgery (PDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> <p><b>participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prognostic factor</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjustment for other</b> </p> <p><b>prognostic factors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> <p><b>and reporting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD015048-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for overall survival (OS) in interval debulking surgery (IDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> <p><b>participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prognostic factor</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjustment for other</b> </p> <p><b>prognostic factors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> <p><b>and reporting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD015048-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for progression‐free survival (PFS) in primary debulking surgery (PDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> <p><b>participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prognostic factor</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjustment for other</b> </p> <p><b>prognostic factors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> <p><b>and reporting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD015048-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for progression‐free survival (PFS) in interval debulking surgery (IDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> <p><b>participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prognostic factor</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjustment for other</b> </p> <p><b>prognostic factors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> <p><b>and reporting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> </tbody> </table> </div> <section id="CD015048-sec-0053"> <h4 class="title">Study participation</h4> <p>Most studies provided adequate details of study participation, which included details of eligible women, descriptions of the population and of the baseline study sample and recruitment, period and place of recruitment, and a description of inclusion and exclusion criteria. We assessed four studies as 'unclear' for this domain (two PDS studies (<a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>) and two IDS studies (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>)), mostly due to a lack of detailed reporting of inclusion criteria. We assessed three studies (one PDS study (<a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>) and two IDS studies (<a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>)) as being at a high risk of bias because they were in abstract form only, providing insufficient information on study participation. </p> <p><b>Applicability: Are there concerns that the included women do not match the review question?</b> </p> <p>All studies matched the review question and there were no applicability concerns. Many studies reported one particular stage of advanced disease, but we were not concerned about this as we performed subgroup analyses by stage. </p> <p>Ten PDS studies appeared to include a strictly representative sample of women with advanced epithelial ovarian cancer, by including stages III and IV combined (<a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>). The <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a> study included a small proportion of women with stage II disease (6.6%) and <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> included 9.3% early stage (I to II) disease, however both were otherwise representative of advanced disease. <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> included a small proportion of women with early‐stage (IA to IIA) disease (3.6%) and an unknown proportion with stage IIB but the main scope was advanced disease so this was likely to be relatively few. The results of the meta‐analyses were robust to the exclusion of this study in sensitivity analyses, so we did not deem the decision to include <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> in the review as being associated with any bias or issues with representativeness of women. </p> <p>Of the 15 IDS included studies, four included a strictly representative sample of participants with advanced ovarian cancer (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). </p> </section> <section id="CD015048-sec-0054"> <h4 class="title">Study attrition</h4> <p>It was unclear if women with incomplete follow‐up were excluded before arriving at the stated sample size in each study. There was insufficient information to permit judgement in all cases as many studies did not examine RD as a prognostic factor as their primary objective. </p> </section> <section id="CD015048-sec-0055"> <h4 class="title">Prognostic factor measurement</h4> <p>Most studies reported a valid and reliable measurement of RD and we assessed these as being at a low risk of bias for the prognostic factor measurement domain. Even though multicentre studies are advantageous in terms of recruitment options and generalisability of participants as well as other positive features, we cautiously assessed the prognostic factor measurement to be unclear in 12 studies (eight PDS studies (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>) and four IDS studies (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>)) that had this design, but these may well have been at a low risk too. </p> <p><b>Applicability: Are there concerns that residual disease, the way that it is measured, or the way that it is interpreted, differ from the review question?</b> </p> <p>RD is measured by the surgeons estimate in all centres and there are no guidelines on how RD should be objectively measured. Therefore, there will be some natural variability in measurement across different centres, but we did not have any concerns about applicability. </p> </section> <section id="CD015048-sec-0056"> <h4 class="title">Outcome measurement</h4> <p>The majority of the studies reported a valid and reliable measurement of outcome for both overall survival and progression‐free survival and we assessed these as being at low risk of bias for the outcome measurement domain. </p> <section id="CD015048-sec-0057"> <h5 class="title">Overall survival</h5> <p>Two studies reported an inappropriate definition of overall survival (one PDS study (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>) and a IDS study (<a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>)) by reporting disease‐specific survival, rather than all‐cause overall survival. Consequently, we assessed these two studies to be at a high risk of bias. Outcome measurement of overall survival was unclear in one PDS study (<a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>) (<a href="#CD015048-tbl-0010">Table 3</a>; <a href="#CD015048-tbl-0011">Table 4</a>). </p> </section> <section id="CD015048-sec-0058"> <h5 class="title">Progression‐free survival</h5> <p>All studies that reported progression‐free survival will have done so based on imaging and tumour markers. However, this is a somewhat subjective outcome and in unblinded studies could be deemed as being at a greater risk of bias. Therefore we judged the outcome measurement domain to be at unclear risk of bias as the measurement of this outcome may or may not have been reliable in certain RD thresholds (<a href="#CD015048-tbl-0012">Table 5</a>; <a href="#CD015048-tbl-0013">Table 6</a>). </p> <p><b>Applicability: Are there concerns that outcome does not match the review question or that follow‐up was not of sufficient duration?</b> </p> <p>We had no applicability concerns for outcome measurement for overall survival and progression‐free survival. </p> </section> </section> <section id="CD015048-sec-0059"> <h4 class="title">Adjustment for other prognostic factors</h4> <p>For this domain, we assessed the appropriateness of confounders and whether important ones that a study should have at least been adjusted for such as age were included in their prognostic models. In cases where other prognostic factors in models were inadequate, we rated the studies as having a high risk of bias. </p> <section id="CD015048-sec-0060"> <h5 class="title">Overall survival</h5> <p>The studies at high risk of bias included seven PDS studies (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>) and nine IDS studies (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). These studies did not adequately adjust for a sufficient number of other prognostic factors in multivariate models or ones included were not pertinent. Adequate adjustment for other prognostic factors was unclear in 12 PDS studies (<a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>) and in three IDS studies (<a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>) (<a href="#CD015048-tbl-0010">Table 3</a>; <a href="#CD015048-tbl-0011">Table 4</a>). </p> </section> <section id="CD015048-sec-0061"> <h5 class="title">Progression‐free survival</h5> <p>The studies at high risk of bias included two PDS studies (<a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>) and six IDS studies (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>; <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). These studies did not adequately adjust for a sufficient number of other prognostic factors in multivariate models or ones included were not pertinent. Adequate adjustment for other prognostic factors was unclear in eight PDS studies (<a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>) and in one IDS study (<a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>) (<a href="#CD015048-tbl-0012">Table 5</a>; <a href="#CD015048-tbl-0013">Table 6</a>). </p> <p><b>Applicability: Did the prognostic factors adjusted for match the review question?</b> </p> <p>There was no reason to doubt the applicability of prognostic factors that were adjusted for in the multivariable models. Some studies may have used a wider range and more pertinent prognostic factors in their models for both overall survival and progression‐free survival, but all studies satisfied our inclusion criteria for appropriateness of prognostic factors in their prognostic models and we had no applicability concerns. </p> <p>Adjusted hazard ratios for survival using multivariable Cox models were used in each study. Any imbalances at baseline between RD thresholds should therefore be accounted for and all adjustments in the included studies met the inclusion criteria for the review. </p> <p>We had applicability concerns in one IDS study (<a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a>), as the multivariable analyses for overall survival and progression‐free survival only adjusted for pathological response to NACT, so there may still be differences between RD thresholds that have not been controlled for. </p> </section> </section> <section id="CD015048-sec-0062"> <h4 class="title">Statistical analysis and reporting</h4> <p>We assessed the statistical analysis and reporting domain as being at high or unclear risk of bias in all included studies for both overall survival and progression‐free survival outcomes. Either no conceptual framework was reported, where the variable selection criteria in the multivariate model was unclear or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. It is also questionable whether this is adequate. </p> <p>Mainly applicable to an IDS setting, it was not possible to distinguish NMRD within the SVRD thresholds in all but one study reporting a comparison of NMRD and SVRD. Only one study separated NMRD from SVRD (RD = 0.1 cm to 1 cm) and all other studies included NMRD in the SVRD group, resulting in serious risk of bias. Inclusion of NMRD in the SVRD category creates a high risk of bias when comparing suboptimal RD. </p> </section> </section> <section id="CD015048-sec-0063"> <h3 class="title" id="CD015048-sec-0063">Findings</h3> <p>Meta‐analyses of survival are based on hazard ratios (HRs) that were adjusted for prognostic variables (see <a href="./appendices#CD015048-sec-0112">Appendix 6</a> (PDS) and <a href="./appendices#CD015048-sec-0113">Appendix 7</a> (IDS) for details). </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may appear to represent substantial or considerable heterogeneity (as measured by the I<sup>2</sup> statistic) in some of the analyses below, but we had no major concerns as the direction of effect was consistent throughout. </p> <p>We have reported the most pertinent comparisons involving SVRD (0.1 cm to 1 cm) versus NMRD, LVRD (&gt; 1 cm) versus NMRD, and LVRD versus SVRD for overall survival and progression‐free survival; these all provided moderate‐certainty evidence. These are the most pertinent comparisons as they are included in clinical guidelines (<a href="./references#CD015048-bbs2-0208" title="National Institute for Health and Care Excellence. Ultra-radical (extensive) surgery for advanced ovarian cancer. NICE Interventional procedure guidance [IPG 470]. https://www.nice.org.uk/guidance/ipg4702013.">NICE 2013</a>), and are the focus of a key area of clinical uncertainty. Other RD comparisons were prespecified and have been provided. </p> <p>The certainty of the evidence assessed using the GRADE approach (<a href="./references#CD015048-bbs2-0189" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490-4.">GRADE Working Group</a>) was moderate for all comparisons involving overall survival and progression‐free survival in a PDS setting and very low in an IDS setting. We restricted to comparisons of the three main reported RD thresholds (NMRD, SVRD and LVRD), since there is no firm guidance for grading the evidence in reviews of prognostic factor analyses (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). Therefore, we did not grade beyond these key RD thresholds (<a href="./full#CD015048-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015048-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD015048-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD015048-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD015048-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD015048-tbl-0006">summary of findings Table 6</a>). The comparison involving any remaining macroscopic disease (RD &gt; 0 cm) and NMRD in an IDS setting was also an important comparison, so this was included in the summary of findings and GRADE assessment (<a href="./full#CD015048-tbl-0007">summary of findings Table 7</a>). </p> <section id="CD015048-sec-0064"> <h4 class="title">Residual disease after upfront primary debulking (cytoreductive) surgery (PDS)</h4> <p>Where possible the meta‐analyses subgrouped studies by FIGO stage (stage III, IIIC, IV and all advanced stages, if studies included all advanced cases together). We conducted subgroup analyses to explore the underlying clinical heterogeneity between the studies. There was no evidence of subgroup differences in any of the subgroup analyses. The results of these subgroup analyses were robust to the findings of the overall pooled estimate for all comparisons, so the results of each subgroup are not discussed in this section (see <a href="./references#CD015048-fig-0005" title="">Analysis 1.1</a> to <a href="./references#CD015048-fig-0031" title="">Analysis 11.2</a>). </p> <p>The SVRD threshold included NMRD in some studies in comparison with LVRD, but only in a small number of studies. In PDS studies, RD &lt; 1 cm means RD 0.1 cm to 1 cm (SVRD), unless otherwise stated. Due to only being an issue in a small number of studies, it was deemed to have a negligible impact on the results and did not affect the risk of bias profiles, the certainty of the evidence or distort the results. We performed sensitivity analyses when necessary. </p> <p>We performed sensitivity analyses in comparisons that included meta‐analysis of more than 10 studies. The use of a fixed‐effect model aided the construction of the pseudo 95% confidence interval lines on the funnel plot (e.g. expected distribution of studies in the absence of heterogeneity and biases (such as publication bias, data irregularities)), as well as allowing us to see how robust the random‐effects model results were in comparison. To further test the robustness of the findings, we additionally conducted a sensitivity analysis excluding studies with the largest weight in the meta‐analyses comparing main RD thresholds, where appropriate. </p> <p>We were cautious about any over‐interpretation of funnel plots as they are typically underpowered. Given the nature of model selection procedures, we did not dismiss the possibility of publication bias. However, it is unclear as to the direction of any bias as, for instance, many highly significant studies only reporting unadjusted analyses found strong evidence that NMRD was associated with prolonged survival compared to other thresholds including SVRD (RD &lt; 1 cm exclusive of 0 cm). </p> </section> <section id="CD015048-sec-0065"> <h4 class="title">Overall survival (risk of death from all causes)</h4> <section id="CD015048-sec-0066"> <h5 class="title">Small‐volume residual disease (SVRD) versus no macroscopic residual disease (NMRD)</h5> <p>Meta‐analysis of 17 studies, assessing 9404 participants, found that women with SVRD after PDS had more than twice the risk of death compared to women with NMRD (hazard ratio (HR) 2.03, 95% confidence interval (CI) 1.80 to 2.29). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent moderate heterogeneity (I<sup>2</sup> = 50%) (<a href="./references#CD015048-fig-0005" title="">Analysis 1.1</a>) (<a href="./full#CD015048-tbl-0001">summary of findings Table 1</a>) (<a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a>; <a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). </p> <p>The results were robust to a sensitivity analysis that used a fixed‐effect model and one that excluded the <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> study, which included a slight proportion of women with early or unknown stage (12.5%) disease. It also contributed the largest weight in the meta‐analysis (see <a href="./references#CD015048-fig-0006" title="">Analysis 1.2</a>; <a href="./references#CD015048-fig-0007" title="">Analysis 1.3</a>). </p> <p>There did not appear to be any evidence of small study biases, such as publication bias, or any irregularities with the data by visual inspection of a funnel plot (<a href="#CD015048-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD015048-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 SVRD (&lt; 1 cm) versus NMRD, outcome: 1.2 Overall survival" data-id="CD015048-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 SVRD (&lt; 1 cm) versus NMRD, outcome: 1.2 Overall survival</p> </div> </div> </div> </section> <section id="CD015048-sec-0067"> <h5 class="title">Large‐volume residual disease (LVRD) (&gt; 1 cm) versus NMRD</h5> <p>Meta‐analysis of 14 studies, assessing 7988 participants, found that women with LVRD after PDS were associated with two and a half times the risk of death compared to women with NMRD (HR 2.50, 95% CI 2.13 to 2.94). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent substantial heterogeneity (I<sup>2</sup> = 63%) (<a href="./references#CD015048-fig-0011" title="">Analysis 2.1</a>) (<a href="./full#CD015048-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a>; <a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a>; <a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a>; <a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a>; <a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>). </p> <p>The results were robust to a sensitivity analysis that used a fixed‐effect model and one that excluded the two studies with the largest weights in the meta‐analysis (<a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>) (see <a href="./references#CD015048-fig-0012" title="">Analysis 2.2</a>; <a href="./references#CD015048-fig-0013" title="">Analysis 2.3</a>). </p> <p>There did not appear to be any evidence of small study biases, such as publication bias, or any irregularities with the data by visual inspection of a funnel plot (<a href="#CD015048-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD015048-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 4 LVRD (&gt; 1 cm) versus NMRD, outcome: 2.2 Overall survival" data-id="CD015048-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 4 LVRD (&gt; 1 cm) versus NMRD, outcome: 2.2 Overall survival</p> </div> </div> </div> </section> <section id="CD015048-sec-0068"> <h5 class="title">LVRD versus SVRD</h5> <p>Meta‐analysis of five studies, assessing 6000 participants, found that women with LVRD after PDS was associated with a greater risk of death compared to women with SVRD &lt; 1 cm (HR 1.22, 95% CI 1.13 to 1.32; 6000 participants). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance is not important (I<sup>2</sup> = 0%) (<a href="./references#CD015048-fig-0015" title="">Analysis 3.1</a>) (<a href="./full#CD015048-tbl-0003">summary of findings Table 3</a>) (<a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). The results were robust to a sensitivity analysis that excluded the <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> study with the largest weight in the meta‐analysis (and a relatively small proportion of women with early or unknown stage (12.5%) disease) (see <a href="./references#CD015048-fig-0016" title="">Analysis 3.2</a>). </p> <p>The results were also robust when only including the three studies that contributed majority of the weight in the meta‐analysis and did not include NMRD in the SVRD category (HR 1.20, 95% CI 1.10 to 1.30; 5594 participants; I<sup>2</sup> = 0%) (<a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a>; <a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a>)(see <a href="./references#CD015048-fig-0017" title="">Analysis 3.3</a>). </p> <p>Similarly, meta‐analysis of two studies that included NMRD in the SVRD category arrived at the same conclusion (HR 1.37, 95% CI 1.09 to 1.72; 435 participants; I<sup>2</sup> = 0%) (<a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). Only <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> reported the proportion of women with NMRD (n = 29/107 of participants in the SVRD category)(see <a href="./references#CD015048-fig-0018" title="">Analysis 3.4</a>). </p> </section> <section id="CD015048-sec-0069"> <h5 class="title">Residual disease (RD) &gt; 0 cm versus NMRD</h5> <p>Meta‐analysis of four studies, assessing 1220 participants, found that women who had RD greater than 0 cm after PDS were associated with a two‐fold increase in the risk of death compared to women with NMRD (HR 1.96, 95% CI 1.44 to 2.67). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent moderate heterogeneity (I<sup>2</sup> = 49%) (<a href="./references#CD015048-fig-0020" title="">Analysis 4.1</a>) (<a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>). The authors of <a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> additionally found that the risk of death for women with any remaining RD after PDS was higher than for those with NMRD (238 participants; P = 0.003), but the magnitude of effect was not reported. </p> </section> <section id="CD015048-sec-0070"> <h5 class="title">RD 1 cm to 2 cm versus NMRD</h5> <p>The <a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a> study, which included only women with stage IIIC disease, found that women who had RD between 1 cm and 2 cm after PDS were associated with a nearly four‐fold increase in the risk of death compared to women with NMRD (HR 3.95, 95% CI 1.33 to 11.78; 68 participants) (<a href="./references#CD015048-fig-0022" title="">Analysis 5.1</a>). </p> </section> <section id="CD015048-sec-0071"> <h5 class="title">RD &gt; 2 cm versus NMRD</h5> <p>The <a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a> study, which included only women with stage IIIC disease, found that women with LVRD &gt; 2 cm after PDS were associated with more than eight times the risk of death compared to women with NMRD (HR 8.24, 95% CI 2.68 to 25.33; 87 participants) (<a href="./references#CD015048-fig-0023" title="">Analysis 6.1</a>). </p> </section> <section id="CD015048-sec-0072"> <h5 class="title">RD 1 cm to 5 cm versus NMRD</h5> <p>The <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> study, which included only women with stage IV disease, found that women who had LVRD between 1 cm and 5 cm after PDS were associated with a greater risk of death compared to women with NMRD (HR 1.83, 95% CI 1.14 to 2.94; 193 participants) (<a href="./references#CD015048-fig-0024" title="">Analysis 7.1</a>). </p> </section> <section id="CD015048-sec-0073"> <h5 class="title">RD &gt; 5 cm versus NMRD</h5> <p>The <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> study, which included only women with stage IV disease, found that women who had LVRD &gt; 5 cm after PDS were associated with more than two and a half times the risk of death compared to women with NMRD (HR 2.72, 95% CI 1.65 to 4.47; 118 participants) (<a href="./references#CD015048-fig-0026" title="">Analysis 8.1</a>). </p> </section> <section id="CD015048-sec-0074"> <h5 class="title">RD 1 cm to 2 cm versus SVRD</h5> <p>The <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> study found that women who had LVRD between 1 cm and 2 cm after PDS were associated with a greater risk of death compared to women with SVRD (HR 1.70, 95% CI 1.10 to 2.60; 144 participants) (<a href="./references#CD015048-fig-0028" title="">Analysis 9.1</a>). The SVRD category in the <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> study included NMRD. </p> </section> <section id="CD015048-sec-0075"> <h5 class="title">RD &gt; 2 cm versus SVRD</h5> <p>The <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> study found that women with LVRD &gt; 2 cm after PDS were associated with twice the risk of death compared to women with SVRD (HR 2.00, 95% CI 1.34 to 2.99; 208 participants) (<a href="./references#CD015048-fig-0029" title="">Analysis 10.1</a>). The SVRD category in the <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> study included NMRD. </p> </section> <section id="CD015048-sec-0076"> <h5 class="title">RD &gt; 2 cm versus RD &lt; 2 cm</h5> <p>Meta‐analysis of two studies, which included only women with stage IV disease and assessed 478 participants, found no statistically significant difference in the risk of death between women with LVRD &gt; 2 cm after PDS and those with RD &lt; 2 cm (HR 1.63, 95% CI 0.83 to 3.23). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance alone may represent considerable heterogeneity (I<sup>2</sup> = 89%) (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). The two studies were inconsistent: the <a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a> study reported a large survival difference in favour of RD &lt; 2 cm, whereas <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> found no difference in overall survival (<a href="./references#CD015048-fig-0030" title="">Analysis 11.1</a>). The &lt; 2 cm category included NMRD in both studies, so this category had a mix of NMRD and SVRD &lt; 1 cm as well as LVRD between 1 cm to 2 cm. </p> <p>The authors of <a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a> reported the same comparison, but found evidence that more RD is associated with increased risk of death (HR 1.83, 95% CI not reported; 219 participants; P &lt; 0.0001). Similarly, in two publications by <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a> in the same cohort of women, survival was significantly worse in women with LVRD &gt; 2 cm compared to less remaining RD (1 cm to 2 cm as no women had SVRD) after PDS (n = 294 women with stage III disease, P &lt; 0.01). The authors note that there was little notable difference in the risk of death between any volume of RD in comparisons of LVRD &gt; 2 cm up to &gt; 10 cm. In a further analysis including all advanced stages of disease (n = 458), women with stage III disease and LVRD &gt; 2 cm had a lower risk of death than either those with stage III disease and LVRD &gt; 2 cm, or those with stage IV disease (P = 0.012). </p> </section> </section> <section id="CD015048-sec-0077"> <h4 class="title">Progression‐free survival (risk of disease progression)</h4> <section id="CD015048-sec-0078"> <h5 class="title">SVRD versus NMRD</h5> <p>Meta‐analysis of 10 studies, assessing 6596 participants, found that women with SVRD after PDS were associated with nearly twice the risk of disease progression compared to women with NMRD (HR 1.88, 95% CI 1.63 to 2.16). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance alone may represent substantial heterogeneity (I<sup>2</sup> = 63%) (<a href="./references#CD015048-fig-0008" title="">Analysis 1.4</a>) (<a href="./full#CD015048-tbl-0001">summary of findings Table 1</a>) (<a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a>; <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). </p> <p>The results were robust to a sensitivity analysis that used a fixed‐effect model and one that excluded the <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> study with the largest weight in the meta‐analysis (and a slight proportion of women with early or unknown stage (12.5%) disease) (see <a href="./references#CD015048-fig-0009" title="">Analysis 1.5</a>; <a href="./references#CD015048-fig-0010" title="">Analysis 1.6</a>). </p> <p>There did not appear to be any evidence of small study biases, such as publication bias, or any irregularities with the data by visual inspection of a funnel plot (<a href="#CD015048-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD015048-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 SVRD (&lt; 1 cm) versus NMRD, outcome: 1.5 Progression‐free survival" data-id="CD015048-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 SVRD (&lt; 1 cm) versus NMRD, outcome: 1.5 Progression‐free survival </p> </div> </div> </div> </section> <section id="CD015048-sec-0079"> <h5 class="title">LVRD (&gt; 1 cm) versus NMRD</h5> <p>Meta‐analysis of six studies, assessing 2629 participants, found that women with LVRD after PDS had more than twice the risk of disease progression compared to women with NMRD (HR 2.10, 95% CI 1.84 to 2.40). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may not be important (I<sup>2</sup> = 24%) (<a href="./references#CD015048-fig-0014" title="">Analysis 2.4</a>) (<a href="./full#CD015048-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a>; <a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a>; <a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a>; <a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a>; <a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a>; <a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>). </p> </section> <section id="CD015048-sec-0080"> <h5 class="title">LVRD versus SVRD</h5> <p>Meta‐analysis of two studies, assessing 3402 participants, found that women with LVRD &gt; 1 cm after PDS had a greater risk of disease progression compared to women with SVRD (HR 1.30, 95% CI 1.08 to 1.56). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance alone may represent moderate heterogeneity (I<sup>2</sup> = 53%) (<a href="./references#CD015048-fig-0019" title="">Analysis 3.5</a>) (<a href="./full#CD015048-tbl-0003">summary of findings Table 3</a>) (<a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>). <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> included NMRD in the SVRD category, but this only represented a small proportion in the analysis (n = 29/107 of participants in the SVRD category). </p> </section> <section id="CD015048-sec-0081"> <h5 class="title">RD &gt; 0 cm versus NMRD</h5> <p>Meta‐analysis of three studies, assessing 1029 participants, found that women who had RD greater than 0 cm after PDS had more than one and a half times the risk of death compared to women with NMRD (HR 1.60, 95% CI 1.36 to 1.89). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance is not important (I<sup>2</sup> = 0%) (<a href="./references#CD015048-fig-0021" title="">Analysis 4.2</a>) (<a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a>; <a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a>; <a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a>). The authors of <a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> additionally found that the risk of disease progression for women with any remaining RD was higher than those with NMRD (n = 259, P = 0.032), but the magnitude of effect was not reported. </p> </section> <section id="CD015048-sec-0082"> <h5 class="title">LVRD 1 cm to 5 cm versus NMRD</h5> <p>The <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> study, which included only women with stage IV disease, found that women who had LVRD between 1 cm and 5 cm after PDS had more than twice the risk of disease progression compared to women with NMRD (HR 2.15, 95% CI 1.38 to 3.34; 193 participants) (<a href="./references#CD015048-fig-0025" title="">Analysis 7.2</a>). </p> </section> <section id="CD015048-sec-0083"> <h5 class="title">LVRD &gt; 5 cm versus NMRD</h5> <p>The <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> study, which included only women with stage IV disease, found that women who had LVRD between 1 cm and 5 cm after PDS had nearly three times the risk of disease progression compared to women with NMRD (HR 2.96, 95% CI 1.86 to 4.71; 118 participants) (<a href="./references#CD015048-fig-0027" title="">Analysis 8.2</a>). </p> </section> <section id="CD015048-sec-0084"> <h5 class="title">RD &gt; 2 cm versus RD &lt; 2 cm</h5> <p>The <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> study, which included only women with stage IV disease, found that women with LVRD &gt; 2 cm after PDS had a slightly greater risk of disease progression compared to those with RD &lt; 2 cm (HR 1.27, 95% CI 1.01 to 1.61; 253 participants) (<a href="./references#CD015048-fig-0031" title="">Analysis 11.2</a>). </p> <p><a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> included NMRD in the &lt; 2 cm category, but this only represented a small proportion in the analysis (n = 29/157 of participants in the RD &lt; 2 cm category). </p> </section> </section> <section id="CD015048-sec-0085"> <h4 class="title">Residual disease after interval debulking surgery (IDS)</h4> <p>All meta‐analyses included studies with participants with stage III and IV disease, other than in three studies where a specific breakdown was not reported (<a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>). Therefore, we could not conduct subgroup analyses by stage to explore any underlying clinical heterogeneity between the studies as planned. However, we did perform subgroup analyses including cycle duration where possible (see <a href="./references#CD015048-fig-0032" title="">Analysis 12.1</a> to <a href="./references#CD015048-fig-0038" title="">Analysis 14.4</a>). There was no evidence of any subgroup differences and all analyses were robust to the findings of the overall pooled estimates for all comparisons, with the exception of overall survival in the comparison of any remaining macroscopic disease versus NMRD (test for subgroup differences P = 0.01) (<a href="./references#CD015048-fig-0039" title="">Analysis 15.1</a>). However, the general direction of effect estimates was consistent and the findings were robust. </p> <p><a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> reported disease‐specific survival (DSS) rather than overall survival, but this study did not appear to introduce statistical heterogeneity from visual inspection of the forest plot and the conclusions were robust to its exclusion in <a href="./references#CD015048-fig-0036" title="">Analysis 14.2</a>. </p> <p>All comparisons involving SVRD included NMRD when compared to LVRD &gt; 1 cm unless otherwise stated. The <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a> study was the only exception to this and reported an adequate comparison of LVRD &gt; 1 cm versus SVRD using recognised RD threshold definitions, i.e. &gt; 0 cm but &lt; 1 cm residual disease as distinct from NMRD. </p> <p>The comparison involving any remaining macroscopic disease (RD &gt; 0 cm) and NMRD in an IDS setting was also an important comparison so we additionally gave this a certainty of the evidence judgement (<a href="./full#CD015048-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD015048-sec-0086"> <h4 class="title">Overall survival (risk of death from all causes)</h4> <section id="CD015048-sec-0087"> <h5 class="title">SVRD versus NMRD</h5> <p>Meta‐analysis of two groups of women from the same study undergoing different chemotherapy schedules found that women with SVRD after IDS had more than twice the risk of death compared to women with NMRD (HR 2.09, 95% CI 1.20 to 3.66; 310 participants) (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent moderate heterogeneity (I<sup>2</sup> = 56%) (<a href="./references#CD015048-fig-0032" title="">Analysis 12.1</a>). The magnitude of this effect was greater in this study in women who received &gt; 4 cycles of neoadjuvant chemotherapy prior to their IDS (HR 2.78, 95% CI 1.66 to 4.65), but there was no significant difference or certainly a suggestion that there may be less of a difference between women with NMRD and those with SVRD when receiving ≤ 4 cycles of chemotherapy prior to IDS (HR 1.57, 95% CI 0.93 to 2.66) (<a href="./full#CD015048-tbl-0004">summary of findings Table 4</a>). </p> <p>The authors of <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> additionally found that the risk of death for women with SVRD after neoadjuvant chemotherapy (the majority received three or four cycles) before IDS was significantly higher than those with NMRD (n = 322, P = 0.001), but the magnitude of effect was not reported. </p> </section> <section id="CD015048-sec-0088"> <h5 class="title">LVRD (&gt; 1 cm) versus NMRD</h5> <p>Meta‐analysis of two groups of women with different chemotherapy schedules, as outlined above, assessing 343 participants, found that women with LVRD &gt; 1 cm after IDS had more than twice the risk of death compared to women with NMRD (HR 2.23, 95% CI 1.49 to 3.34). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent moderate heterogeneity (I<sup>2</sup> = 35%) (<a href="./references#CD015048-fig-0034" title="">Analysis 13.1</a>) (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). The magnitude of this effect was more pronounced in this study in women who received &gt; 4 cycles of neoadjuvant chemotherapy prior to IDS (HR 2.67, 95% CI 1.76 to 4.06) (<a href="./full#CD015048-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD015048-sec-0089"> <h5 class="title">RD &gt; 1 cm versus RD &lt; 1 cm</h5> <p>Only <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a> compared SVRD versus LVRD &gt; 1 cm in the strict sense that SVRD is mutually exclusive of NMRD. This was an important comparison and meta‐analysis of the two groups in the study (three to six chemotherapy cycles) showed little difference in the risk of death between the SVRD and LVRD thresholds (HR 1.02, 95% CI 0.68 to 1.55; 343 participants). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important (I<sup>2</sup> = 0%) (<a href="./references#CD015048-fig-0035" title="">Analysis 14.1</a>). </p> <p>The other five studies included NMRD in the SVRD category (referring to it as ‘optimal’) in their multivariate analyses. Nearly half of the women (261/550 (47%)) in the SVRD thresholds included NMRD in three studies (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>). This was not reported in the other two studies (<a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). </p> <p>A sensitivity analysis that meta‐analysed all six studies, assessing 1572 participants, found that women with LVRD &gt; 1 cm after IDS had a statistically significant greater risk of death compared to women with SVRD or NMRD (HR 1.60, 95% CI 1.21 to 2.11). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent substantial heterogeneity (I<sup>2</sup> = 58%) (<a href="./references#CD015048-fig-0036" title="">Analysis 14.2</a>) (<a href="./full#CD015048-tbl-0006">summary of findings Table 6</a>) (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). </p> <p>Sensitivity analysis, excluding <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>, led to an increase in effect estimates in a meta‐analysis involving the five remaining studies (HR 1.84, 95% CI 1.34 to 2.52; 1429 participants; I<sup>2</sup> = 61%) (<a href="./references#CD015048-fig-0037" title="">Analysis 14.3</a>). </p> </section> <section id="CD015048-sec-0090"> <h5 class="title">RD &gt; 0 cm versus NMRD</h5> <p>Meta‐analysis of four studies, assessing 906 women, found that any macroscopic RD after IDS was associated with more than twice the risk of death compared with NMRD (HR 2.11, 95% CI 1.35 to 3.29). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent considerable heterogeneity (I<sup>2</sup> = 81%) (<a href="./references#CD015048-fig-0039" title="">Analysis 15.1</a>) (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>). For subgroup analysis by duration of NACT, we found evidence of a subgroup difference (P = 0.01, median of six cycles in two studies: N = 242, median four cycles in one study: N = 193, all range of cycles in one study: N = 471). However, the direction of effect was consistent in all studies, showing a survival benefit in the NMRD group (<a href="./references#CD015048-fig-0039" title="">Analysis 15.1</a>). </p> <p>The authors of <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> additionally found that the risk of death for women with any remaining RD (&gt; 0 cm) after IDS was significantly higher than those with NMRD (n = 163, P &lt; 0.01), but the magnitude of effect was not reported (<a href="./full#CD015048-tbl-0007">summary of findings Table 7</a>). </p> </section> </section> <section id="CD015048-sec-0091"> <h4 class="title">Progression‐free survival (risk of disease progression)</h4> <section id="CD015048-sec-0092"> <h5 class="title">SVRD (&lt; 1 cm) versus NMRD</h5> <p>Meta‐analysis of two studies, assessing 248 women, found no difference in disease progression in women with SVRD after IDS and those with NMRD (HR 3.03, 95% CI 0.81 to 11.38). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance alone may represent considerable heterogeneity (I<sup>2</sup> = 94%) (<a href="./references#CD015048-fig-0033" title="">Analysis 12.2</a>) (<a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a>; <a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a>). </p> <p>The authors of <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> found that the risk of disease progression for women with SVRD after IDS was higher than those with NMRD (n = 322, P = 0.001), but the magnitude of effect was not reported. </p> </section> <section id="CD015048-sec-0093"> <h5 class="title">LVRD (&gt; 1 cm) versus SVRD</h5> <p>Meta‐analysis of four studies found that achieving LVRD &gt; 1 cm after IDS was associated with a greater risk of disease progression compared to women in whom SVRD was achieved after surgery (HR 1.76, 95% CI 1.23 to 2.52; 1145 participants). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance alone may represent substantial heterogeneity (I<sup>2</sup> = 60%) (<a href="./references#CD015048-fig-0038" title="">Analysis 14.4</a>) (<a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>). These four studies included NMRD in the SVRD category (referring to it as ‘optimal’) in their multivariate analyses. </p> </section> <section id="CD015048-sec-0094"> <h5 class="title">RD &gt; 0 cm versus NMRD</h5> <p>The <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> study, assessing 471 women, found that RD &gt; 0 cm after IDS was associated with an increased risk of disease progression compared those in whom NMRD was achieved (HR 1.36, 95% CI 1.05 to 1.76) (<a href="./references#CD015048-fig-0040" title="">Analysis 15.2</a>). </p> <p>The authors of <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> found that the risk of disease progression for women with RD &gt; 0 cm after IDS was higher than those with NMRD (n = 163, P &lt; 0.01), but the magnitude of effect was not reported (<a href="./full#CD015048-tbl-0007">summary of findings Table 7</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015048-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015048-sec-0095"></div> <section id="CD015048-sec-0096"> <h3 class="title" id="CD015048-sec-0096">Summary of main results</h3> <p>We found 46 studies reporting multivariate prognostic analyses that included residual disease (RD) as a prognostic factor, which met our inclusion criteria. These studies assessed survival after upfront primary debulking surgery (PDS) followed by adjuvant chemotherapy and neoadjuvant chemotherapy with interval debulking surgery (IDS) in advanced epithelial ovarian cancer. The review included 22,376 women who underwent PDS and 3697 women who underwent IDS, all with varying levels of RD. The main results of our review are summarised in the summary of findings tables (<a href="./full#CD015048-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015048-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD015048-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD015048-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD015048-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD015048-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD015048-tbl-0007">summary of findings Table 7</a>). </p> <p>In PDS studies, meta‐ and single‐study analyses demonstrate the prognostic importance of achieving no macroscopic residual disease (NMRD) after PDS for both overall and progression‐free survival. Most studies showed an association with an increased risk of death in all groups with visible disease after surgery when compared to NMRD. The most pertinent comparison found that women who were debulked to leave small‐volume residual disease (SVRD) after PDS had more than twice the risk of death compared to women with NMRD (meta‐analysis of 17 studies: hazard ratio (HR) 2.03, 95% confidence interval (CI) 1.80 to 2.29; I<sup>2</sup> = 50%; 9404 participants; moderate‐certainty evidence). Progression‐free survival was not reported in all of the studies, but was sufficiently documented to allow conclusions to be drawn. The main comparison found that women who were debulked to SVRD after PDS had nearly twice the risk of disease progression compared to women with NMRD (meta‐analysis of 10 studies: HR 1.88, 95% CI 1.63 to 2.16; I<sup>2</sup> = 63%; 6596 participants; moderate‐certainty evidence). The fact that all of the studies included at least 100 women and used multivariate adjustment for important prognostic factors increased the level of certainty in the estimates. </p> <p>When we compared large‐volume residual disease (LVRD) (&gt; 1 cm) versus SVRD cytoreduction the estimates were attenuated compared to the macroscopic RD comparisons. All analyses showed a survival benefit in women who had been debulked to leave SVRD (HR 1.22, 95% CI 1.13 to 1.32, I<sup>2</sup> = 0%, 6000 participants; moderate‐certainty evidence). The results were robust to analyses of progression‐free survival. </p> <p>For neoadjuvant chemotherapy with IDS, the main comparisons involved any visible RD versus NMRD and LVRD (&gt; 1 cm) versus SVRD. Unfortunately, it was not possible to distinguish those with NMRD after surgery within the SVRD thresholds in all but one study. A study reporting two groups of women on different chemotherapy schedules found that women who were debulked to leave SVRD and LVRD (&gt; 1 cm) after IDS had more than twice the risk of death compared to women who had NMRD (HR 2.09, 95% CI 1.20 to 3.66; 310 participants; I<sup>2</sup> = 56% and HR 2.23, 95% CI 1.49 to 3.34; 343 participants; I<sup>2</sup> = 35%; very low‐certainty evidence, for SVRD versus NMRD and LVRD versus NMRD, respectively). Women who had any amount of macroscopic RD (&gt; 0 cm) after IDS had more than twice the risk of death compared to women with NMRD (HR 2.11, 95% CI 1.35 to 3.29, I<sup>2</sup> = 81%; 906 participants; very low‐certainty evidence). Another study also found prolonged survival when RD was cytoreduced to NMRD (P &lt; 0.01). </p> <p>Unfortunately, in IDS studies the SVRD threshold included those with NMRD in all but one study (nearly half of women in the SVRD threshold had NMRD in three studies where it was reported). Therefore the reported comparison of NMRD or SVRD versus LVRD &gt; 1 cm was of much lesser importance in IDS studies. Meta‐analysis found that women who were debulked leaving LVRD &gt; 1 cm had a greater risk of death and disease progression compared to women who were debulked to leave SVRD or NMRD (HR 1.60, 95% CI 1.21 to 2.11; 1572 participants; I<sup>2</sup> = 58% for overall survival and HR 1.76, 95% CI 1.23 to 2.52; 1145 participants; I<sup>2</sup> = 60% for progression‐free survival; moderate‐certainty evidence). The SVRD category included NMRD in all but one study, which suggests that only two categories of RD after IDS are being recognised at present, where NMRD remains of paramount prognostic importance. </p> </section> <section id="CD015048-sec-0097"> <h3 class="title" id="CD015048-sec-0097">Overall completeness and applicability of evidence</h3> <p>The evidence from this review indicates that cytoreduction to NMRD after primary surgical cytoreduction is associated with prolonged survival in advanced epithelial ovarian cancer in both PDS and IDS settings. There is more strength in the evidence from studies reporting PDS, but the results suggest that the same conclusions apply in terms of the prognostic importance of NMRD in an IDS setting. More studies, including a larger number of women, will be needed to give more certainty in the effect estimates in comparisons of other RD thresholds, but there has been an emergence of studies using IDS in the last decade, so we expect this to be the case when the review is updated in the future. Interestingly, the comparison of SVRD versus LVRD (&gt; 1 cm) is heterogeneously reported in the PDS and IDS analyses, as in the latter (IDS studies) the SVRD threshold included NMRD in all but one of the studies in the meta‐analysis. Most studies included in the PDS analyses presented mutually exclusive RD thresholds, so there was less of a problem with NMRD being included in the SVRD category. The existing evidence does not currently support three categories of RD after IDS, as was recommended for PDS. </p> <p>Although this review does not enable us to determine whether prolonged survival is a direct effect of the surgical intervention whereby women with NMRD do better, it appears that every effort should be made to attempt this, where possible, in both PDS and IDS settings. It may be particularly important in the latter due to issues with chemotherapy reaching allocation and further treatment options potentially being more limited thereafter. Where NMRD is considered not achievable for PDS, attempts should be made to obtain SVRD, defined as RD greater than 0 cm and less than or equal to 1 cm. There is limited evidence in this review to suggest that this may not be the case for IDS. Further data are needed, as understanding whether there is a benefit to IDS, if NMRD cannot be achieved, would be an important clinical question. However, as this is a prognostic review, we cannot answer this question from these data. Additionally, the data are of very low certainty ‐ we are therefore very uncertain of this finding and drawing any conclusions would be unwise. Answering this question about the benefit of IDS, if NMRD cannot be achieved, would require an intervention study randomised controlled trial (RCT), rather than retrospective analysis of prognostic factors. </p> <p>We found statistical heterogeneity between the studies in some analyses, but the direction of effect was consistent throughout so we had no concerns. We also did not have too many concerns about clinical heterogeneity as we applied restrictive inclusion criteria in terms of patient population, standardised measurement of RD as a prognostic factor and standard definitions of survival. Evaluation of other prognostic factors and biomarkers can often use different criteria for the interpretation of the results and different cut‐off values may introduce levels of heterogeneity. Therefore, RD as a prognostic factor is unlikely to impact on the results or introduce any bias. That is, false‐positive classifications seem much more unlikely than in other prognostic areas. </p> <p>One of the strengths regarding the prognostic factor studies in this review was the ease of reporting in their statistical analyses. Authors mainly reported appropriate methods for their statistical analyses, with only a few studies not reporting the magnitude of effect estimates. We used hazard ratios (HRs) as the effect measure for time‐to‐event data in this review. We were able to provide pooled data for the majority of the included studies in the review. Of the studies that did not report appropriate statistics to extract for inclusion in the meta‐analysis, we could not estimate the HR using other available data (<a href="./references#CD015048-bbs2-0211" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>), as we restricted studies to those using multivariate analyses. We had limited success when contacting chief investigators to provide us with additional information or data from adjusted analyses. </p> <p>In order to minimise bias, we only included studies of multivariate Cox regression models that used sensible adjustment factors associated with survival in women with advanced epithelial ovarian cancer (e.g. age, stage, grade, extent of disease at diagnosis). We excluded studies that only reported unadjusted results. To assess the adequacy of adjustment factors used in multivariate Cox models, we used the 'adjustment for other prognostic factors' and 'statistical analysis and reporting' domains of the quality in prognosis studies (QUIPS) tool (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). Therefore, we prespecified in our protocol that we would only pool adjusted associations of the index prognostic factor. We felt that it was important to suggest a set of pertinent and established covariates a priori that were important to the disease under review (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). This meant that we could better judge which models were adequate. We took these issues around the reporting in the studies into account when we assessed risk of bias and GRADE. The reported results in univariate analyses would have potentially been at a great risk of overestimating survival of RD as a prognostic factor. It is widely accepted that adjusting the predictive effect of a specific prognostic factor for the contribution of other prognostic factors strengthens the robustness of the evidence on the clinically relevant prognostic ability of that factor (<a href="./references#CD015048-bbs2-0162" title="AldinA , UmlauffL , EstcourtLJ , CollinsG , MoonsKG , EngertA , et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD012643. [DOI: 10.1002/14651858.CD012643.pub3]">Aldin 2020</a>; <a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). </p> <p>Treatment‐related morbidity very often degrades the quality of the time that women live, which is especially important after the completion of treatment for advanced cancer where women have poor prognosis and will want to enjoy a comfortable standard of living during their final months. It is unlikely that studies on prognosis will measure or report adverse events, so our focus was on survival as an outcome. This needs to be considered in the context of the findings from this review in that NMRD after PDS is associated with better survival ‐ median survival for NMRD was 85.8 months (95% CI 77.5 to 94.1 months) in the <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> study, which included the largest analysis in the review. This study did include a small proportion of women with stage I and II cancer, but not to the extent of diluting the results too much. The next largest included study reporting median overall survival (71.9 months) also suggested that the potential benefits of prolonging survival may outweigh the disadvantages of any short‐term morbidities associated with the surgical procedure (<a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a>). Similarly, median survival in the NMRD group in IDS studies ranged from 50 months (<a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>) to 51.8 (95% CI 45 to 58.5) months (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>), the second largest analysis of IDS in this review. In terms of the overall survival rate in the NMRD group in IDS studies, <a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a> reported a two‐year and five‐year overall survival rate of 88.8% and 43.4% respectively. </p> </section> <section id="CD015048-sec-0098"> <h3 class="title" id="CD015048-sec-0098">Certainty of the evidence</h3> <p>Our certainty of the evidence is presented in the summary of findings tables (<a href="./full#CD015048-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015048-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD015048-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD015048-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD015048-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD015048-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD015048-tbl-0007">summary of findings Table 7</a>). </p> <p>The 46 studies that met our inclusion criteria had reasonable risk of bias profiles when assessed using QUIPS as a prognostic risk of bias tool (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). We included only sufficiently large studies that controlled for various co‐prognostic factors using multivariate analysis in order to reduce the possibility of bias. </p> <p>The studies reported adjusted hazard ratio estimates using Cox proportional hazards models. A hazard ratio is the best statistic to summarise the difference in risk between groups over the duration of a study when there is 'censoring', that is the time to death (or disease progression) is unknown for some women as they are still alive (or disease‐free) at the end of the study. Most studies were at moderate risk of bias as they satisfied some but not all of the criteria used to assess risk of bias. There were no real applicability concerns in any of the domains. This was largely due to the stringent and restrictive eligibility criteria. We were also cautious when deciding whether studies were selectively reported or whether any additional source of bias may have been present and assessed these items as being unclear. </p> <p>In a PDS setting, for overall survival, all studies in the meta‐analyses used adjusted results from multivariable analyses including important and well‐established prognostic factors in women with advanced ovarian cancer, and the analyses all indicated the independent prognostic ability of thresholds of RD to predict overall survival. For comparisons of the three main reported RD thresholds (NMRD, SVRD and LVRD), we judged the certainty of the evidence as 'moderate' for all these comparisons (<a href="./full#CD015048-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015048-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD015048-tbl-0003">summary of findings Table 3</a>). We downgraded by one level for risk of bias due to some risk of bias concerns. With no firm guidance for grading the evidence in reviews of prognostic factor analyses (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>), we did not grade beyond these key RD thresholds. Similarly, progression‐free survival was reported using the same methodology but in fewer studies. There was still a sufficient number to show that RD thresholds have an independent prognostic ability to predict progression‐free survival. We also judged this outcomes to provide moderate‐certainty evidence and we downgraded by one level for some risk of bias concerns (<a href="./full#CD015048-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015048-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD015048-tbl-0003">summary of findings Table 3</a>). We made the same certainty of the evidence judgements in an IDS setting for overall survival and progression‐free survival. Only one study reported a comparison involving NMRD as a unique group (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). Furthermore, this same study was the only one to report the comparison of SVRD (&lt; 1 cm) versus LVRD (&gt; 1 cm) in the strict sense that SVRD was mutually exclusive of NMRD. The other studies reporting this outcome included NMRD in their SVRD group. Therefore, we downgraded overall survival and progression‐free survival outcomes by one level. We also downgraded for some risk of bias concerns and insufficient and sparse data in the meta‐analyses. Therefore the certainty of the evidence for overall survival and progression‐free survival in an IDS setting was very low (<a href="./full#CD015048-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD015048-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD015048-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD015048-tbl-0007">summary of findings Table 7</a>). The comparison of SVRD versus LVRD (&gt; 1 cm) included one more study than the corresponding analysis involving PDS, but there were significantly fewer women in the analysis (less than a third) and the lack of separation of NMRD from the SVRD threshold was misleading, so that was reason it was judged to provide very low‐certainty evidence (<a href="./full#CD015048-tbl-0006">summary of findings Table 6</a>). Only one study truly reported an adequate comparison of LVRD versus SVRD. </p> <p>In some cases, more data would be needed to see the full impact of leaving behind more considerable disease, although the evidence suggests that if it cannot be minimised to NMRD or SVRD it may not make a significant difference in terms of prolonged survival. The results are consistent and appear to be reliable and precise in terms of the conclusions drawn. Some comparisons were sparse, with wide confidence intervals, but even the lower 95% confidence interval would have been highly significant as a point estimate in many cases. </p> <p>Further research is very unlikely to change our confidence in the estimates of effect in the larger and most pertinent meta‐analyses (exclusively reported in a PDS setting), but may change the estimates for some of the comparisons involving head‐to‐head LVRD thresholds and in analyses that included IDS. However, in the latter the evidence base is likely to be strengthened in future years as there has been an emergence of evidence in the last decade that is expanding, given four RCTs have now demonstrated similar survival outcomes of PDS versus IDS, as reviewed by <a href="./references#CD015048-bbs2-0172" title="ColeridgeSL , BryantA , KehoeS , MorrisonJ . Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD005343. [DOI: 10.1002/14651858.CD005343]">Coleridge 2021</a>. However, this evidence needs to assess whether SVRD is associated with a survival benefit over LVRD in an IDS setting as the evidence is currently very uncertain. </p> </section> <section id="CD015048-sec-0099"> <h3 class="title" id="CD015048-sec-0099">Strengths and weaknesses of the review</h3> <p>We performed a comprehensive search, including a thorough search of the grey literature, and two review authors working independently sifted and data extracted all studies. To prevent bias in this review, at least two review authors, along with willing arbiters, also independently performed all other relevant processes, such as risk of bias and GRADE assessment, and verification of all analyses. Although the methods for grading the evidence from prognosis studies are still under development, we felt that omitting it would be less transparent and potentially create bias in the review. Therefore we followed standard methodology for grading the certainty of the evidence and used specific exemplars from the Cochrane prognostic group for guidance, as well as examining other relevant prognostic factor reviews (<a href="./references#CD015048-bbs2-0162" title="AldinA , UmlauffL , EstcourtLJ , CollinsG , MoonsKG , EngertA , et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD012643. [DOI: 10.1002/14651858.CD012643.pub3]">Aldin 2020</a>). We were not restrictive in our inclusion criteria with regards to types of studies, but limited to prognostic models that used multivariate analyses. This was to ensure that we minimised bias in getting accurate and reflective effect estimates for the prognostic performance of RD. We restricted to studies including at least 100 women in their analyses due to limiting the analyses to multivariate ones and the potential issue with adjustment for multiple prognostic factors in sparse data (<a href="./references#CD015048-bbs2-0209" title="OgundimuEO , AltmanDG , CollinsGS . Adequate sample size for developing prediction models is not simply related to events per variable. Journal of Clinical Epidemiology2016;76:175-82. [DOI: 10.1016/j.jclinepi.2016.02.031]">Ogundimu 2016</a>). There was more chance of drawing satisfactory conclusions in the review as the number of women in each study was adequate. We also conducted analyses using appropriate statistical methods for survival outcomes, namely hazard ratios, which correctly allow for censoring (see above). </p> <p>In the analyses comparing SVRD versus LVRD (&gt; 1 cm) for both PDS and IDS, we included studies that either treated NMRD as a distinct category of SVRD (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>), or included NMRD within the SVRD category (<a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a>; <a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a>; <a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a>; <a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a>; <a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>; <a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a>; <a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a>; <a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>; <a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a>; <a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a>) during analyses. In keeping with the view that there is a dose‐response relationship between RD thresholds and survival, the inclusion of these latter studies will have introduced an overestimation of the survival benefit of SVRD compared to LVRD (&gt; 1 cm) and introduced serious bias. We attempted to determine the extent of this bias by identifying the number of participants with NMRD included in these latter studies, however this information was only provided in four studies – NMRD ranged from 27% (<a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a>) to 72% (<a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a>). Results of analyses in PDS studies were robust to the exclusion of studies that included NMRD within their SVRD category. Similar sensitivity analyses were not practical in the IDS case as only <a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a> adequately reported the comparison involving SVRD that did not include NMRD. </p> <p>A significant threat to the validity of the review is likely to be publication bias; that is, studies that did not find a positive association with the degree of surgical debulking achieved may not have been published. Although we conducted a test for funnel plot asymmetry and there did not appear to be any evidence of small study bias, such as publication bias, this type of test is not necessarily recommended for survival data due to issues of censoring (<a href="./references#CD015048-bbs2-0175" title="DebrayTPA , MoonsKGM , RileyRD . Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests. Research Synthesis Methods2018;9(1):41-50.">Debray 2018</a>). Therefore, we cannot exclude potential publication bias and the presence of small study effects in our review (<a href="./references#CD015048-bbs2-0216" title="RileyRD , MoonsKGM , SnellKIE , EnsorJ , HooftL , AltmanDG , et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ2019;364:k4597.">Riley 2019</a>). Further investigation is beyond the scope of this review. Most included studies included in this review were retrospective and were probably not pre‐registered. Studies are also not always labelled or indexed as prognosis studies, and search filters for studies on prognosis are still under development. Therefore the search had much wider scope than was necessary, but we felt it was better to be overly inclusive to reduce the chance of missing eligible studies for inclusion in the review. </p> </section> <section id="CD015048-sec-0100"> <h3 class="title" id="CD015048-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>In our review, we included studies that have assessed residual disease (RD) as a prognostic factor after primary surgery in women with advanced epithelial ovarian cancer. Overall, the findings from this review are in agreement with similar reviews and studies that have investigated the prognostic value of NMRD in both PDS and IDS settings. They also support the findings that, in general, small‐volume RD is associated with better survival after surgery. The majority of these studies reported univariate analyses and that was one of the exclusion criteria in our review. These univariate analyses widely reported larger magnitudes of effect giving greater levels of statistical significance, but our analyses restricted to estimates that adjusted for sensible covariates that were likely to give less biased and more reliable estimates. Many of these studies are documented in the <a href="./references#CD015048-sec-0123" title="">Characteristics of excluded studies</a> table. </p> <p>The association with improved survival outcomes associated with NMRD categorisation consolidates use of the term 'optimal cytoreduction' by the Gynaecological Cancer Inter‐Group (GCIG) to mean 'NMRD', from its former definition of &lt; 1 cm RD, which we categorised as SVRD. Although the results of our review show that cytoreduction to SVRD is still superior to LVRD (&gt; 1 cm). </p> <p>In a PDS setting, if the term macroscopic cytoreduction is to be used solely for the group where there is NMRD, the moderate‐certainty evidence in this review that women who undergo PDS and achieve SVRD still do better than women who achieve LVRD should prompt the surgical community to retain this category as well as SVRD for RD &lt; 1 cm (and consider the term 'near‐optimal'), while reserving the term LVRD (and consider using 'suboptimal') to cases where the RD is &gt; 1 cm (a three‐category classification of NMRD, SVRD and LVRD, or alternatively consider the terms 'optimal', 'near‐optimal' and 'suboptimal' RD). In contrast, we obtained very low‐certainty evidence from a single IDS study that showed a survival benefit for NMRD compared to SVRD (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). All but one study included NMRD in their comparison of SVRD versus LVRD (&gt; 1 cm) so strong inferences were not possible. Evidence from this one study that reported a valid comparison found little difference in survival outcomes in this comparison of RD thresholds (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). Further evidence from a meta‐analysis including four studies showed that achieving NMRD was associated with superior survival outcomes to having any remaining RD (&gt; 0 cm) (<a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a>; <a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a>; <a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a>; <a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a>). Therefore, given the available evidence, the strongest conclusion renderable is a two‐category classification following IDS (NMRD versus any RD &gt; 0 cm). </p> <p>The debate regarding whether a three‐category classification should hold in both PDS and IDS has also surfaced amongst the surgical community in recent publications. To our knowledge, two retrospective studies of women with advanced epithelial ovarian cancer provided evidence pertinent to this debate (<a href="./references#CD015048-bbs2-0185" title="GhirardiV , MoruzziMC , BizzarriN , VargiuV , D'IndinosanteM , GarganeseG , et al. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: a survival analysis. Gynecologic Oncology2020;157(1):209-13.">Ghirardi 2020</a>; <a href="./references#CD015048-bbs2-0197" title="KobalB , NoventaM , CvjeticaninB , BarbicM , MeglicL , HerzogM , et al. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals. Radiology and Oncology2018;52(3):307-19.">Kobal 2018</a>). One rationale behind these studies was to address whether women in whom PDS achieved SVRD would be conferred similar or better survival compared to those in whom NMRD was achieved following IDS. In the <a href="./references#CD015048-bbs2-0197" title="KobalB , NoventaM , CvjeticaninB , BarbicM , MeglicL , HerzogM , et al. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals. Radiology and Oncology2018;52(3):307-19.">Kobal 2018</a> study, amongst women achieving NMRD, the IDS group had poorer overall survival (36.3 versus 54.7 months; P = 0.012) but similar progression‐free survival (19.9 versus 20.7 months; P = 0.251) compared to the PDS group. On the other hand, achieving NMRD following IDS was associated with similar overall survival (36.3 versus 34.7 months; P = 0.073), but better progression‐free survival (19.9 versus 11.2 months; P = 0.005) compared to achieving SVRD following PDS. In contrast, <a href="./references#CD015048-bbs2-0185" title="GhirardiV , MoruzziMC , BizzarriN , VargiuV , D'IndinosanteM , GarganeseG , et al. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: a survival analysis. Gynecologic Oncology2020;157(1):209-13.">Ghirardi 2020</a> found that achieving NMRD following IDS was associated with poorer overall survival compared to achieving SVRD following PDS (41.4 versus 52.4 months; P = 0.022). Given the unadjusted estimates and retrospective nature of these studies, and that these compare prognostic factors and not treatment effects, conclusions about the relative merits of different treatments cannot be made. However, they do reflect an ongoing point of discussion, and contribute towards a burgeoning empirical basis for either a two‐threshold 'all‐or‐nothing' classification system following IDS (NMRD versus RD &gt; 0 cm) or the retention of the three‐threshold classification. The results of our review appear to lend support for the two‐threshold classification following IDS based on the conduct of the included studies, although this is more on the grounds that there is a lack of evidence of significant differences in survival between SVRD and LVRD (&gt; 1 cm) thresholds due to lack of reporting of this comparison. </p> <p>A Cochrane Review by <a href="./references#CD015048-bbs2-0172" title="ColeridgeSL , BryantA , KehoeS , MorrisonJ . Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD005343. [DOI: 10.1002/14651858.CD005343]">Coleridge 2021</a> compared intervention RCTs directly comparing PDS versus IDS (<a href="./references#CD015048-bbs2-0066" title="ChekmanC , LayouneR , HocineO , RaissiN , FerhatHA , Ali KhodjaH , et al. An open prospective randomized trial comparing primary complete cytoreduction surgery to debulking surgery after chemotherapy in advanced stage (FIGO's IIIC) ovarian carcinoma. In: 19th International Meeting of the European Society of Gynaecological Oncology, ESGO 2015; 2015 Oct 24-27; Nice, France. 2015:1316. [12185451]">Chekman 2015</a>; <a href="./references#CD015048-bbs2-0079" title="FagottiA , FerrandinaG , VizzielliG , FanfaniF , GallottaV , ChianteraV , et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. European Journal of Cancer2016;59:22-33. [12185453]FagottiA , FerrandinaMG , VizzielliG , PasciutoT , FanfaniF , GallottaV , et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer2020;30(11):1657-64. [PMID: 10.1136/ijgc-2020- 001640]FagottiA , VizzielliG , FerrandinaG , FanfaniF , GallottaV , ChianteraV , et al. Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial). Journal of Clinical Oncology2018;36(15):5516. [12185454]">Fagotti 2020</a>; <a href="./references#CD015048-bbs2-0098" title="KehoeS , HookJ , NankivellM , JaysonGC , KitchenerH , LopesT , et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet2015;386(9990):249-57. [12185455]KehoeS , HookJ , NankivellM . Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Journal of Clinical Oncology2013;31 Suppl(15):Abstract 5500. [12185456]KehoeS , WheelerS . CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=9 (accessed 18/6/2012). [12185457]LawK , MurrayC , KehoeS . CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. In: Annual Meeting of the British Gynaecological Cancer Society; 2006 Nov 30-Dec 1; Manchester, UK. 2006:90. [12185459]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185460]">Kehoe 2015</a>; <a href="./references#CD015048-bbs2-0113" title="OndaT , MatsumotoK , ShibataT , SatoA , FukudaH , KonishiI , et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Japanese Journal of Clinical Oncology2008;38(1):74-7. [12185462]OndaT , SatohT , OgawaG , SaitoT , KasamatsuT , NakanishiT , et al, Japan Clinical Oncology Group. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. European Journal of Cancer2020;130:114-25. OndaT , SatohT , SaitoT , KasamatsuT , NakanishiT , NakamuraK , et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. European Journal of Cancer2016;64:22-31. [12185463]OndaT , SatohT , SaitoT , KasamatsuT , NakanishiT , TakeharaK , et al. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. Journal of Clinical Oncology2018;36(15 Suppl). [12185464]">Onda 2020</a>; <a href="./references#CD015048-bbs2-0150" title="GreimelE , KristensenG , VergoteI , HoskinsP , van derBurgME , Casado HerraezA , et al. Quality of life in advanced ovarian cancer patients: a randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy. International Journal of Gynaecological Cancer2011;21:S620. [12185466]GreimelE , KristensenGB , van derBurgME , CoronadoP , RustinG , delRioAS , et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology2013;131(2):437-44. [12185467]VergoteI , AmantF , KristensenG , EhlenT , ReedNS , CasadoA . Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer2011;47(Suppl 3):S88-91. [12185468]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185469]VergoteI , PecorelliS , StuartG . Intergroup Study (EORTC 55971/NCIC OV13). Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/clinicaltrials/EORTC-55971 2003 (accessed 17 June 2012). [12185470]VergoteI , TropéCG , AmantF , EhlenT , ReedNS , CasadoA . Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology2011;29(31):4076-8. [12185471]VergoteI , TropeCG , AmantF , KristensenGB , EhlenT , JohnsonN , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine2010;363(10):943-53. [12185472] [Incl. Supplementary Appendix and Protocol]VerleyeL , OttevangerPB , KristensenGB , EhlenT , JohnsonN , van derBurgME , et al. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. European Journal of Cancer2011;47(1):57-64. [12185473]">Vergote 2010</a>). The included studies did not meet our inclusion criteria, as they did not report results across RD thresholds. Within this review, <a href="./references#CD015048-bbs2-0098" title="KehoeS , HookJ , NankivellM , JaysonGC , KitchenerH , LopesT , et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet2015;386(9990):249-57. [12185455]KehoeS , HookJ , NankivellM . Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Journal of Clinical Oncology2013;31 Suppl(15):Abstract 5500. [12185456]KehoeS , WheelerS . CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=9 (accessed 18/6/2012). [12185457]LawK , MurrayC , KehoeS . CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. In: Annual Meeting of the British Gynaecological Cancer Society; 2006 Nov 30-Dec 1; Manchester, UK. 2006:90. [12185459]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185460]">Kehoe 2015</a> and <a href="./references#CD015048-bbs2-0150" title="GreimelE , KristensenG , VergoteI , HoskinsP , van derBurgME , Casado HerraezA , et al. Quality of life in advanced ovarian cancer patients: a randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy. International Journal of Gynaecological Cancer2011;21:S620. [12185466]GreimelE , KristensenGB , van derBurgME , CoronadoP , RustinG , delRioAS , et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology2013;131(2):437-44. [12185467]VergoteI , AmantF , KristensenG , EhlenT , ReedNS , CasadoA . Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer2011;47(Suppl 3):S88-91. [12185468]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185469]VergoteI , PecorelliS , StuartG . Intergroup Study (EORTC 55971/NCIC OV13). Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/clinicaltrials/EORTC-55971 2003 (accessed 17 June 2012). [12185470]VergoteI , TropéCG , AmantF , EhlenT , ReedNS , CasadoA . Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology2011;29(31):4076-8. [12185471]VergoteI , TropeCG , AmantF , KristensenGB , EhlenT , JohnsonN , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine2010;363(10):943-53. [12185472] [Incl. Supplementary Appendix and Protocol]VerleyeL , OttevangerPB , KristensenGB , EhlenT , JohnsonN , van derBurgME , et al. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. European Journal of Cancer2011;47(1):57-64. [12185473]">Vergote 2010</a> randomised 1270 participants (of which 1220 were assessed), compared PDS versus IDS and provided a breakdown of extent of disease by type of surgery (but did not give breakdown of differences within RD thresholds for each type of surgery, so did not meet our inclusion criteria). Both trials recruited participants with stage IIIC and IV epithelial ovarian cancer. Both trials reported RD thresholds that included NMRD (optimal), SVRD (RD &lt; 1 cm) and LVRD (RD &gt; 1 cm). The two trials found no significant difference in overall survival for the comparison of extent of RD threshold (NMRD, SVRD and LVRD) by primary surgery (upfront versus interval). The trial <a href="./references#CD015048-bbs2-0150" title="GreimelE , KristensenG , VergoteI , HoskinsP , van derBurgME , Casado HerraezA , et al. Quality of life in advanced ovarian cancer patients: a randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy. International Journal of Gynaecological Cancer2011;21:S620. [12185466]GreimelE , KristensenGB , van derBurgME , CoronadoP , RustinG , delRioAS , et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic Oncology2013;131(2):437-44. [12185467]VergoteI , AmantF , KristensenG , EhlenT , ReedNS , CasadoA . Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer2011;47(Suppl 3):S88-91. [12185468]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185469]VergoteI , PecorelliS , StuartG . Intergroup Study (EORTC 55971/NCIC OV13). Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/clinicaltrials/EORTC-55971 2003 (accessed 17 June 2012). [12185470]VergoteI , TropéCG , AmantF , EhlenT , ReedNS , CasadoA . Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology2011;29(31):4076-8. [12185471]VergoteI , TropeCG , AmantF , KristensenGB , EhlenT , JohnsonN , et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine2010;363(10):943-53. [12185472] [Incl. Supplementary Appendix and Protocol]VerleyeL , OttevangerPB , KristensenGB , EhlenT , JohnsonN , van derBurgME , et al. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. European Journal of Cancer2011;47(1):57-64. [12185473]">Vergote 2010</a> reported no significant difference between PDS and IDS for SVRD or NMRD (RD &lt; 1cm including 0 cm) (HR 1.17, 95% CI 0.82 to 1.67). There were also no significant differences observed for SVRD (&lt; 1 cm) (HR 1.22, 95% CI 0.84 to 1.77) and LVRD thresholds (HR 0.91, 95% CI 0.89 to 1.30) by type of surgery. Similarly, the authors of <a href="./references#CD015048-bbs2-0098" title="KehoeS , HookJ , NankivellM , JaysonGC , KitchenerH , LopesT , et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet2015;386(9990):249-57. [12185455]KehoeS , HookJ , NankivellM . Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Journal of Clinical Oncology2013;31 Suppl(15):Abstract 5500. [12185456]KehoeS , WheelerS . CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=9 (accessed 18/6/2012). [12185457]LawK , MurrayC , KehoeS . CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. In: Annual Meeting of the British Gynaecological Cancer Society; 2006 Nov 30-Dec 1; Manchester, UK. 2006:90. [12185459]VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19:1680-7. [12185460]">Kehoe 2015</a> reported a P value of 0.98 for the interaction between treatment and extent of RD after debulking. It should be emphasised that these studies were RCTs designed to measure the effect of PDS versus IDS and were not designed to evaluate the intervention of differing degrees of surgical effort. </p> <p>The results of the SOCQER‐2 study assessing quality of life and progression‐free survival found that patients with late‐stage ovarian cancer had no important differences in EORTC QLQ‐C30 global scores measured across six weeks, six months and 12 months post‐surgery when undergoing surgery of varying complexity, despite a higher preoperative disease burden in patients undergoing more radical surgical procedures (<a href="./references#CD015048-bbs2-0221" title="SundarS , CumminsC , KumarS , LongJ , AroraV , BalegaJ , et al. Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. British Journal of Obstetrics and Gynaecology2022;129(7):1122-32. [DOI: 10.1111/1471-0528.17041] [PMCID: PMC9306902] [PMID: 34865316]">Sundar 2022</a>). The authors of the study found that patients who underwent low‐complexity surgery had higher rates of residual disease and lower survival compared with those with a similar disease burden undergoing surgery of intermediate complexity. However, no statistical adjustment was performed in these analyses. Postoperative residual disease was associated with poorer overall survival, particularly in patients undergoing low‐complexity surgery, but again no statistical adjustment was made and, as this was not an intervention study, it is not able to determine the causal effect of this relationship. </p> <p>Women with FIGO stage IIIC disease with extra pelvic metastases smaller than 5 cm have been shown to have better progression‐free survival after upfront debulking (<a href="./references#CD015048-bbs2-0151" title="VergoteI , CoensC , NankivellM , KristensenG , ParmerM , EhlenT , et al. Meta-analysis of the randomized EORTC and chorus neoadjuvant versus primary debulking trials in advanced tubo-ovarian cancer. International Journal of Gynecological Cancer2016;26(Suppl 3):24-5. VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19(12):1680-7. VergoteI , CoensC , NankivellM , KristensenGB , ParmarMK , EhlenT , et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology2018;19(12):1680-7. ">Vergote 2018</a>). An investigation of NMRD during the initial treatment of epithelial ovarian cancer comparing PDS versus IDS has been investigated in a TRUST (Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)) trial, which is due to report in 2024 (<a href="./references#CD015048-bbs2-0214" title="ReussA , du BoisA , HarterP , FotopoulouC , SehouliJ , AlettiG , et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). International Journal of Gynecologic Cancer2019;29:1327-31.">Reuss 2019</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015048-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD015048-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 SVRD (&lt; 1 cm) versus NMRD, outcome: 1.2 Overall survival" data-id="CD015048-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 SVRD (&lt; 1 cm) versus NMRD, outcome: 1.2 Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 4 LVRD (&gt; 1 cm) versus NMRD, outcome: 2.2 Overall survival" data-id="CD015048-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 4 LVRD (&gt; 1 cm) versus NMRD, outcome: 2.2 Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 SVRD (&lt; 1 cm) versus NMRD, outcome: 1.5 Progression‐free survival" data-id="CD015048-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 SVRD (&lt; 1 cm) versus NMRD, outcome: 1.5 Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 1: Overall survival" data-id="CD015048-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 2: Overall survival ‐ sensitivity analysis using fixed‐effect model" data-id="CD015048-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 2: Overall survival ‐ sensitivity analysis using fixed‐effect model </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 3: Overall survival ‐ sensitivity analysis excluding Klar 2016" data-id="CD015048-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 3: Overall survival ‐ sensitivity analysis excluding Klar 2016 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 4: Progression‐free survival" data-id="CD015048-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 4: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 5: Progression‐free survival ‐ sensitivity analysis using fixed‐effect model" data-id="CD015048-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 5: Progression‐free survival ‐ sensitivity analysis using fixed‐effect model </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 6: Progression‐free survival ‐ sensitivity analysis excluding Klar 2016" data-id="CD015048-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: PDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 6: Progression‐free survival ‐ sensitivity analysis excluding Klar 2016 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 1: Overall survival" data-id="CD015048-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: PDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 2: Overall survival ‐ sensitivity analysis using fixed effects model" data-id="CD015048-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: PDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 2: Overall survival ‐ sensitivity analysis using fixed effects model </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 3: Overall survival ‐ sensitivity analysis excluding Melamed 2017b and Winter 2007" data-id="CD015048-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: PDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 3: Overall survival ‐ sensitivity analysis excluding Melamed 2017b and Winter 2007 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 4: Progression‐free survival" data-id="CD015048-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: PDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 4: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 1: Overall survival" data-id="CD015048-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 2: Overall survival sensitivity analysis excluding Klar 2016" data-id="CD015048-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 2: Overall survival sensitivity analysis excluding Klar 2016 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 3: Overall survival sensitivity analysis excluding 0 cm" data-id="CD015048-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 3: Overall survival sensitivity analysis excluding 0 cm </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 4: Overall survival sensitivity analysis including studies that included 0 cm" data-id="CD015048-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 4: Overall survival sensitivity analysis including studies that included 0 cm </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 5: Progression‐free survival" data-id="CD015048-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 5: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: PDS: RD &gt; 0 cm versus NMRD, Outcome 1: Overall survival" data-id="CD015048-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: PDS: RD &gt; 0 cm versus NMRD, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: PDS: RD &gt; 0 cm versus NMRD, Outcome 2: Progression‐free survival" data-id="CD015048-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: PDS: RD &gt; 0 cm versus NMRD, Outcome 2: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: PDS: LVRD 1 cm to 2 cm versus NMRD (stage IIIC), Outcome 1: Overall survival" data-id="CD015048-fig-0022" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: PDS: LVRD 1 cm to 2 cm versus NMRD (stage IIIC), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: PDS: LVRD (&gt; 2 cm) versus NMRD (stage IIIC), Outcome 1: Overall survival" data-id="CD015048-fig-0023" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: PDS: LVRD (&gt; 2 cm) versus NMRD (stage IIIC), Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PDS: LVRD 1 cm to 5 cm versus NMRD (stage IV disease), Outcome 1: Overall survival" data-id="CD015048-fig-0024" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: PDS: LVRD 1 cm to 5 cm versus NMRD (stage IV disease), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: PDS: LVRD 1 cm to 5 cm versus NMRD (stage IV disease), Outcome 2: Progression‐free survival" data-id="CD015048-fig-0025" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: PDS: LVRD 1 cm to 5 cm versus NMRD (stage IV disease), Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PDS: LVRD (&gt; 5 cm) versus NMRD (stage IV disease), Outcome 1: Overall survival" data-id="CD015048-fig-0026" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: PDS: LVRD (&gt; 5 cm) versus NMRD (stage IV disease), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: PDS: LVRD (&gt; 5 cm) versus NMRD (stage IV disease), Outcome 2: Progression‐free survival" data-id="CD015048-fig-0027" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: PDS: LVRD (&gt; 5 cm) versus NMRD (stage IV disease), Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: PDS: LVRD 1 cm to 2 cm versus SVRD (&lt; 1 cm), Outcome 1: Overall survival" data-id="CD015048-fig-0028" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: PDS: LVRD 1 cm to 2 cm versus SVRD (&lt; 1 cm), Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: PDS: LVRD (&gt; 2 cm) versus SVRD (&lt; 1 cm), Outcome 1: Overall survival" data-id="CD015048-fig-0029" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: PDS: LVRD (&gt; 2 cm) versus SVRD (&lt; 1 cm), Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: PDS: LVRD (&gt; 2 cm) versus RD &lt; 2 cm (stage IV disease), Outcome 1: Overall survival" data-id="CD015048-fig-0030" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: PDS: LVRD (&gt; 2 cm) versus RD &lt; 2 cm (stage IV disease), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: PDS: LVRD (&gt; 2 cm) versus RD &lt; 2 cm (stage IV disease), Outcome 2: Progression‐free survival" data-id="CD015048-fig-0031" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: PDS: LVRD (&gt; 2 cm) versus RD &lt; 2 cm (stage IV disease), Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: IDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 1: Overall survival" data-id="CD015048-fig-0032" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: IDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: IDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 2: Progression‐free survival" data-id="CD015048-fig-0033" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: IDS: SVRD (&lt; 1 cm) versus NMRD, Outcome 2: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: IDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 1: Overall survival" data-id="CD015048-fig-0034" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: IDS: LVRD (&gt; 1 cm) versus NMRD, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 1: Overall survival" data-id="CD015048-fig-0035" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 2: Overall survival sensitivity analysis including 0 cm" data-id="CD015048-fig-0036" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 2: Overall survival sensitivity analysis including 0 cm </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 3: Overall survival sensitivity analysis excluding Phillips 2018" data-id="CD015048-fig-0037" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 3: Overall survival sensitivity analysis excluding Phillips 2018 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 4: Progression‐free survival" data-id="CD015048-fig-0038" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm), Outcome 4: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: IDS: RD &gt; 0 cm versus NMRD, Outcome 1: Overall survival" data-id="CD015048-fig-0039" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: IDS: RD &gt; 0 cm versus NMRD, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015048-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/urn:x-wiley:14651858:media:CD015048:CD015048-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: IDS: RD &gt; 0 cm versus NMRD, Outcome 2: Progression‐free survival" data-id="CD015048-fig-0040" src="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_t/tCD015048-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: IDS: RD &gt; 0 cm versus NMRD, Outcome 2: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/media/CDSR/CD015048/image_n/nCD015048-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015048-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Small‐volume residual disease (SVRD) &lt; 1 cm versus NMRD in PDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Small‐volume residual disease (SVRD) (&lt; 1 cm) compared with NMRD after upfront primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after PDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> SVRD compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up<sup>1</sup>: </p> <p>Range: 28 to 77.7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.03</b> (1.80 to 2.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9404 participants<br/>(17 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms so we did not attempt it, as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p> </p> <p>There were no concerns with inconsistency and imprecision across studies due to restrictive inclusion criteria in a generally representative cohort of women with advanced EOC. Data were considerable in size in PDS studies with &gt; 9000 and &gt; 6500 women in the analyses of OS and PFS, respectively. </p> <p> </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may appear to represent moderate heterogeneity (as measured by the I<sup>2</sup> statistic), but we had no major concerns as the direction of effect was consistent throughout. </p> <p> </p> <p>There did not appear to be any evidence of small study biases, such as publication bias, or any irregularities with the data by visual inspection of funnel plots. While publication bias cannot be dismissed, it would take a lot of large statistically insignificant studies to overhaul the current results. Furthermore, studies showing harmful survival in women with NMRD compared to other thresholds of RD is implausible. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up<sup>1</sup>: </p> <p>Range: 28 to 77.7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR</b> </p> <p><b>1.88</b> (1.63 to 2.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6596 participants<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival; <b>SVRD:</b> small‐volume residual disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Range in <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> was 0 to 144 months. </p> <p><sup>2</sup>Downgraded by one level because was assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Small‐volume residual disease (SVRD) &lt; 1 cm versus NMRD in PDS studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015048-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus no macroscopic residual disease (NMRD) in PDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>LVRD (&gt; 1 cm) compared with NMRD after upfront primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced ovarian cancer after PDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> LVRD &gt; 1 cm compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up:</p> <p>Range: 28 to 77.7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR</b> </p> <p><b>2.50</b> (2.13 to 2.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7988 participants<br/>(14 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms so we did not attempt it, as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p> </p> <p>There were no concerns with inconsistency and imprecision across studies due to restrictive inclusion criteria in a generally representative cohort of women with advanced EOC. Data were considerable in size in PDS studies with nearly n = 8000 in the analysis of OS and to lesser extent &gt; 2500 for PFS. </p> <p> </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may appear to represent moderate heterogeneity (as measured by the I<sup>2</sup> statistic), but we had no major concerns as the direction of effect was consistent throughout. </p> <p> </p> <p>There did not appear to be any evidence of small study biases, such as publication bias, or any irregularities with the data by visual inspection of funnel plots. While publication bias cannot be dismissed, it would take a lot of large statistically insignificant studies to overhaul the current results. Furthermore, studies showing harmful survival in women with NMRD compared to other thresholds of RD is implausible. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up:</p> <p>Range: 28 to 77.7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.10</b> (1.84 to 2.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2629 participants<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>LVRD</b> : large‐volume residual disease; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus no macroscopic residual disease (NMRD) in PDS studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015048-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus small‐volume residual disease (SVRD) &lt; 1 cm in PDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>LVRD (&gt; 1 cm) compared with SVRD (&lt; 1 cm) after upfront primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after PDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> LVRD &gt; 1 cm compared with SVRD &lt; 1 cm </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up<sup>1</sup>: </p> <p>Range: 28 to 34.1 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 1.22</b> (1.13 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6000 participants<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms, so we did not attempt it as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p> </p> <p>There were no concerns with inconsistency and imprecision across studies (the smallest study comparison (n = 100) was imprecise but there were only n = 23 women with sub‐optimal RD) due to restrictive inclusion criteria in a generally representative cohort of women with advanced EOC. Data were considerable in size in PDS studies with n &gt; 6000 in the analysis of OS and to lesser extent &gt; 3000 for PFS. </p> <p> </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may not be important (as measured by the I<sup>2</sup> statistic) in meta‐analyses including PDS studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up<sup>1</sup>: 28 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR</b> </p> <p>1.30 (1.08 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3402 participants<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>LVRD</b> : large‐volume residual disease; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival; <b>SVRD:</b> small‐volume residual disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Range in <a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> was 0 to 144 months. </p> <p><sup>2</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus small‐volume residual disease (SVRD) &lt; 1 cm in PDS studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015048-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Small‐volume residual disease (SVRD) (&lt; 1 cm) versus NMRD in IDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>SVRD (&lt; 1 cm) compared with NMRD after primary interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after primary IDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> SVRD &lt; 1 cm compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.09</b> (1.20 to 3.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310 participants<br/>(1 study reporting on 2 groups) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms so we did not attempt it, as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up: 47 months</p> <p>Range: 3 to 181 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors of <a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> found that the risk of disease progression for women with RD &lt; 1 cm after IDS was significantly higher than those with complete cytoreduction, but the magnitude of effect was not reported. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>IDS:</b> interval debulking surgery; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival; <b>SVRD:</b> small‐volume residual disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> <p><sup>2</sup>Downgraded by one level for sparse data. </p> <p><sup>3</sup>Downgraded by one level for lack of generalisability and validity of results as reported in single analysis or very few included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Small‐volume residual disease (SVRD) (&lt; 1 cm) versus NMRD in IDS studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015048-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus no macroscopic residual disease (NMRD) in IDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Large‐volume residual disease (LVRD) (&gt; 1 cm) compared with NMRD after primary interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after primary IDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> LVRD &gt; 1 cm compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up:</p> <p>Not reported</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.23</b> (1.49 to 3.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343 participants<br/>(1 study reporting on 2 groups)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>123</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms, so we did not attempt it as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>IDS:</b> interval debulking surgery; <b>LVRD:</b> large‐volume residual disease; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> <p><sup>2</sup>Downgraded by one level for sparse data. </p> <p><sup>3</sup>Downgraded by one level for lack of generalisability and validity of results as reported in single analysis or very few included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus no macroscopic residual disease (NMRD) in IDS studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015048-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus small‐volume residual disease (SVRD) &lt; 1 cm in IDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Large‐volume residual disease (LVRD) &gt; 1 cm compared with small‐volume residual disease (SVRD) &lt; 1 cm after primary interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after primary IDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> LVRD &gt; 1 cm compared with SVRD &lt; 1 cm </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up:</p> <p>Range: 34.3 to 43.5 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 1.60</b> (1.21 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1572 participants<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>verylow<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms, so we did not attempt it as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p> </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance) may represent substantial heterogeneity (as measured by the I<sup>2</sup> statistic) in meta‐analyses. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up</p> <p>Range: 38 to 43.5 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 1.76</b> (1.23 to 2.52)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1145 participants<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>verylow<sup>123</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>IDS:</b> interval debulking surgery; <b>LVRD:</b> large‐volume residual disease; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival; <b>SVRD:</b> small‐volume residual disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> <p><sup>2</sup>Downgraded by one level for heterogeneity across studies. </p> <p><sup>3</sup>Only one study reported a comparison of SVRD &lt; 1 cm versus LVRD &gt; 1 cm in the strict sense that SVRD &lt; 1 cm was mutually exclusive of NMRD (<a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Large‐volume residual disease (LVRD) &gt; 1 cm versus small‐volume residual disease (SVRD) &lt; 1 cm in IDS studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015048-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Residual disease (RD) &gt; 0 cm versus NMRD in IDS studies</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Any remaining residual disease (RD) (&gt; 0 cm) compared with NMRD after primary interval debulking surgery (IDS) in women with advanced epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Population:</b> women with advanced EOC after primary IDS </p> <p><b>Settings:</b> all settings in adult women aged 18 years or older worldwide </p> <p><b>Prognostic factor:</b> RD &gt; 0 cm compared with NMRD </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival:</b> </p> <p>Median length of follow‐up: range: 37 to 39 (reported in 2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 2.11</b> (1.35 to 3.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>906 participants<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not present illustrative absolute effects because a representative control group risk could not be ascertained from the studies. The HR estimates were adjusted for in multivariable analyses and this cannot be done in absolute terms, so we did not attempt it as the numbers were likely to mislead with any bias potentially favouring the NMRD threshold. </p> <p>The percentage of the variability in effect estimates that was due to heterogeneity rather than chance may represent considerable heterogeneity (I<sup>2</sup> = 81%). </p> <p>The authors of <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> additionally found that the risk of death for women with any remaining RD (&gt; 0 cm) after IDS was significantly higher than those with NMRD (n = 163, P &lt; 0.01), but the magnitude of effect was not reported. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival:</b> </p> <p>Median length of follow‐up: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adjusted HR 1.36</b> (1.05 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>123</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors of <a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> additionally found that the risk of disease progression for women with RD &gt; 0 cm after IDS was significantly higher than those with NMRD (n = 163, P &lt; 0.01), but the magnitude of effect was not reported. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>EOC:</b> epithelial ovarian cancer; <b>IDS:</b> interval debulking surgery; <b>NMRD:</b> no macroscopic residual disease; <b>OS:</b> overall survival; <b>PDS:</b> upfront primary debulking surgery; <b>PFS:</b> progression‐free survival </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because we assessed the statistical analysis and reporting domain in the QUIPS tool as being at high or unclear risk of bias in all included studies. Either no conceptual framework was reported, where the variable selection criteria in multivariate model was unclear, or quite often the authors reported that significant variables from the univariate analysis were included in the multivariable model, but with no further details. This was the most serious bias from the QUIPS domains that could influence the effect estimates. </p> <p><sup>2</sup>Downgraded by one level for heterogeneity across studies. </p> <p><sup>3</sup>Downgraded by one level for lack of generalisability and validity of results as reported in single analysis or very few included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Residual disease (RD) &gt; 0 cm versus NMRD in IDS studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015048-tbl-0008"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of stage and residual disease in included upfront primary debulking surgery (PDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p> <b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No.</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Stage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Optimal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Suboptimal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median age in years</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>III n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IV n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Months</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>(Range)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2: 70 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2: 155 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.5 (13 to 112)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> <p>(26 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 46 (24)</p> <p>&lt; 1: 85 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2: 22 (11)</p> <p>&gt; 2: 41 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.4</p> <p>(0.2 to 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> <p>(24 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 157 (55)</p> <p>&lt; 1: 88 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 41 (14)</p> <p>NS: n = 40 exc.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> <p>(IQR: 12 to 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 65: 205 (63)</p> <p>&gt; 65: 121 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> <p>Austria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>0: 209 (52)</p> <p>&lt; 1: 196 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(Range not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> <p>(81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1: 71 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 33 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> <p>(6 to 142)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean was 50.5 years</p> <p>and 61 years for younger</p> <p>and older women, respectively</p> <p>(Range: 22 and 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> <p>(93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> <p>(7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 63 (31)</p> <p>&lt; 1: 77 (38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 63 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(1 to 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> <p>(30 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 61 (32)</p> <p>&lt; 1: 67 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 61 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> <p>(30 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> <p>(77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1: 71 (25)</p> <p>1 to 2: 73 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2: 137 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 to 139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(22 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 67 (14)</p> <p>&lt; 1: 169 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 229 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>(1 to 199)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> <p>(22 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>0: 55 (25)</p> <p>&lt; 1: 163 (75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (18 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 351 (86)</p> <p>&lt; 1: 41 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 16 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.8</p> <p>(24 to 91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>n = 567 (91) stage III/IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 209 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0: 416 (67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (3 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (30 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> <p>(83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 121 (63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0: 70 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 57: 98</p> <p>&gt; 57: 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428</p> <p>(54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365</p> <p>(46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 482 (61)</p> <p>&lt; 1: 226 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> <p>(IQR: 18 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (19 to 88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5055</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>4488/5130 (87.5)</p> <p>stage III/IV; n = 4850 in RD analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 1779 (37)</p> <p>&lt; 1: 1442 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 1629 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: 57.4</p> <p>(SD 10.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> <p>France</p> <p>Denmark</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> <p>(76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> <p>(24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 61 (22)</p> <p>&lt; 1: 120 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 95 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 years</p> <p>(0 to 15.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: 73.5</p> <p>(65 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 133 (75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0: 45 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.6</p> <p>(IQR 32.9 to 66.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 years (IQR 50.8 to 72.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 (67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All sub‐optimal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2 cm:</p> <p>85 (18.6)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2 cm:</p> <p>373 (81.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241</p> <p>(78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> <p>(22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 141 (59)</p> <p>&lt; 1: 77 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 23 (9)</p> <p>n = 66 missing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 60: 200 (65)</p> <p>&gt; 60: 107 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4954</p> <p>(77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1506</p> <p>(23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 2048 (46)</p> <p>&lt; 1: 1848 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 546 (12)</p> <p>1571 missing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 60: 2803 (47)</p> <p>&gt; 60: 3210 (53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370</p> <p>(88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> <p>(12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 107 (26)</p> <p>&lt; 1: 147 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 165 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (3 to 164)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean = 54.5 (SD 10.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199 (76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 115 (44)</p> <p>&lt; 1: 83 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2: 18 (7)</p> <p>&gt; 2: 43 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (22 to 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 99 (41)</p> <p>&lt; 1: 106 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 32 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.7 (22 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II: 15 (7)</p> <p>III: 174 (77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 157 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 0: 69 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0</p> <p>(1 to 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: 57.5 (SD 11.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>III/IV (n = 276)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (20 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1241</p> <p>(72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 (28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 85 (5)</p> <p>&lt; 1: 701 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 932 (54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.5 to 60.2 for 0 to &gt; 1 cm RD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>794</p> <p>(81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> <p>(19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 408 (42)</p> <p>&lt; 1: 378 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 192 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.7 (1 to 198)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (19 to 95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2 cm: 92 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2 cm:</p> <p>127 (58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (24 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>573</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 70 (12)</p> <p>&lt; 1: 168 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 335 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(19 to 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> <p>France</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1895</p> <p>(100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 437 (23)</p> <p>&lt; 1: 791 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 667 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> <p>(16 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 cm: 29 (8)</p> <p>&lt;  1 cm: 79 (22)</p> <p>Total: 108 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> <p>(24 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>IQR:</b> interquartile range; <b>RD:</b> residual disease; <b>SD:</b> standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of stage and residual disease in included upfront primary debulking surgery (PDS) studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015048-tbl-0009"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of stage and residual disease in included interval debulking surgery (IDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No.</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Stage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Optimal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Suboptimal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median age in years</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> </tr> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>III n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IV n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Months</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>(Range)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 37 (44)</p> <p>&lt; 1: 20 (23)<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1: 28 (33)<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age</p> <p>≥ 70 years: 74.5 (41%)<br/>&lt; 70 years: 58.3 (59%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>IIIC: 114 (40)</p> <p>IV: 101 (36)</p> <p>Assumed AOC: 57 (20)</p> <p>Unknown: 10 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 165 (59)<sup>‡</sup> </p> <p>≤ 1: 63 (22)<sup>‡</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1 to 2: 6 (2)<sup>‡</sup> </p> <p>&gt; 2: 37 (13)<sup>‡</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.9 (34.1 to 84.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIIB: 6 (5)</p> <p>IIIC: 77 (62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 1: 113 (91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1: 11 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5 (5 to 142)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (29 to 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 1: 165 (81)<sup>§</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 36 (19)<sup>§</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5 (1 to 124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (28 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251 (78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No definition of optimal given</p> <p>0: 236 (73)</p> <p>≤ 1: 36 (11)</p> <p>&gt; 1: 50 (16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (3 to 181)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 65: 226 (70%)</p> <p>&gt; 65: 96 (30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 255 (64)</p> <p>&lt; 1: 55 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1: 88 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean: 63.9</p> <p>(95% CI 42.2 to 85.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 (69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 80 (68)</p> <p>&lt; 1: 31 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1: 7 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (37 to 88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 (85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: 59 (30)</p> <p>&lt; 1: 38 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2: 8 (4)</p> <p>&gt; 2: 30 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.5 (IQR 38.5 to 56.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (38 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564 (84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 1: 486 (72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1: 186 (28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (5 to 103)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (30 to 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>†</sup>85/102 participants underwent debulking surgery following neoadjuvant chemotherapy. </p> <p><sup>‡</sup>Residual disease data available for n = 271/282. </p> <p><sup>§</sup>Residual disease data available for n = 201/203. </p> <p><b>AOC:</b> advanced ovarian cancer; <b>CI:</b> confidence interval; <b>IQR:</b> interquartile range </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of stage and residual disease in included interval debulking surgery (IDS) studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015048-tbl-0010"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for overall survival (OS) in primary debulking surgery (PDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> <p><b>participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prognostic factor</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjustment for other</b> </p> <p><b>prognostic factors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> <p><b>and reporting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0001" title="AkahiraJI , YoshikawaH , ShimizuY , TsunematsuR , HirakawaT , KuramotoH . Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology2001;81(3):398-403. ">Akahira 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0002" title="AlettiGD , DowdySC , GostoutBS , JonesMB , StanhopeCR , WilsonTO , et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology2006;107:77–85. AlettiGD , DowdySC , PodratzKC , ClibyWA . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology2007;197(6):1-7. AlettiGD , DowdySC , PodratzKC , ClibyWA . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology2006;100(2):283-7. AlettiGD , PodratzKC , JonesMB , ClibyWA . Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons2006;203(4):521-6. ">Aletti 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0003" title="AtasevenB , GrimmC , HarterP , HeitzF , TrautA , PraderS , et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology2016;140(2):215-20. ">Ataseven 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0005" title="BristowRE , UedaS , GerardiMA , AjiboyeOB , IbeanuOA . Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecologic Oncology2011;122(2):319-23. ">Bristow 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0006" title="ChanJK , LoizziV , LinYG , OsannK , BrewsterWR , DiSaiaPJ . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics and Gynecology2003;102(1):156-61. ">Chan 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0009" title="ChiDS , LiaoJB , LeonLF , VenkatramanES , HensleyML , BhaskaranD , et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology2001;82(3):532-7. ">Chi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0010" title="ChiDS , EisenhauerEL , LangJ , HuhJ , HaddadL , Abu-RustumNR , et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006;103:559–64. EisenhauerEL , Abu-RustumNR , SonodaY , AghajanianC , BarakatRR , ChiDS . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology2008;108(2):276-81. ">Chi 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0014" title="EisenkopSM , FriedmanRL , WangHJ . Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology1998;69(2):103-8. EisenkopSM , SpirtosNM , FriedmanRL , LinWC , PisaniAL , PerticucciS . Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology2003;90(2):390-6. ">Eisenkop 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0016" title="HofstetterG , ConcinN , BraicuI , ChekerovR , SehouliJ , CadronI . The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic Oncology2013;131(1):15-20. ">Hofstetter 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0019" title="KahlA , du BoisA , HarterP , PraderS , SchneiderS , HeitzF , et al. Prognostic value of the age-adjusted Charlson comorbidity index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Annals of Surgical Oncology2017;24:3692-9. ">Kahl 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0021" title="LangstraatC , AlettiGD , ClibyWA . Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology2011;123(2):187-91. ">Langstraat 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0028" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0029" title="MelamedA , Manning-GeistB , BregarAJ , DiverEJ , GoodmanA , delCarmenMG , et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology2017;14(7):250-6. ">Melamed 2017b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0032" title="PeirettiM , BristowRE , ZapardielI , GerardiM , ZanagnoloV , BiffiR , et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic Oncology2012;126(2):220-3. ">Peiretti 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0041" title="Van GeeneP , VarmaR , DunnJ , ChanKK , LuesleyDM . The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer1996;6(3):219-24. ">Van Geene 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for overall survival (OS) in primary debulking surgery (PDS) studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015048-tbl-0011"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for overall survival (OS) in interval debulking surgery (IDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> <p><b>participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prognostic factor</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjustment for other</b> </p> <p><b>prognostic factors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> <p><b>and reporting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0013" title="DavidsonBA , BroadwaterG , CrimA , BoccacioR , BixelK , BackesF , et al. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology2019;152(3):554-9. ">Davidson 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0017" title="IwaseH , TakadaT , IitsukaC , NomuraH , AbeA , TaniguchiT , et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. Journal of Gynecologic Oncology2015;26(4):303-10. ">Iwase 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0018" title="KabanA , TopuzS , SaipP , SozenH , CelebiK , SalihogluY . Poor prognostic factors in patients undergoing surgery after neoadjuvant chemotherapy for ovarian, tubal, or peritoneal cancer. Journal of Obstetrics and Gynaecology2017;39(12):1163-70. ">Kaban 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0025" title="LorussoD , BoganiG , MatteucciL , DittoA , TamberiS , ArcangeliV , et al. Number of cycles of neoadjuvant chemotherapy might influence survival of patients undergoing interval debulking surgery for non-cytoreducible ovarian cancer: results from a multi-institutional study. International Journal of Gynecological Cancer2016;26:647. ">Lorusso 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0034" title="PhillipsA , SundarS , SinghK , NevinJ , ElattarA , KehoeS , et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology2018;44(6):760-5. ">Phillips 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0038" title="StoeckleE , BourdariasL , GuyonF , CroceS , BrousteV , ThomasL , et al. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery. Annals of Surgical Oncology2014;21(2):629-36. ">Stoeckle 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for overall survival (OS) in interval debulking surgery (IDS) studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015048-tbl-0012"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for progression‐free survival (PFS) in primary debulking surgery (PDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> <p><b>participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prognostic factor</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjustment for other</b> </p> <p><b>prognostic factors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> <p><b>and reporting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0007" title="ChangSJ , BristowRE , RyuHS . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology2012;19(13):4059-67. ">Chang 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0008" title="ChangSJ , BristowRE , RyuHS . Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology2012;126(3):381-6. ">Chang 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0012" title="CuylanZF , MeydanliMM , SariME , AkbayirO , CelikH , DedeM , et al. Prognostic factors for maximising or optimally cytoreduced stage III non serous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research2018;44(7):1284-93. ">Cuylan 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0015" title="FengZ , WenH , BiR , YangW , WuX . Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology2016;141:466-70. ">Feng 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0020" title="du BoisA ,  LückH , MeierW , AdamsHP , MöbusV , CostaS , et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute2003;95(17):1320-9. du BoisA , WeberB , RochonJ , MeierW , GoupilA , OlbrichtS , , et al. Addition of epirubicin as a third drug to carboplatin/paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Journal of Clinical Oncology2006;24(7):1127-35. du Bois AHJ , Hardy-BessardAC , MullerHH , HarterP , KristensenG . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of Clinical Oncology2010;28(27):4162-9. KlarM , HasenburgA , HasenovM , HilpertF , MeierW , PfistererJ , et al. Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. European Journal of Cancer2016;66:114-24. MahnerS , EulenburgC , StaehleA , WegscheiderK , ReussA , Pujade-LauraineE , et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European Journal of Cancer2013;49(1):142-9. PfistererJWB , ReussA , KimmigR , du BoisA , WagnerU , et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute2006;98(15):1036-45. ">Klar 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0026" title="LugerAK , SteinkohlF , AignerF , JaschkeW , MarthC , ZeimetAG , et al. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica2020;99:1092–9. ">Luger 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0027" title="HoskinsWJ , McGuireWP , BradyMF , HomesleyHD , CreasmanWT , BermanM , et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology1994;170(4):974-80. McGuireWP , HoskinsWJ , BradyMF , HomesleyHD , CreasmanWT , BermanML , et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology1995;13:1589-99. ">McGuire 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0030" title="PaikES , KimJH , KimTJ , LeeJW , KimBG , BaeDS , et al. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology2018;29(1):e13. ">Paik 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0031" title="PeirettiM , ZanagnoloV , AlettiGD , BoccioloneL , ColomboN , LandoniF , et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Gynecologic Oncology2010;119(2):259-64. ">Peiretti 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0035" title="PolterauerS , VergoteI , ConcinN , BraicuI , ChekerovR , MahnerS . Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer2012;22(3):380-5. ">Polterauer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0037" title="ShimSH , KimDY , JungPS , KimJH , KimYM , SuhDS , et al. Prognostic impact of the time interval from surgery to chemotherapy in patients with advanced ovarian cancer. Gynecologic Oncology2016;141(S1):49. ">Shim 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0039" title="TewariKS , JavaJJ , EskanderRN , MonkBJ , BurgerRA . Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Annals of Oncology2016;27:114-21. ">Tewari 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0040" title="TsengJH , CowanRA , ZhouQ , LasonosA , ByrneM , PolcinoT , et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete Gross resection rates independently lead to increased progression-free and overall survival?Gynecologic Oncology2018;151(1):24-31. ">Tseng 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0042" title="WimbergerP , WehlingM , LehmannN , KimmigR , SchmalfeldtB , BurgesA . Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology2010;17(6):1642-8. ">Wimberger 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0043" title="ArmstrongDK , BundyBW , WenzelL , HuangHQ , BaergenRL , ShashikantL , et al, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine2006;354(1):34-43. MarkmanM , BundyBM , AlbertsDS , FowlerJM , Clark-PearsonDL , CarsonLF , et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology2001;19(4):1001-7. McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonGN , TheodoreHL , SamuelLA , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. OzolsRF , BundyBN , GreerBE , FowlerJM , Clarke-PearsonDB , RobertAM , et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally Resected stage III ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2003;21(17):3194-200. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. WinterWE , Maxwell IIIGL , TianC , CarlsonJW , OzolsRF , RosePG , et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(24):3621-7. ">Winter 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0044" title="McGuireWP , HoskinsWJ , BradyMF , KuceraPR , PartridgeEE , LookKY , et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine1996;334(1):1-6. MuggiaFM , BralyPS , BradyMF , SuttonG , NiemannHL , LentzSL , et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2000;18(1):106-15. RosePG , NerenstoneS , BradyMF , Clarke-PearsonD , OltG , RubinSC , et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine2004;351(24):2489-97. SpriggsDR ,  BradyMF ,  VaccarelloL ,  Clarke-PearsonDL ,  BurgerRA ,  MannelR ,  et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2007;25(28):4466-71. WinterWE , MaxwellGL , TianC , SundborgMJ , RoseGS , RosePG , et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology2008;26(1):83-9. ">Winter 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for progression‐free survival (PFS) in primary debulking surgery (PDS) studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015048-tbl-0013"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for progression‐free survival (PFS) in interval debulking surgery (IDS) studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> <p><b>participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study attrition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prognostic factor</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> <p><b>measurement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adjustment for other</b> </p> <p><b>prognostic factors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> <p><b>and reporting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0004" title="BixelK , VetterM , DavidsonB , BerchuckA , CohnD , CopelandL , et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecologic Oncology2020;156:530–4. ">Bixel 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0011" title="CioffiR , BergaminiA , RabaiottiE , PetroneM , PellaF , FerrariD , et al. Neoadjuvant chemotherapy in high-risk ovarian cancer patients: role of age. Tumori Journal2018;105(2):168-73. ">Cioffi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0022" title="LecointreL , VeltenM , LodiM , SaadehR , LavouéV , OuldamerL , et al. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: a French national multicenter study (FRANCOGYN). European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;245:64–72. ">Lecointre 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0023" title="LecuruF , Pujade-LauraineE , HamiziS , Caumont-PrimA , RabanN , MalaurieE , et al. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): results of the CHIVA randomized phase II GINECO study. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September - 1 October 2019, Barcelona, Spain2019;30:v415. ">Lecuru 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0024" title="LiuY , CaoL , ChenW , WangJ , WangW , LiangZ . Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: a single-center experience. Medicine2020;99(36):e22100. ">Liu 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0033" title="PetrilloM , ZannoniGF , TortorellaL , PedoneAL , SalutariV , ErcoliA , et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. American Journal of Obstetrics and Gynecology2014;211(6):632.e1-8. ">Petrillo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0036" title="ShibutaniT , NagaoS , SuzukiK , KanedaM , YamamotoK , JimiT . Dose‑dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. International Journal of Clinical Oncology2020;25:502–7. ">Shibutani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0045" title="ZhangJ , NingL , ZhangA , XiangxiangB . Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. Journal of Obstetrics and Gynaecology Research2018;44(9):1808-16. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015048-bbs2-0046" title="ZhuJ , WangH , Cheng-ChengL , LuY , TangH . The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology2016;142(11):2339-45. ">Zhu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Risk of bias assessment according to QUIPS (Quality in Prognostic Studies) for progression‐free survival (PFS) in interval debulking surgery (IDS) studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/full#CD015048-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PDS: SVRD (&lt; 1 cm) versus NMRD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.80, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.55, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.66, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.98, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.34, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Overall survival ‐ sensitivity analysis using fixed‐effect model <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.91, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.84, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.83, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.98, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.34, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Overall survival ‐ sensitivity analysis excluding Klar 2016 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.75, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.46, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.66, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.98, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.34, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.63, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.43, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.54, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.25, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.26, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Progression‐free survival ‐ sensitivity analysis using fixed‐effect model <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.80, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.77, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.76, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.25, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.26, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Progression‐free survival ‐ sensitivity analysis excluding Klar 2016 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.56, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.33, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.54, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.25, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.26, 2.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PDS: SVRD (&lt; 1 cm) versus NMRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PDS: LVRD (&gt; 1 cm) versus NMRD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [2.13, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [1.90, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [2.09, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.27 [2.42, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [1.57, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Overall survival ‐ sensitivity analysis using fixed effects model <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [2.09, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.87, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [2.09, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.27 [2.42, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [1.57, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Overall survival ‐ sensitivity analysis excluding Melamed 2017b and Winter 2007 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [2.20, 3.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [1.99, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.27 [2.42, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [1.57, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.84, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.62, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [2.04, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Stage IIIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [1.54, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.4 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.28, 2.59]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PDS: LVRD (&gt; 1 cm) versus NMRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.13, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.11, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.00, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Overall survival sensitivity analysis excluding Klar 2016 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.08, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.03, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.00, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Overall survival sensitivity analysis excluding 0 cm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.10, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.10, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Overall survival sensitivity analysis including studies that included 0 cm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.09, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.03, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.00, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.08, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Advanced stage (III/IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.12, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.16, 1.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PDS: RD &gt; 0 cm versus NMRD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.44, 2.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.36, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PDS: RD &gt; 0 cm versus NMRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">PDS: LVRD 1 cm to 2 cm versus NMRD (stage IIIC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">PDS: LVRD 1 cm to 2 cm versus NMRD (stage IIIC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">PDS: LVRD (&gt; 2 cm) versus NMRD (stage IIIC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">PDS: LVRD (&gt; 2 cm) versus NMRD (stage IIIC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PDS: LVRD 1 cm to 5 cm versus NMRD (stage IV disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PDS: LVRD 1 cm to 5 cm versus NMRD (stage IV disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">PDS: LVRD (&gt; 5 cm) versus NMRD (stage IV disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">PDS: LVRD (&gt; 5 cm) versus NMRD (stage IV disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">PDS: LVRD 1 cm to 2 cm versus SVRD (&lt; 1 cm)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">PDS: LVRD 1 cm to 2 cm versus SVRD (&lt; 1 cm)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">PDS: LVRD (&gt; 2 cm) versus SVRD (&lt; 1 cm)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">PDS: LVRD (&gt; 2 cm) versus SVRD (&lt; 1 cm)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">PDS: LVRD (&gt; 2 cm) versus RD &lt; 2 cm (stage IV disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.83, 3.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">PDS: LVRD (&gt; 2 cm) versus RD &lt; 2 cm (stage IV disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">IDS: SVRD (&lt; 1 cm) versus NMRD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.20, 3.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 ≤ 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.93, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 &gt; 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [1.66, 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.81, 11.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">IDS: SVRD (&lt; 1 cm) versus NMRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">IDS: LVRD (&gt; 1 cm) versus NMRD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.49, 3.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 ≤ 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.07, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 &gt; 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [1.76, 4.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">IDS: LVRD (&gt; 1 cm) versus NMRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.68, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 ≤ 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.58, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 &gt; 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.57, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Overall survival sensitivity analysis including 0 cm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.21, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 3 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.94, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.2 Median 4 cycles of NACT (disease‐specific survival)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.06, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.3 Mean/median ~ 6 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.07, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.4 ≤ 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.58, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.5 &gt; 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.57, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Overall survival sensitivity analysis excluding Phillips 2018 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.34, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 3 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.94, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.2 Median 4 cycles of NACT (disease‐specific survival)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.06, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.3 Mean/median ~ 6 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.07, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.23, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.1 3 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.90, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.2 Mean ~ 6 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [1.08, 4.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.3 All cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.12, 2.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">IDS: LVRD (&gt; 1 cm) versus SVRD (&lt; 1 cm)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015048-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">IDS: RD &gt; 0 cm versus NMRD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.35, 3.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 Median 6 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [1.68, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.2 Median 4 cycles of NACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.98, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.3 All cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.53, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.05, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">IDS: RD &gt; 0 cm versus NMRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015048.pub2/references#CD015048-tbl-0028">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015048.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD015048-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015048-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015048-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD015048-note-0019">Magyar</a> </li> <li class="section-language"> <a class="" href="ko#CD015048-note-0015">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD015048-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD015048-note-0014">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015048-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015048-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015048\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015048\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015048\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015048\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015048\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015048.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015048.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015048.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015048.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015048.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729118208"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015048.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729118212"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015048.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed5120ee5f56f',t:'MTc0MDcyOTExOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 